BE2018C020I2 - - Google Patents

Info

Publication number
BE2018C020I2
BE2018C020I2 BE2018C020C BE2018C020C BE2018C020I2 BE 2018C020 I2 BE2018C020 I2 BE 2018C020I2 BE 2018C020 C BE2018C020 C BE 2018C020C BE 2018C020 C BE2018C020 C BE 2018C020C BE 2018C020 I2 BE2018C020 I2 BE 2018C020I2
Authority
BE
Belgium
Application number
BE2018C020C
Other languages
Dutch (nl)
Original Assignee
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=14346708&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2018C020(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kyowa Hakko Kirin Co Ltd filed Critical Kyowa Hakko Kirin Co Ltd
Publication of BE2018C020I2 publication Critical patent/BE2018C020I2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
BE2018C020C 1999-04-09 2018-05-17 BE2018C020I2 (browse.php)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP10315899 1999-04-09
EP00915403.0A EP1176195B1 (en) 1999-04-09 2000-04-07 Method for controlling the activity of immunologically functional molecule

Publications (1)

Publication Number Publication Date
BE2018C020I2 true BE2018C020I2 (browse.php) 2019-03-06

Family

ID=14346708

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2018C020C BE2018C020I2 (browse.php) 1999-04-09 2018-05-17

Country Status (14)

Country Link
US (15) US7214775B2 (browse.php)
EP (11) EP2270148A3 (browse.php)
JP (3) JP4368530B2 (browse.php)
AU (1) AU3672800A (browse.php)
BE (1) BE2018C020I2 (browse.php)
CA (2) CA2369292C (browse.php)
CY (4) CY1114164T1 (browse.php)
DK (8) DK2270147T4 (browse.php)
ES (9) ES2571230T3 (browse.php)
FR (1) FR18C1021I2 (browse.php)
LU (1) LUC00074I2 (browse.php)
NL (1) NL300939I2 (browse.php)
PT (2) PT1914244E (browse.php)
WO (1) WO2000061739A1 (browse.php)

Families Citing this family (1742)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP2270148A3 (en) 1999-04-09 2011-06-08 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US6693176B1 (en) * 1999-07-23 2004-02-17 University Of Massachusetts Antitumor antibodies, proteins, and uses thereof
FR2807767B1 (fr) * 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
AU2016204535C1 (en) * 2000-04-12 2017-02-23 Laboratoire Français Du Fractionnement Et Des Biotechnologies Anti-D monoclonal antibodies
US20060034828A1 (en) * 2000-06-28 2006-02-16 Gerngross Tillman U Immunoglobulins comprising predominantly a GlcNAcMAN5GLCNAC2 glycoform
EP1522590B1 (en) 2000-06-28 2009-08-26 Glycofi, Inc. Methods for producing modified glycoproteins
US20060024304A1 (en) * 2000-06-28 2006-02-02 Gerngross Tillman U Immunoglobulins comprising predominantly a Man5GlcNAc2 glycoform
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US7598055B2 (en) 2000-06-28 2009-10-06 Glycofi, Inc. N-acetylglucosaminyltransferase III expression in lower eukaryotes
US20060034830A1 (en) * 2000-06-28 2006-02-16 Gerngross Tillman U Immunoglobulins comprising predominantly a GalGlcNAcMan5GLcNAc2 glycoform
US8697394B2 (en) 2000-06-28 2014-04-15 Glycofi, Inc. Production of modified glycoproteins having multiple antennary structures
US20060029604A1 (en) * 2000-06-28 2006-02-09 Gerngross Tillman U Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform
US7863020B2 (en) * 2000-06-28 2011-01-04 Glycofi, Inc. Production of sialylated N-glycans in lower eukaryotes
US7625756B2 (en) 2000-06-28 2009-12-01 GycoFi, Inc. Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
PL218428B1 (pl) * 2000-10-06 2014-12-31 Kyowa Hakko Kogyo Kk Komórka, sposoby wytwarzania przeciwciał, leki zawierające przeciwciała, komórka CHO i przeciwciało klasy IgG
JP4986370B2 (ja) 2000-12-22 2012-07-25 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ Ｒｇｍおよびそのモジュレーターの用途
AU2002236234B2 (en) * 2001-03-06 2007-12-20 Phyton Holdings, LLC. Plant cell having animal-type sugar chain adding function
ES2326964T3 (es) * 2001-10-25 2009-10-22 Genentech, Inc. Composiciones de glicoproteina.
US7935338B2 (en) * 2001-12-11 2011-05-03 University Of Massachusetts Antibodies to treat cancer
US20040093621A1 (en) * 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
JP4820055B2 (ja) 2001-12-27 2011-11-24 グライコフィ， インコーポレイテッド 哺乳動物型糖質構造を操作するための方法
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US7657380B2 (en) 2003-12-04 2010-02-02 Xencor, Inc. Methods of generating variant antibodies with increased host string content
US6964784B2 (en) * 2002-03-07 2005-11-15 Optigenex, Inc. Method of preparation and composition of a water soluble extract of the bioactive component of the plant species uncaria for enhancing immune, anti-inflammatory, anti-tumor and dna repair processes of warm blooded animals
CA2481657A1 (en) * 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cells of which genome is modified
AU2003236020B2 (en) * 2002-04-09 2009-03-19 Kyowa Hakko Kirin Co., Ltd. Cell with depression or deletion of the activity of protein participating in GDP-fucose transport
CA2481925A1 (en) * 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for patients having human fc.gamma.riiia
WO2004022597A1 (ja) 2002-09-04 2004-03-18 Chugai Seiyaku Kabushiki Kaisha Gpc3の血中可溶化ｎ端ﾍﾟﾌﾟﾁﾄﾞに対する抗体
CA2481920A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Antibody composition-containing medicament
AU2003236018A1 (en) 2002-04-09 2003-10-20 Kyowa Hakko Kirin Co., Ltd. METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa
WO2003085118A1 (fr) * 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Procede de production de composition anticorps
FR2844455B1 (fr) * 2002-09-13 2007-12-14 Lab Francais Du Fractionnement Traitement des pathologies echappant a la reponse immune par des anticorps optimises
KR100960560B1 (ko) 2002-09-27 2010-06-03 젠코어 인코포레이티드 최적화된 Ｆｃ 변이체 및 그의 제조 방법
US20040115204A1 (en) * 2002-12-11 2004-06-17 Fanger Gary R. Antibodies to treat cancer
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US7332299B2 (en) 2003-02-20 2008-02-19 Glycofi, Inc. Endomannosidases in the modification of glycoproteins in eukaryotes
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
EP1616880A4 (en) 2003-03-13 2006-07-26 Chugai Pharmaceutical Co Ltd LIGAND WITH AGONISTIC ACTIVITY AGAINST A MUTED RECEPTOR
JP2007527696A (ja) * 2003-04-03 2007-10-04 ラボラトワール フランセ デュ フラクションヌメント エ デ バイオテクノロジーズ 細胞機能を調節する能力が増強された治療産物
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
EP2228445A1 (en) * 2003-06-18 2010-09-15 Chugai Seiyaku Kabushiki Kaisha Fucose Transporter
WO2005005636A1 (ja) 2003-07-15 2005-01-20 Chugai Seiyaku Kabushiki Kaisha 形質転換細胞によるIｇMの産生とその定量方法
FR2858235B1 (fr) * 2003-07-31 2006-02-17 Lab Francais Du Fractionnement Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs
EP2311468B1 (en) 2003-08-08 2014-01-15 Perseus Proteomics Inc. Gene overexpressed in cancer
JPWO2005014651A1 (ja) 2003-08-11 2006-11-24 中外製薬株式会社 糖鎖改変抗ｈｍ１．２４抗体
US8883147B2 (en) 2004-10-21 2014-11-11 Xencor, Inc. Immunoglobulins insertions, deletions, and substitutions
US8399618B2 (en) 2004-10-21 2013-03-19 Xencor, Inc. Immunoglobulin insertions, deletions, and substitutions
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
US20050287138A1 (en) * 2003-10-08 2005-12-29 Kyowa Hakko Kogyo Co., Ltd. CCR4-specific antibody composition
WO2005035582A1 (ja) * 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Ｃｃｒ４に特異的に結合する抗体組成物
EP1688439A4 (en) 2003-10-08 2007-12-19 Kyowa Hakko Kogyo Kk COMPOSITION OF CONDENSED PROTEINS
JPWO2005035583A1 (ja) * 2003-10-08 2007-11-22 協和醗酵工業株式会社 Ｉｌ−５受容体に特異的に結合する抗体組成物
US20050226867A1 (en) * 2003-10-08 2005-10-13 Kyowa Hakko Kogyo Co., Ltd. IL-5R-specific antibody composition
US20060021071A1 (en) * 2003-10-09 2006-01-26 Kyowa Hakko Kogyo Co., Ltd. Cell in which genome is modified
US7691810B2 (en) 2003-10-09 2010-04-06 Kyowa Hakko Kirin Co., Ltd Method of producing recombinant antithrombin III composition
WO2005035574A1 (ja) 2003-10-09 2005-04-21 Chugai Seiyaku Kabushiki Kaisha IgM高濃度安定化溶液
CA2542125A1 (en) * 2003-10-09 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Process for producing antibody composition by using rna inhibiting the function of .alpha.1,6-fucosyltransferase
CA2542121A1 (en) * 2003-10-09 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Genomically modified cell neutralized to serum-free system
JPWO2005035741A1 (ja) * 2003-10-09 2006-12-21 協和醗酵工業株式会社 ゲノムが改変された細胞
HRP20100303T1 (hr) 2003-11-05 2010-07-31 Roche Glycart Ag Cd20 antitijela s povećanim afinitetom vezivanja fc receptora i efektorskim djelovanjem
WO2005053742A1 (ja) * 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. 抗体組成物を含有する医薬
KR101225299B1 (ko) 2003-12-10 2013-01-24 메다렉스, 인코포레이티드 인터페론 알파 항체 및 그의 용도
EP2383295B1 (en) 2003-12-10 2015-03-11 E. R. Squibb & Sons, L.L.C. IP-10 antibodies and their uses
AU2004299053B2 (en) * 2003-12-15 2011-01-06 Alexion Pharmaceuticals, Inc. Novel anti-DC-SIGN antibodies
CN100467488C (zh) 2003-12-30 2009-03-11 默克专利有限公司 Il-7融合蛋白
JP2005224240A (ja) * 2004-01-13 2005-08-25 Kyowa Hakko Kogyo Co Ltd ノックアウト非ヒト動物から樹立された不死化細胞株
PT1706428E (pt) 2004-01-22 2009-12-29 Merck Patent Gmbh Anticorpos anticancerígenos com fixação de complemento reduzida
JP4932699B2 (ja) * 2004-03-17 2012-05-16 グライコフィ， インコーポレイテッド 真菌および酵母におけるシチジンモノホスフェート−シアル酸合成経路を操作する方法
EP2053062A1 (en) 2004-03-24 2009-04-29 Xencor, Inc. Immunoglobin variants outside the Fc region
MXPA06014067A (es) * 2004-06-04 2007-02-15 Genentech Inc Metodo para tratar lupus.
BRPI0510915A (pt) * 2004-06-04 2007-11-13 Genentech Inc método para o tratamento da esclerose múltipla e artigo manufaturado
EP1781705B1 (en) 2004-06-21 2014-10-08 Medarex, L.L.C. Interferon alpha receptor i antibodies and their uses
KR101300545B1 (ko) 2004-07-09 2013-09-02 츄가이 세이야꾸 가부시키가이샤 항 글리피칸 3 항체
CA2573505C (en) 2004-07-14 2013-06-25 Igeneon Krebs-Immuntherapie Forschungs-Und Entwicklungs-Ag N-glycosylated antibody
US20150010550A1 (en) 2004-07-15 2015-01-08 Xencor, Inc. OPTIMIZED Fc VARIANTS
ES2530340T3 (es) 2004-07-15 2015-03-02 Xencor Inc Variantes de Fc optimizadas
JP4733042B2 (ja) 2004-08-24 2011-07-27 中外製薬株式会社 抗グリピカン３抗体を用いたアジュバント療法
ZA200702335B (en) 2004-10-05 2009-05-27 Genentech Inc Method for treating vasculitis
UA93488C2 (uk) * 2004-10-26 2011-02-25 Чугаі Сейяку Кабусікі Кайся Композиція анти-гліпікан 3-антитіл, що мають модифікований цукровий ланцюг
EP2325206B1 (en) 2004-11-12 2014-03-19 Xencor, Inc. Fc variants with altered binding to fcrn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
JPWO2006067847A1 (ja) 2004-12-22 2008-06-12 中外製薬株式会社 フコーストランスポーターの機能が阻害された細胞を用いた抗体の作製方法
PL1871805T3 (pl) 2005-02-07 2020-03-31 Roche Glycart Ag Cząsteczki wiążące antygen, które wiążą egfr, wektory kodujące te cząsteczki oraz ich zastosowania
KR101289537B1 (ko) 2005-02-15 2013-07-31 듀크 유니버시티 항-ｃｄ19 항체 및 종양학에서 이의 용도
AU2006214032B2 (en) * 2005-02-18 2012-03-08 E. R. Squibb & Sons, L.L.C. Monoclonal antibodies against prostate specific membrane antigen (PSMA) lacking in fucosyl residues
CN119119271A (zh) 2005-03-23 2024-12-13 根马布股份公司 用于治疗多发性骨髓瘤的cd38抗体
EP1865981A2 (en) 2005-04-07 2007-12-19 Chiron Corporation Cacna1e in cancer diagnosis, detection and treatment
US20090220495A1 (en) 2005-04-07 2009-09-03 Abdallah Fanidi Cancer Related Genes (PRLR)
WO2006113665A2 (en) 2005-04-15 2006-10-26 Macrogenics, Inc. Covalent diabodies and uses thereof
EP1885755A4 (en) 2005-05-05 2009-07-29 Univ Duke CD19 ANTIBODY THERAPY FOR AUTOIMMUNE DISEASES
NZ563193A (en) 2005-05-09 2010-05-28 Ono Pharmaceutical Co Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
RU2007147426A (ru) 2005-05-20 2009-06-27 Дженентек, Инк. (Us) Предварительная обработка биологического образца, взятого у индивидуума с аутоиммунным заболеванием
AU2006261920A1 (en) 2005-06-23 2007-01-04 Medimmune, Llc Antibody formulations having optimized aggregation and fragmentation profiles
CN103172737A (zh) 2005-06-30 2013-06-26 Abbvie公司 Il-12/p40结合蛋白
UA99701C2 (ru) 2005-07-01 2012-09-25 Медарекс, Инк. Человеческое моноклональное антитело, которое специфически связывается с лигандом-1 запрограммированной гибели клеток (pd-l1)
EP2004695A2 (en) 2005-07-08 2008-12-24 Xencor, Inc. Optimized anti-ep-cam antibodies
EP2573114B1 (en) 2005-08-10 2016-03-30 MacroGenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
JP5364870B2 (ja) 2005-08-19 2013-12-11 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2500359A3 (en) 2005-08-19 2012-10-17 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
TWI615407B (zh) 2005-08-26 2018-02-21 羅齊克雷雅公司 具有經改變細胞傳訊活性之改質抗原結合分子
MX2008003054A (es) * 2005-08-31 2008-03-25 Centocor Inc Lineas de celulas hospederas para la produccion de la region constante de anticuerpos, con fusion efectora mejorada.
CA2620515A1 (en) * 2005-09-02 2007-03-08 Glycofi, Inc. Immunoglobulins comprising predominantly a glcnacman3glcnac2 glycoform
CA2620713A1 (en) * 2005-09-09 2007-03-15 Glycofi, Inc. Immunoglobulin comprising predominantly a man7glcnac2, man8glcnac2 glycoform
ES2542501T3 (es) 2005-09-30 2015-08-06 Abbvie Deutschland Gmbh & Co Kg Dominios de unión de proteínas de la familia de proteínas de moléculas de orientación repulsiva (RGM) y fragmentos funcionales de las mismas, así como su uso
CA2624189A1 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
JP4860703B2 (ja) 2005-10-06 2012-01-25 ゼンコー・インコーポレイテッド 最適化された抗ｃｄ３０抗体
US20070087005A1 (en) 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
WO2007046439A1 (ja) 2005-10-18 2007-04-26 National Institute Of Agrobiological Sciences 抗体を産生するトランスジェニックカイコとその製造方法
JP5006330B2 (ja) 2005-10-21 2012-08-22 ノバルティス アーゲー Ｉｌ１３に対するヒト抗体および治療的使用
DK1945665T3 (da) 2005-10-21 2012-02-06 Genzyme Corp Antistof-baserede terapimidler med forhøjet ADCC-aktivitet
FR2892724B1 (fr) * 2005-11-02 2008-01-04 Lab Francais Du Fractionnement Anticorps cytotoxiques diriges contre des anticorps inhibiteurs du facteur viii.
EP1957099B1 (en) * 2005-11-07 2015-03-25 The Rockefeller University Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
PT1954718E (pt) 2005-11-30 2014-12-16 Abbvie Inc Anticorpos anti-globulómeros aβ, suas porções de ligação ao antigénio, correspondentes hibridomas, ácidos nucleicos, vectores, células hospedeiras, métodos de produção dos ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos para uso dos ditos anticorpos
WO2007064972A2 (en) 2005-11-30 2007-06-07 Abbott Laboratories Monoclonal antibodies against amyloid beta protein and uses thereof
AU2006342792A1 (en) 2005-12-02 2007-11-08 Genentech, Inc. Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to IL-22 and IL-22R
SG174783A1 (en) 2005-12-08 2011-10-28 Medarex Inc Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1 antibodies
ES2426468T3 (es) 2005-12-30 2013-10-23 Merck Patent Gmbh Anticuerpos anti-CD19 con inmunogenicidad reducida
BRPI0620648B1 (pt) 2005-12-30 2022-12-20 Merck Patent Gesellschaft Mit Beschrãnkter Haftung Variante de il-12 p40, proteínas il-12, il-23 e de fusão, composição farmacêutica e uso da mesma
KR20080085080A (ko) * 2006-01-04 2008-09-22 노파르티스 아게 항체-의존성 세포 세포독성 분석법
ES2526204T3 (es) 2006-01-05 2015-01-08 Genentech, Inc. Anticuerpos anti-EphB4 y métodos para usar los mismos
US20090060921A1 (en) * 2006-01-17 2009-03-05 Biolex Therapeutics, Inc. Glycan-optimized anti-cd20 antibodies
AU2007205939B2 (en) 2006-01-17 2012-12-13 Synthon Biopharmaceuticals B.V. Compositions and methods for humanization and optimization of N-glycans in plants
US7964191B2 (en) 2006-02-02 2011-06-21 Allergan, Inc. Compositions and methods for the treatment of ophthalmic disease
EP2540741A1 (en) 2006-03-06 2013-01-02 Aeres Biomedical Limited Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
AR059851A1 (es) 2006-03-16 2008-04-30 Genentech Inc Anticuerpos de la egfl7 y metodos de uso
EP2389949A1 (en) 2006-03-23 2011-11-30 Novartis AG Anti-tumor cell antigen antibody therapeutics
US20080014203A1 (en) * 2006-04-11 2008-01-17 Silke Hansen Antibodies against insulin-like growth factor I receptor and uses thereof
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
CN103030696B (zh) 2006-05-30 2016-09-28 健泰科生物技术公司 抗体和免疫偶联物及其用途
SG175615A1 (en) 2006-06-06 2011-11-28 Genentech Inc Anti-dll4 antibodies and methods using same
RU2008152435A (ru) * 2006-06-06 2010-07-20 Дженентек, Инк. (Us) Композиции и способы регулирования развития сосудов
EP1878747A1 (en) 2006-07-11 2008-01-16 greenovation Biotech GmbH Glyco-engineered antibodies
WO2008011081A2 (en) 2006-07-19 2008-01-24 The Trustees Of The University Of Pennsylvania Wsx-1/p28 as a target for anti-inflammatory responses
AR062223A1 (es) 2006-08-09 2008-10-22 Glycart Biotechnology Ag Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
SI2059536T1 (sl) 2006-08-14 2014-06-30 Xencor, Inc. Optimirana protitelesa, ki ciljajo CD19
EP2548576B1 (en) 2006-08-14 2016-11-30 Chugai Seiyaku Kabushiki Kaisha Diagnosis of cancer using anti-desmoglein-3 antibodies
CN101627055A (zh) 2006-09-05 2010-01-13 梅达雷克斯公司 骨形成蛋白及其受体的抗体以及它们的使用方法
CA2662701C (en) 2006-09-08 2015-12-08 Abbott Laboratories Interleukin-13 binding proteins
EP2066349B1 (en) 2006-09-08 2012-03-28 MedImmune, LLC Humanized anti-cd19 antibodies and their use in treatment of tumors, transplantation and autoimmune diseases
PT2073842E (pt) 2006-09-10 2015-04-07 Glycotope Gmbh Utilização de células humanas provenientes de uma leucemia mielóide para expressão de anticorpos
AU2007299843B2 (en) 2006-09-18 2012-03-08 Xencor, Inc Optimized antibodies that target HM1.24
HUE027165T2 (en) 2006-10-02 2016-08-29 Squibb & Sons Llc Human antibodies that bind to CXCR4 and their uses
CN103396486A (zh) 2006-10-12 2013-11-20 中外制药株式会社 使用抗ereg抗体的癌症的诊断和治疗
CA2665644A1 (en) 2006-10-12 2008-05-29 Genentech, Inc. Antibodies to lymphotoxin-alpha
CA2666559A1 (en) 2006-10-20 2008-04-24 Forerunner Pharma Research Co., Ltd. Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient
ES2387924T3 (es) 2006-10-27 2012-10-04 Genentech, Inc. Anticuerpos e inmunoconjugados y usos para los mismos
US8618248B2 (en) 2006-10-31 2013-12-31 President And Fellows Of Harvard College Phosphopeptide compositions and anti-phosphopeptide antibody compositions and methods of detecting phosphorylated peptides
KR20090088891A (ko) 2006-11-15 2009-08-20 메다렉스, 인코포레이티드 비티엘에이에 대한 인간 단일클론 항체 및 이용 방법
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
ES2678060T3 (es) 2006-12-01 2018-08-08 E. R. Squibb & Sons, L.L.C. Anticuerpos, en particular, anticuerpos humanos, que se unen a CD22 y usos de los mismos
US20080127996A1 (en) * 2006-12-04 2008-06-05 Weinhold Dennis G Method and apparatus to remediate an acid and/or liquid spill
CL2007003622A1 (es) 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
CA2672581A1 (en) 2006-12-14 2008-06-19 Forerunner Pharma Research Co., Ltd. Anti-claudin 3 monoclonal antibody and treatment and diagnosis of cancer using the same
US20100150950A1 (en) 2006-12-14 2010-06-17 Medarex, Inc. Human antibodies that bind cd70 and uses thereof
US9127064B2 (en) 2006-12-21 2015-09-08 Novo Nordisk A/S Antibodies against human NKG2D and uses thereof
JPWO2008090960A1 (ja) 2007-01-24 2010-05-20 協和発酵キリン株式会社 ガングリオシドｇｍ２に特異的に結合する遺伝子組換え抗体組成物
JP2010518115A (ja) 2007-02-09 2010-05-27 ジェネンテック， インコーポレイテッド 抗Ｒｏｂｏ４抗体およびそれらのための使用
EP3118221B1 (en) 2007-02-26 2019-08-21 Oxford BioTherapeutics Ltd Proteins
WO2008104803A2 (en) 2007-02-26 2008-09-04 Oxford Genome Sciences (Uk) Limited Proteins
EP2486928A1 (en) 2007-02-27 2012-08-15 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
JP2010519930A (ja) * 2007-03-07 2010-06-10 グライコフィ， インコーポレイテッド 糖タンパク質の修飾フコシル化を用いる産生
EP2136838B1 (en) 2007-03-08 2017-03-08 KaloBios Pharmaceuticals, Inc. Epha3 antibodies for the treatment of solid tumors
EP2737907A3 (en) 2007-05-07 2014-11-05 MedImmune, LLC Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
DK2068927T3 (da) 2007-05-14 2016-01-18 Medimmune Llc Fremgangsmåder til reducering af eosinofilniveauer
US8063187B2 (en) 2007-05-30 2011-11-22 Xencor, Inc. Methods and compositions for inhibiting CD32B expressing cells
EP3424951A1 (en) 2007-06-21 2019-01-09 MacroGenics, Inc. Covalent diabodies and uses thereof
WO2009001840A1 (ja) 2007-06-25 2008-12-31 Forerunner Pharma Research Co., Ltd. ADCC活性又はCDC活性を有する抗Prominin-1抗体
US8546546B2 (en) 2007-07-04 2013-10-01 Forerunner Pharma Research Co., Ltd. Anti-Muc 17 antibody
EP2178916B1 (en) * 2007-07-31 2014-12-17 Regeneron Pharmaceuticals, Inc. Human antibodies to human cd20 and method of using thereof
EP2069401A4 (en) 2007-07-31 2011-02-23 Medimmune Llc MULTISPECIENT EPITOP BINDING PROTEINS AND THEIR USE
US8501907B2 (en) 2007-08-10 2013-08-06 Janssen Biotech, Inc. Immunoglobulin cleavage fragments as disease indicators and compositions for detecting and binding such
ES2537580T3 (es) 2007-09-04 2015-06-09 Compugen Ltd. Polipéptidos y polinucleótidos, y usos de los mismos como una diana farmacológica para producir fármacos y agentes biológicos
CA3222170A1 (en) 2007-09-26 2009-04-02 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
WO2009045894A1 (en) 2007-09-28 2009-04-09 Centocor, Inc. Methods and structural conformations of antibody preparations with increased resistance to proteases
CA2700986A1 (en) * 2007-09-28 2009-04-02 Chugai Seiyaku Kabushiki Kaisha Anti-glypican-3 antibody having improved kinetics in plasma
AR068767A1 (es) 2007-10-12 2009-12-02 Novartis Ag Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
ES2560532T3 (es) 2007-11-02 2016-02-19 Novartis Ag Moléculas y métodos de modulación de la proteína 6 relacionada con el receptor de lipoproteína de baja densidad (LRP6)
MX373155B (es) 2007-11-07 2020-04-21 Genentech Inc Composiciones y metodos para el tratamiento de trastornos microbianos.
JP5676107B2 (ja) 2007-11-14 2015-02-25 中外製薬株式会社 抗ｇｐｒ４９抗体を用いる癌の診断および治療
AR069501A1 (es) 2007-11-30 2010-01-27 Genentech Inc Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
BRPI0822099A2 (pt) 2007-12-21 2017-05-23 Medimmune Ltd membro de ligação isolado, uso de um membro de ligação isolado, método parav tratar um distúrbio, molécula de ácido nucléico isolada, célula hospedeira, e, método para produzir um membro de ligação
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
CA2703997C (en) 2007-12-26 2017-04-04 Xencor, Inc. Fc variants with altered binding to fcrn
JP5848863B2 (ja) 2008-01-11 2016-01-27 国立大学法人 東京大学 抗ｃｌｄｎ６抗体
US20110033378A1 (en) 2008-01-18 2011-02-10 Medlmmune, Llc. Cysteine Engineered Antibodies For Site-Specific Conjugation
BRPI0906387A2 (pt) 2008-02-05 2015-07-07 Bristol Myers Squibb Co Anticorpos alfa 5 - beta 1 e seus usos
PT2250279E (pt) 2008-02-08 2016-06-03 Medimmune Llc Anticorpos anti-ifnár1 com afinidade reduzida para o ligando fc
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
PT2247304T (pt) 2008-04-02 2016-08-29 Macrogenics Inc Anticorpos especificos de her2/neu e métodos de utilização dos mesmos
JP5785490B2 (ja) 2008-04-02 2015-09-30 マクロジェニクス，インコーポレーテッド Ｂｃｒ複合体特異的抗体およびその使用方法
CL2009000647A1 (es) 2008-04-04 2010-06-04 Chugai Pharmaceutical Co Ltd Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.
SI2708559T1 (en) 2008-04-11 2018-07-31 Chugai Seiyaku Kabushiki Kaisha An antigen-binding molecule capable of repeatably binding to two or more antigenic molecules
JP5522405B2 (ja) 2008-04-25 2014-06-18 協和発酵キリン株式会社 安定な多価抗体
EP2899209A1 (en) 2008-04-29 2015-07-29 Abbvie Inc. Dual Variable Domain Immunoglobulins and uses thereof
EP2274331B1 (en) 2008-05-02 2013-11-06 Novartis AG Improved fibronectin-based binding molecules and uses thereof
MX2010012142A (es) 2008-05-09 2011-04-05 Abbott Gmbh & Co Kg Anticuerpos para receptor de productos finales de glucacion avanzada (rage) y usos de los mismos.
EP2283862B1 (en) 2008-06-02 2018-08-08 The University of Tokyo Combination treatment of cancer comprising anti-mfg-e8 antibody
KR20110016958A (ko) 2008-06-03 2011-02-18 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
UY31861A (es) 2008-06-03 2010-01-05 Abbott Lab Inmunoglobulina con dominio variable dual y usos de la misma
WO2010033279A2 (en) 2008-06-04 2010-03-25 Macrogenics, Inc. Antibodies with altered binding to fcrn and methods of using same
US9023999B2 (en) 2008-06-30 2015-05-05 Kyowa Hakko Kirin Co., Ltd Anti-CD27 antibody
KR101054362B1 (ko) * 2008-07-03 2011-08-05 재단법인 목암생명공학연구소 재조합 단백질의 푸코스 함량을 감소시키는 방법
EP2310049A4 (en) 2008-07-08 2013-06-26 Abbvie Inc PROSTAGLANDIN E2 BINDING PROTEINS AND USES THEREOF
US8822645B2 (en) 2008-07-08 2014-09-02 Abbvie Inc. Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
KR20160039295A (ko) 2008-08-05 2016-04-08 도레이 카부시키가이샤 암의 검출 방법
RS54113B1 (en) 2008-08-05 2015-12-31 Novartis Ag COMPOSITIONS AND PROCEDURES FOR ANTIBODIES ON THE C5 COMPLEMENTARY PROTEIN
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
WO2010018846A1 (ja) * 2008-08-13 2010-02-18 協和発酵キリン株式会社 ガングリオシドgm2に特異的に結合する抗体組成物を含む医薬
TW201438738A (zh) 2008-09-16 2014-10-16 Genentech Inc 治療進展型多發性硬化症之方法
ES2727677T3 (es) 2008-09-17 2019-10-17 Xencor Inc Composiciones y métodos para el tratamiento de trastornos mediados por IgE
KR20110057244A (ko) 2008-09-19 2011-05-31 메디뮨 엘엘씨 Ｄｌｌ4에 대한 항체 및 이의 용도
CN102216452B (zh) 2008-09-26 2013-08-21 尤里卡治疗公司 具有变异糖基化方式的细胞系和蛋白质
KR102100066B1 (ko) * 2008-10-14 2020-04-10 제넨테크, 인크. 이뮤노글로불린 변이체 및 그의 용도
BRPI0921845A2 (pt) 2008-11-12 2019-09-17 Medimmune Llc formulação aquosa estéril estável, forma de dosagem unitária farmacêutica, seringa pré-carregada, e, métodos para tratar uma doença ou distúrbio, para tratar ou prevenir rejeição, para esgotar células t que expressam icos em um paciente humano, e para interromper arquitetura central germinal em um órgão linfóide secundário de um primata
CA2745492A1 (en) 2008-12-08 2010-06-17 Compugen Ltd. A polyclonal or monoclonal antibody or antibody binding fragment that binds to a tmem154 polypeptide
GB2466025A (en) 2008-12-08 2010-06-09 Univ Francois Rabelais De Tour C3/ITGAM polymorphisms and cancer prognosis
MX2011006416A (es) 2008-12-19 2011-07-12 Macrogenics Inc Diacuerpos covalentes y sus usos.
EP2388320B1 (en) 2008-12-22 2017-02-15 Chugai Seiyaku Kabushiki Kaisha Anti-hs6st2 antibodies and uses thereof
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
EP2382234A2 (en) 2008-12-23 2011-11-02 Genentech, Inc. Immunoglobulin variants with altered binding to protein a
WO2010073694A1 (ja) 2008-12-25 2010-07-01 国立大学法人東京大学 抗tm4sf20抗体を用いた癌の診断と治療
CN102395603A (zh) 2008-12-26 2012-03-28 国立大学法人东京大学 使用抗lgr7抗体的癌症的诊断和治疗
EP2374883B1 (en) 2008-12-26 2016-08-10 Kyowa Hakko Kirin Co., Ltd. Anti-cd4 antibody
WO2010081890A1 (en) 2009-01-19 2010-07-22 Innate Pharma Anti-kir3d antibodies
CA2750581A1 (en) 2009-01-21 2010-07-29 Oxford Biotherapeutics Ltd. Pta089 protein
US8030026B2 (en) 2009-02-24 2011-10-04 Abbott Laboratories Antibodies to troponin I and methods of use thereof
DK2403878T3 (en) 2009-03-05 2017-09-18 Squibb & Sons Llc CADM1-SPECIFIC FULLY HUMAN ANTIBODIES
NZ594514A (en) 2009-03-05 2013-06-28 Abbott Lab Interleukin-17 BINDING PROTEINS
US8834870B2 (en) 2009-03-06 2014-09-16 Kalobios Pharmaceuticals, Inc. Treatment of leukemias and chronic myeloproliferative diseases with antibodies to EphA3
US8283162B2 (en) 2009-03-10 2012-10-09 Abbott Laboratories Antibodies relating to PIVKAII and uses thereof
MA33198B1 (fr) 2009-03-20 2012-04-02 Genentech Inc Anticorps anti-her di-spécifiques
EP2233500A1 (en) 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
KR101822663B1 (ko) 2009-03-25 2018-01-29 제넨테크, 인크. 항-ｆｇｆｒ３ 항체 및 그의 사용 방법
CN103755808B (zh) 2009-03-25 2016-02-10 霍夫曼-拉罗奇有限公司 抗-α5β1抗体及其应用
AR075982A1 (es) 2009-03-31 2011-05-11 Roche Glycart Ag Terapia de combinacion de un anticuerpo afucosilado y una o mas de las citoquinas seleccionadas de gm- csf humano, m -csf humano y/o il-3 humano y composicion
MX2011010159A (es) 2009-04-02 2011-10-17 Roche Glycart Ag Anticuerpos multiespecificos que comprenden anticuerpos de longitud completa y fragmentos fab de cadena sencilla.
WO2010115552A1 (en) 2009-04-07 2010-10-14 Roche Glycart Ag Bispecific anti-erbb-3/anti-c-met antibodies
BRPI1014449A2 (pt) 2009-04-07 2017-06-27 Roche Glycart Ag anticorpos biespecíficos anti-erbb-2/ anti-c-met.
JP5616428B2 (ja) 2009-04-07 2014-10-29 ロシュ グリクアート アクチェンゲゼルシャフト 三価の二重特異性抗体
JP5653909B2 (ja) 2009-04-09 2015-01-14 第一三共株式会社 抗Ｓｉｇｌｅｃ−１５抗体
US8647623B2 (en) 2009-04-10 2014-02-11 Kyowa Hakko Kirin Co., Ltd Method for treatment of blood tumor using anti-TIM-3 antibody
EP2420515A4 (en) 2009-04-16 2013-08-28 Univ Tokyo DIAGNOSIS AND TREATMENT OF CANCER WITH ANTI-TMPRSS11E ANTIBODY
JP5694921B2 (ja) 2009-04-20 2015-04-01 協和発酵キリン株式会社 アミノ酸変異が導入されたＩｇＧ２を有する抗体
CN106188295A (zh) 2009-04-20 2016-12-07 牛津生物疗法有限公司 特异于钙粘素‑17的抗体
EP2426148B1 (en) 2009-04-27 2015-08-05 Kyowa Hakko Kirin Co., Ltd. Anti-il-3ra antibody for use in treatment of blood tumor
AU2010230311B9 (en) 2009-04-27 2012-09-20 Novartis Ag Composition and methods of use for therapeutic antibodies specific for the IL-12 receptore betal subunit
BRPI1014522B8 (pt) 2009-04-27 2021-05-25 Novartis Ag anticorpo anti-actriib ou fragmento funcional, processo de produção dos mesmos, composição farmacêutica e usos
JP5723270B2 (ja) * 2009-05-01 2015-05-27 国立大学法人 東京大学 抗カドヘリン抗体
EP2431393B1 (en) 2009-05-15 2018-05-02 Chugai Seiyaku Kabushiki Kaisha Anti-axl antibody
CA2761233A1 (en) 2009-05-27 2010-12-02 F. Hoffmann-La Roche Ag Tri- or tetraspecific antibodies
US8815242B2 (en) * 2009-05-27 2014-08-26 Synageva Biopharma Corp. Avian derived antibodies
US20120141501A1 (en) 2009-05-29 2012-06-07 Forerunner Pharma Research Co. Ltd Pharmaceutical Composition Containing Antagonist of EGF Family Ligand as Component
PL3279326T3 (pl) 2009-06-02 2021-03-08 Regeneron Pharmaceuticals, Inc. Komórki z deficytem fukozylacji
SG177247A1 (en) 2009-06-11 2012-02-28 Kek High Energy Accelerator Process for production of protein
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US20100316639A1 (en) 2009-06-16 2010-12-16 Genentech, Inc. Biomarkers for igf-1r inhibitor therapy
MX337468B (es) 2009-06-18 2016-03-02 Pfizer Anticuerpos anti notch-1.
RU2012101999A (ru) 2009-06-22 2013-07-27 МЕДИММЬЮН, ЭлЭлСи РЕКОМБИНАНТНЫЕ УЧАСТКИ Fc ДЛЯ САЙТ-СПЕЦИФИЧЕСКОЙ КОНЪЮГАЦИИ
AR077595A1 (es) 2009-07-27 2011-09-07 Genentech Inc Tratamientos de combinacion
EP3199551A3 (en) 2009-07-31 2017-10-18 E. R. Squibb & Sons, L.L.C. Fully human antibodies to btla
SG178177A1 (en) 2009-07-31 2012-03-29 Genentech Inc Inhibition of tumor metastasis using bv8- or g-csf-antagonists
CN102597234B (zh) 2009-08-07 2014-10-29 协和发酵麒麟株式会社 人源化抗淀粉样-b寡聚体抗体
JP5692073B2 (ja) 2009-08-07 2015-04-01 協和発酵キリン株式会社 抗アミロイドβオリゴマーヒト化抗体
TWI409079B (zh) 2009-08-14 2013-09-21 Roche Glycart Ag 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法
AU2010281867A1 (en) 2009-08-14 2012-02-02 Roche Glycart Ag Combination therapy of an afucosylated CD20 antibody with fludarabine and/or mitoxantrone
CA2771436A1 (en) 2009-08-17 2011-02-24 Forerunner Pharma Research Co., Ltd. Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient
WO2011021146A1 (en) 2009-08-20 2011-02-24 Pfizer Inc. Osteopontin antibodies
TW201113037A (en) 2009-08-28 2011-04-16 Hoffmann La Roche Antibodies against CDCP1 for the treatment of cancer
TWI412375B (zh) 2009-08-28 2013-10-21 Roche Glycart Ag 人類化抗ｃｄｃｐ１抗體
SG178567A1 (en) 2009-08-31 2012-04-27 Roche Glycart Ag Affinity-matured humanized anti cea monoclonal antibodies
MX2012002651A (es) 2009-09-01 2012-05-22 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
ES2599076T3 (es) 2009-09-02 2017-01-31 Genentech, Inc. Smoothened mutante y métodos de utilización del mismo
WO2011029823A1 (en) 2009-09-09 2011-03-17 Novartis Ag Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells
KR20120108967A (ko) 2009-09-16 2012-10-05 제넨테크, 인크. 코일드 코일 및/또는 테더 함유 단백질 복합체 및 그의 용도
BR112012006388B1 (pt) 2009-09-22 2022-01-04 Probiogen Ag Método para produzir uma molécula, e, método para produzir uma proteína
LT2486141T (lt) 2009-10-07 2018-05-25 Macrogenics, Inc. Fc regioną turintys polipeptidai, pasižymintys pagerinta efektorine funkcija dėl fukozilinimo laipsnio pasikeitimų, ir jų naudojimo būdai
EP2470569A1 (en) 2009-10-13 2012-07-04 Oxford Biotherapeutics Ltd. Antibodies against epha10
PT2488554T (pt) 2009-10-14 2019-09-13 Humanigen Inc Anticorpos para epha3
CN102666875A (zh) 2009-10-15 2012-09-12 雅培制药有限公司 双重可变结构域免疫球蛋白及其用途
US8435511B2 (en) 2009-10-22 2013-05-07 Genentech, Inc. Anti-hepsin antibodies and methods using same
AR078751A1 (es) 2009-10-23 2011-11-30 Millennium Pharm Inc Moleculas de anticuerpo anti-gcc (guanililo ciclasa c) y composiciones y metodos relacionados
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
SG10201510640QA (en) 2009-10-26 2016-01-28 Hoffmann La Roche Method For The Production Of A Glycosylated Immunoglobulin
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
MX2012005006A (es) 2009-10-29 2012-06-19 Janssen Biotech Inc Variantes de glicosilacion de anticuerpos.
WO2011051327A2 (en) 2009-10-30 2011-05-05 Novartis Ag Small antibody-like single chain proteins
TW201121568A (en) 2009-10-31 2011-07-01 Abbott Lab Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
US20120282177A1 (en) 2009-11-02 2012-11-08 Christian Rohlff ROR1 as Therapeutic and Diagnostic Target
WO2011051466A1 (en) 2009-11-02 2011-05-05 Novartis Ag Anti-idiotypic fibronectin-based binding molecules and uses thereof
EP2496600A1 (en) 2009-11-04 2012-09-12 Fabrus LLC Methods for affinity maturation-based antibody optimization
ES2784123T3 (es) 2009-11-04 2020-09-22 Merck Sharp & Dohme Anticuerpo anti TSLP genomodificado
RU2585488C2 (ru) 2009-11-05 2016-05-27 Дженентек, Инк. Способы и композиция для секреции гетерологичных полипептидов
PL2504364T3 (pl) 2009-11-24 2017-12-29 Medimmune Limited Ukierunkowane środki wiążące przeciwko B7-H1
US9428586B2 (en) 2009-12-01 2016-08-30 Compugen Ltd Heparanase splice variant
AU2010329955A1 (en) 2009-12-08 2012-05-24 Abbott Gmbh & Co. Kg Monoclonal antibodies against the RGM A protein for use in the treatment of retinal nerve fiber layer degeneration
WO2011071577A1 (en) 2009-12-11 2011-06-16 Genentech, Inc. Anti-vegf-c antibodies and methods using same
US20130011401A1 (en) 2009-12-22 2013-01-10 Novartis Ag Soluble proteins for use as therapeutics
SG181894A1 (en) 2009-12-22 2012-08-30 Roche Glycart Ag Anti-her3 antibodies and uses thereof
NZ600826A (en) 2009-12-23 2014-09-26 Genentech Inc Anti-bv8 antibodies and uses thereof
WO2011091078A2 (en) 2010-01-19 2011-07-28 Xencor, Inc. Antibody fc variants with enhanced complement activity
WO2011092233A1 (en) 2010-01-29 2011-08-04 Novartis Ag Yeast mating to produce high-affinity combinations of fibronectin-based binders
EP2530091B1 (en) 2010-01-29 2018-04-04 Chugai Seiyaku Kabushiki Kaisha Anti-dll3 antibody
WO2011097527A2 (en) 2010-02-04 2011-08-11 Xencor, Inc. Immunoprotection of therapeutic moieties using enhanced fc regions
CN102770767A (zh) 2010-02-10 2012-11-07 诺瓦提斯公司 用于肌肉生长的方法和组合物
CA2789629A1 (en) 2010-02-10 2011-08-18 Immunogen, Inc. Cd20 antibodies and uses thereof
RS57008B1 (sr) 2010-02-10 2018-05-31 Fujifilm Ri Pharma Co Ltd Anti-kadherin antitelo obeleženo radioaktivnim metalom
ES2519348T3 (es) 2010-02-18 2014-11-06 Genentech, Inc. Antagonistas de neurregulina y uso de los mismos en el tratamiento del cáncer
US20110200595A1 (en) 2010-02-18 2011-08-18 Roche Glycart TREATMENT WITH A HUMANIZED IgG CLASS ANTI EGFR ANTIBODY AND AN ANTIBODY AGAINST INSULIN LIKE GROWTH FACTOR 1 RECEPTOR
EP2536761B1 (en) 2010-02-19 2017-09-20 The Board Of Regents Of The University Of Oklahoma Monoclonal antibodies that inhibit the wnt signaling pathway and methods of production and use thereof
US20120321557A1 (en) 2010-02-26 2012-12-20 Forerunner Pharma Research Co., Ltd. Anti-icam3 antibody and use thereof
CN102782131B (zh) 2010-03-02 2015-08-05 协和发酵麒麟株式会社 修饰抗体组合物
EP2542256B1 (en) 2010-03-04 2019-05-22 MacroGenics, Inc. Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
GB201003701D0 (en) 2010-03-05 2010-04-21 Cilian Ag System for the expression of a protein
JP6093692B2 (ja) 2010-03-24 2017-03-08 ジェネンテック， インコーポレイテッド 抗ｌｒｐ６抗体
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
WO2011118739A1 (ja) 2010-03-26 2011-09-29 協和発酵キリン株式会社 新規修飾部位導入抗体および抗体フラグメント
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
CA3079122A1 (en) 2010-03-26 2011-09-29 Trustees Of Dartmouth College Vista regulatory t cell mediator protein, vista binding agents and use thereof
US20130108623A1 (en) 2010-03-29 2013-05-02 Zymeworks Inc Antibodies with Enhanced or Suppressed Effector Function
TWI667346B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
EP4501956A2 (en) 2010-03-30 2025-02-05 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecules that promote antigen clearance
WO2011130377A2 (en) 2010-04-15 2011-10-20 Abbott Laboratories Amyloid-beta binding proteins
EP2563391B1 (en) 2010-04-27 2020-08-26 Roche Glycart AG Combination therapy of an afucosylated cd20 antibody with a mtor inhibitor
JP2013527761A (ja) 2010-05-06 2013-07-04 ノバルティス アーゲー 治療的低密度リポタンパク質関連タンパク質６（ｌｒｐ６）多価抗体の組成物および使用方法
ES2949159T3 (es) 2010-05-06 2023-09-26 Novartis Ag Composiciones y métodos de uso para anticuerpos terapéuticos de proteína 6 relacionada con lipoproteínas de baja densidad (LRP6)
TWI615405B (zh) 2010-05-14 2018-02-21 艾伯維有限公司 Ｉｌ-１結合蛋白
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
US9169329B2 (en) 2010-06-01 2015-10-27 Ludwig Institute For Cancer Research Antibodies directed to the receptor tyrosine kinase c-Met
BR112012029866A2 (pt) 2010-06-03 2017-03-07 Genentech Inc método para a determinação da presença de uma proteína steap-1
TR201807750T4 (tr) 2010-06-11 2018-06-21 Kyowa Hakko Kirin Co Ltd Anti-TIM-3 antikoru.
JP5940061B2 (ja) 2010-06-18 2016-06-29 ジェネンテック， インコーポレイテッド 抗ａｘｌ抗体及び使用方法
WO2011160119A2 (en) 2010-06-19 2011-12-22 Memorial Sloan-Kettering Cancer Center Anti-gd2 antibodies
WO2011161119A1 (en) 2010-06-22 2011-12-29 F. Hoffmann-La Roche Ag Antibodies against insulin-like growth factor i receptor and uses thereof
EP2585476A4 (en) 2010-06-22 2014-01-22 Neogenix Oncology Inc ANTIGENS AND ANTIBODIES SPECIFIC TO COLON AND PANCREATIC CANCER
WO2011161189A1 (en) 2010-06-24 2011-12-29 F. Hoffmann-La Roche Ag Anti-hepsin antibodies and methods of use
US9534246B2 (en) 2010-07-01 2017-01-03 Glaxo Group Limited Method for selecting high producing cell lines
WO2012006500A2 (en) 2010-07-08 2012-01-12 Abbott Laboratories Monoclonal antibodies against hepatitis c virus core protein
JP5619162B2 (ja) 2010-07-08 2014-11-05 本田技研工業株式会社 高周波加熱用コイル
AU2011274528B2 (en) 2010-07-09 2015-04-23 Genentech, Inc. Anti-neuropilin antibodies and methods of use
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2012010582A1 (en) 2010-07-21 2012-01-26 Roche Glycart Ag Anti-cxcr5 antibodies and methods of use
US9120862B2 (en) 2010-07-26 2015-09-01 Abbott Laboratories Antibodies relating to PIVKA-II and uses thereof
DK3029066T3 (da) 2010-07-29 2019-05-20 Xencor Inc Antistoffer med modificerede isoelektriske punkter
WO2012013823A2 (en) 2010-07-30 2012-02-02 Glycode A yeast artificial chromosome carrying the mammalian glycosylation pathway
CN103154025B (zh) 2010-08-02 2015-07-01 宏观基因有限公司 共价双抗体及其用途
TW201206473A (en) 2010-08-03 2012-02-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
WO2012018771A1 (en) 2010-08-03 2012-02-09 Genentech, Inc. Chronic lymphocytic leukemia (cll) biomarkers
WO2012019061A2 (en) 2010-08-05 2012-02-09 Stem Centrx, Inc. Novel effectors and methods of use
BR112013002532A2 (pt) 2010-08-05 2016-05-31 Hoffmann La Roche proteína de fusão de citocina anti-viral do anticorpo anti-mhc
NO2603530T3 (browse.php) 2010-08-13 2018-04-07
BR112013002444A2 (pt) 2010-08-13 2016-05-24 Roche Glycart Ag anticorpo, polinucleotídeo e polipeotídeo isolados, composição, vetor, cécula hospedeira, conjulgado de anticorpo, formulação farmacêutica, uso do anticorpo, métodos para produzir um anticorpo, tratar um indivíduo, induzir a lise celular de uma célula tumorosa e diagnosticar uma doença em um indivíduo
CA2808187A1 (en) 2010-08-14 2012-02-23 Abbvie Inc. Amyloid-beta binding proteins
WO2012022734A2 (en) 2010-08-16 2012-02-23 Medimmune Limited Anti-icam-1 antibodies and methods of use
NZ604510A (en) 2010-08-17 2013-10-25 Csl Ltd Dilutable biocidal compositions and methods of use
TW201208703A (en) 2010-08-17 2012-03-01 Roche Glycart Ag Combination therapy of an afucosylated CD20 antibody with an anti-VEGF antibody
EP2606070B1 (en) 2010-08-20 2016-12-21 Novartis AG Antibodies for epidermal growth factor receptor 3 (her3)
MX340558B (es) 2010-08-24 2016-07-14 F Hoffmann-La Roche Ag * Anticuerpos biespecificos que comprenden fragmento fv estabilizado con disulfuro.
MX340555B (es) 2010-08-25 2016-07-14 F Hoffmann-La Roche Ag * Anticuerpos contra il-18r1 y usos de los mismos.
KR20130139884A (ko) 2010-08-26 2013-12-23 애브비 인코포레이티드 이원 가변 도메인 면역글로불린 및 이의 용도
CA2809369A1 (en) 2010-08-27 2012-03-01 Stem Centrx, Inc. Notum protein modulators and methods of use
BR112013004673A8 (pt) 2010-08-31 2018-01-02 Genentech Inc biomarcadores e métodos de tratamento.
KR20140014064A (ko) 2010-09-03 2014-02-05 스템 센트알엑스 인코포레이티드 신규한 조절 인자 및 사용 방법
EP2616100B1 (en) 2010-09-17 2016-08-31 Compugen Ltd. Compositions and methods for treatment of drug resistant multiple myeloma
CA2812556C (en) 2010-09-23 2023-02-14 Xue-Ping Wang Colon and pancreas cancer peptidomimetics
WO2012045085A1 (en) 2010-10-01 2012-04-05 Oxford Biotherapeutics Ltd. Anti-rori antibodies
CN103154037A (zh) 2010-10-05 2013-06-12 诺瓦提斯公司 抗IL12Rβ1抗体及它们在治疗自身免疫病和炎性疾病中的用途
AU2011312205B2 (en) 2010-10-05 2015-08-13 Curis, Inc. Mutant smoothened and methods of using the same
DK2636736T3 (en) 2010-10-29 2016-07-04 Daiichi Sankyo Co Ltd Novel anti-dr5 antibody
HUE047228T2 (hu) 2010-11-05 2020-04-28 Zymeworks Inc Stabil heterodimer antitest-kialakítás az FC doménben mutációval
PH12013500933A1 (en) 2010-11-10 2017-08-23 Genentech Inc Methods and compositions for neural disease immunotherapy
EP3318633A1 (en) 2010-11-17 2018-05-09 Chugai Seiyaku Kabushiki Kaisha Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
EP2640414A4 (en) * 2010-11-19 2016-06-15 Janssen Biotech Inc VACCINE COMPOSITIONS WITH IMMUNOGLOBULIN SPLITTING FRAGMENTS
EP2643018B1 (en) 2010-11-23 2020-10-14 AlderBio Holdings LLC Anti-il-6 antibodies for the treatment of oral mucositis
PH12013501036B1 (en) 2010-11-23 2019-05-10 Glaxo Group Ltd Antigen binding proteins to oncostatin m (osm)
KR20130121886A (ko) 2010-11-24 2013-11-06 글락소 그룹 리미티드 Ｈｇｆ를 표적으로 하는 다중특이적 항원 결합 단백질
TWI761912B (zh) 2010-11-30 2022-04-21 日商中外製藥股份有限公司 具有鈣依存性的抗原結合能力之抗體
CA2820885A1 (en) 2010-12-08 2012-09-07 Stem Centrx, Inc. Novel modulators and methods of use
KR101026999B1 (ko) 2010-12-08 2011-04-11 재단법인 목암생명공학연구소 재조합 단백질의 푸코스 함량을 감소시키는 방법
US9458240B2 (en) 2010-12-10 2016-10-04 Novartis Pharma Ag Anti-BAFFR antibody formulations
CN103261414A (zh) 2010-12-15 2013-08-21 大学共同利用机关法人情报·系统研究机构 蛋白质的生产方法
RU2622083C2 (ru) 2010-12-15 2017-06-09 ВАЙЕТ ЭлЭлСи Антитела против notch1
EP2653541B1 (en) 2010-12-15 2017-11-08 Kyowa Hakko Kirin Co., Ltd. Method for producing proteins
BR112013014522A2 (pt) 2010-12-16 2017-09-26 Roche Glycart Ag anticorpo anti-cd20 afucosilado e seu uso, composição e método para tratamento de um paciente que sofre de câncer
BR122020012255B1 (pt) 2010-12-16 2022-08-09 Genentech, Inc Uso de um anticorpo anti-il-13, usos de um inibidor da via de th2 e anticorpos anti-periostina
PH12013501323A1 (en) 2010-12-20 2013-08-28 Genentech Inc Anti-mesothelin antibodies and immunoconjugates
MY163368A (en) 2010-12-21 2017-09-15 Abbvie Inc Il-1-alpha and -beta bispecific dual variable domain immunoglobulins and their use
AU2011348232A1 (en) 2010-12-22 2013-07-18 Genentech, Inc. Anti-PCSK9 antibodies and methods of use
PH12013501332B1 (en) 2010-12-23 2019-01-16 Janssen Biotech Inc Active protease-resistant antibody fc mutants
WO2012085111A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
EP3763740A1 (en) 2011-01-26 2021-01-13 Celldex Therapeutics, Inc. Anti-kit antibodies and uses thereof
FR2971250A1 (fr) 2011-02-07 2012-08-10 Univ Nantes Anticorps anti-gb3 utiles dans le traitement des maladies associees a l'angiogenese
BR112013019083A2 (pt) 2011-02-10 2017-04-04 Roche Glycart Ag combinação de (a) um imunoconjugado, composição farmacêutica, uso de (a) um imunoconjugado, método de tratamento de uma doença em um individuo, método de estímulo de função celular efetora em um indivíduo e kit destinado ao tratamento de uma doença.
SA112330278B1 (ar) 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
CA2825081A1 (en) 2011-02-28 2012-09-07 Birgit Bossenmaier Antigen binding proteins
EP2681240B1 (en) 2011-02-28 2017-08-16 F. Hoffmann-La Roche AG Monovalent antigen binding proteins
WO2012117002A1 (en) 2011-03-02 2012-09-07 Roche Glycart Ag Cea antibodies
WO2012127045A1 (en) 2011-03-23 2012-09-27 Glycode A yeast recombinant cell capable of producing gdp-fucose
PL2691417T5 (pl) 2011-03-29 2025-02-10 Roche Glycart Ag Warianty fc przeciwciała
EP2694551A1 (en) 2011-04-07 2014-02-12 Genentech, Inc. Anti-fgfr4 antibodies and methods of use
CA2830923A1 (en) 2011-04-15 2012-10-18 Compugen Ltd. Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
US20140193420A1 (en) 2011-04-18 2014-07-10 Chugai Seiyaku Kabushiki Kaisha Diagnosis and treatment of cancer using anti-itm2a antibody
PL2699602T3 (pl) 2011-04-19 2017-11-30 Merrimack Pharmaceuticals, Inc. Bispecyficzne przeciwciała anty-IGF-1R i anty-ErbB3
HRP20180640T1 (hr) 2011-04-25 2018-06-01 Daiichi Sankyo Company, Limited Anti-b7-h3 antitijelo
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
WO2012146630A1 (en) 2011-04-29 2012-11-01 F. Hoffmann-La Roche Ag N-terminal acylated polypeptides, methods for their production and uses thereof
CA2833212C (en) 2011-05-12 2020-06-09 Genentech, Inc. Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature peptides
NO2707391T3 (browse.php) 2011-05-13 2018-04-07
EP3219730A1 (en) 2011-05-16 2017-09-20 F. Hoffmann-La Roche AG Fgfr1 agonists and methods of use
EA201391753A1 (ru) 2011-05-21 2014-08-29 Макродженикс, Инк. Домены, связывающиеся с деиммунизованной сывороткой, и их применение для увеличения времени полужизни в сыворотке
KR102046666B1 (ko) 2011-05-25 2019-11-19 이나뜨 파르마 염증성 장애의 치료를 위한 항-kir 항체
EA028220B1 (ru) 2011-05-27 2017-10-31 Глаксо Груп Лимитед Иммуноконъюгат на основе белка, связывающегося с bcma (cd269/tnfrsf17), его медицинское применение и фармацевтическая композиция
WO2012170740A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
US9561274B2 (en) 2011-06-07 2017-02-07 University Of Hawaii Treatment and prevention of cancer with HMGB1 antagonists
CN116063522A (zh) 2011-06-13 2023-05-05 美国全心医药生技股份有限公司 抗psgl-1抗体及其用途
WO2012172495A1 (en) 2011-06-14 2012-12-20 Novartis Ag Compositions and methods for antibodies targeting tem8
RU2013158627A (ru) 2011-06-15 2015-07-20 Ф. Хоффманн-Ля Рош Аг Антитела к рецептору человеческого эритропоэтина и способы их применения
MX2013014789A (es) 2011-06-16 2014-01-20 Novartis Ag Proteinas solubles para utilizarse como productos terapeuticos.
US20140120555A1 (en) * 2011-06-20 2014-05-01 Pierre Fabre Medicament Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer
WO2012176779A1 (ja) 2011-06-20 2012-12-27 協和発酵キリン株式会社 抗ｅｒｂＢ３抗体
CA2839508A1 (en) 2011-06-22 2012-12-27 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-axl antibodies and uses thereof
FR2976811A1 (fr) 2011-06-22 2012-12-28 Lfb Biotechnologies Utilisation d'un anticorps anti-cd20 a haute adcc pour le traitement de la maladie de waldenstrom
PH12013502499A1 (en) 2011-06-22 2019-03-22 Hoffmann La Roche Removal of target cells by circulating virus-specific cytotoxic t-cells using mhc class i comprising complexes
EP2723377B1 (en) 2011-06-22 2018-06-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-axl antibodies and uses thereof
CA2840537C (en) 2011-06-28 2021-12-14 Oxford Biotherapeutics Ltd. Antibodies to adp-ribosyl cyclase 2
ME02632B (me) 2011-06-28 2017-06-20 Oxford Biotherapeutics Ltd Terapeutski i dijagnostički cilj
CA2836855C (en) 2011-06-30 2020-07-14 Compugen Ltd. Polypeptides and uses thereof for treatment of autoimmune disorders and infection
KR20140045440A (ko) 2011-06-30 2014-04-16 제넨테크, 인크. 항-c-met 항체 제제
PT2726099T (pt) 2011-07-01 2018-11-13 Novartis Ag Método para o tratamento de distúrbios metabólicos
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
SG10201505454SA (en) 2011-07-13 2015-09-29 Abbvie Inc Methods and compositions for treating asthma using anti-il-13 antibodies
WO2013010955A1 (en) 2011-07-15 2013-01-24 Morphosys Ag Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt)
EA028886B1 (ru) 2011-07-27 2018-01-31 Глаксо Груп Лимитед ОТДЕЛЬНЫЕ ВАРИАБЕЛЬНЫЕ ДОМЕНЫ ПРОТИВ VEGF, СЛИТЫЕ С Fc-ДОМЕНАМИ
WO2013022855A1 (en) 2011-08-05 2013-02-14 Xencor, Inc. Antibodies with modified isoelectric points and immunofiltering
WO2013025944A1 (en) 2011-08-17 2013-02-21 Genentech, Inc. Inhibition of angiogenesis in refractory tumors
KR20140057326A (ko) 2011-08-17 2014-05-12 제넨테크, 인크. 뉴레귤린 항체 및 그의 용도
CA2844538C (en) 2011-08-23 2020-09-22 Roche Glycart Ag Bispecific antigen binding molecules
CN103890006A (zh) 2011-08-23 2014-06-25 罗切格利卡特公司 抗mcsp抗体
CN103857700A (zh) 2011-08-26 2014-06-11 梅里麦克制药股份有限公司 串联fc双特异性抗体
RU2014109395A (ru) 2011-09-15 2015-10-20 Дженентек, Инк. Способы стимуляции дифференциации
MX2014002990A (es) 2011-09-19 2014-05-21 Genentech Inc Tratamientos combinados que comprenden antagonistas de c-met y antagonistas de b-raf.
BR112014006537A2 (pt) 2011-09-23 2017-11-28 Roche Glycart Ag anticorpos biespecíficos, formulação farmacêutica, usos de um anticorpo biespecífico, método de tratamento, ácido nucleico, vetores de expressão, célula hospedeira e método para a produção de um anticorpo biespecífico
EA201490644A1 (ru) 2011-09-30 2014-09-30 Дана-Фарбер Кэнсер Инститьют, Инк. Терапевтические пептиды
US20150050269A1 (en) 2011-09-30 2015-02-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
TW201817744A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
US10556949B2 (en) 2011-09-30 2020-02-11 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule inducing immune response to target antigen
US20130089562A1 (en) 2011-10-05 2013-04-11 Genenthech, Inc. Methods of treating liver conditions using notch2 antagonists
AU2012323287B2 (en) 2011-10-10 2018-02-01 Xencor, Inc. A method for purifying antibodies
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
JP2014530816A (ja) 2011-10-14 2014-11-20 ノバルティスアーゲー Ｗｎｔ経路関連疾患のための抗体および方法
BR112014008862A2 (pt) 2011-10-14 2018-08-07 Genentech Inc anticorpo isolado que se liga à htra1, ácido nucleico isolado, célula hospedeira, imunoconjugado, formulação farmacêutica, métodos e usos
WO2013056148A2 (en) 2011-10-15 2013-04-18 Genentech, Inc. Methods of using scd1 antagonists
WO2013059531A1 (en) 2011-10-20 2013-04-25 Genentech, Inc. Anti-gcgr antibodies and uses thereof
SG11201401791WA (en) 2011-10-24 2014-08-28 Abbvie Inc Immunobinders directed against sclerostin
MX2014004991A (es) 2011-10-28 2014-05-22 Genentech Inc Combinaciones terapeuticas y metodos para tratar el melanoma.
WO2013062083A1 (ja) 2011-10-28 2013-05-02 ファーマロジカルズ・リサーチ プライベート リミテッド 癌幹細胞特異的分子
WO2013067054A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Antibodies and methods of treating cancer
ES2697674T3 (es) 2011-11-01 2019-01-25 Bionomics Inc Procedimientos para bloquear el crecimiento de células madre cancerosas
AU2012332593B2 (en) 2011-11-01 2016-11-17 Bionomics, Inc. Anti-GPR49 antibodies
AU2012332590B2 (en) 2011-11-01 2016-10-20 Bionomics, Inc. Anti-GPR49 antibodies
EP2773671B1 (en) 2011-11-04 2021-09-15 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
AU2012336069A1 (en) 2011-11-07 2014-05-22 Medimmune, Llc Multispecific and multivalent binding proteins and uses thereof
BR112014012005A2 (pt) 2011-11-21 2017-12-19 Genentech Inc composições, métodos, formulação farmacêutica e artigo
US20130302274A1 (en) 2011-11-25 2013-11-14 Roche Glycart Ag Combination therapy
TW201328707A (zh) 2011-12-05 2013-07-16 Novartis Ag 針對表皮生長因子受體３（ｈｅｒ３）之區域ｉｉ之ｈｅｒ３抗體
AU2012349735B2 (en) 2011-12-05 2016-05-19 Novartis Ag Antibodies for epidermal growth factor receptor 3 (HER3)
WO2013083497A1 (en) 2011-12-06 2013-06-13 F. Hoffmann-La Roche Ag Antibody formulation
WO2013087789A1 (en) 2011-12-13 2013-06-20 Glykos Finland Ltd. Antibody isoform arrays and methods thereof
HRP20201004T1 (hr) 2011-12-20 2020-10-16 Medimmune, Llc Modificirani polipeptidi za skelete bispecifičnog protutijela
CN106831985A (zh) 2011-12-21 2017-06-13 诺华股份有限公司 用于抗体靶定p因子的组合物和方法
SG10201900915WA (en) 2011-12-22 2019-03-28 Hoffmann La Roche Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides
MX2014007262A (es) 2011-12-22 2014-08-01 Hoffmann La Roche Sistema de exhibicion de anticuerpos de longitud completa para celulas eucarioticas y su uso.
US9963511B2 (en) 2011-12-22 2018-05-08 Hoffmann-La Roche Inc. Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides
CA2859755C (en) 2011-12-23 2021-04-20 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
AR089434A1 (es) 2011-12-23 2014-08-20 Genentech Inc Procedimiento para preparar formulaciones con alta concentracion de proteinas
TWI593705B (zh) 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
EP2797955A2 (en) 2011-12-30 2014-11-05 AbbVie Inc. Dual variable domain immunoglobulins against il-13 and/or il-17
WO2013101771A2 (en) 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
CA2863224A1 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
EP2802601B1 (en) 2012-01-09 2019-11-13 The Scripps Research Institute Humanized antibodies with ultralong cdr3s
AR089752A1 (es) 2012-01-18 2014-09-17 Genentech Inc Anticuerpos anti-lrp5 y metodos de uso
WO2013109856A2 (en) 2012-01-18 2013-07-25 Genentech, Inc. Methods of using fgf19 modulators
EP2807192B1 (en) 2012-01-27 2018-04-18 Abbvie Deutschland GmbH & Co. KG Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
US20130243750A1 (en) 2012-01-31 2013-09-19 Genentech, Inc. Anti-ige antibodies and methods using same
AU2013216320A1 (en) 2012-02-01 2014-04-03 Compugen Ltd. C10RF32 antibodies, and uses thereof for treatment of cancer
WO2013117647A1 (en) 2012-02-07 2013-08-15 Innate Pharma Mica binding agents
CN104204204A (zh) 2012-02-09 2014-12-10 中外制药株式会社 抗体的Fc区变异体
JP6486686B2 (ja) 2012-02-10 2019-03-20 ジェネンテック， インコーポレイテッド 単鎖抗体及び他のヘテロ多量体
EP2812350B1 (en) 2012-02-11 2019-04-03 F.Hoffmann-La Roche Ag R-spondin translocations and methods using the same
CA3159061A1 (en) 2012-02-15 2013-08-22 F. Hoffmann-La Roche Ag Fc-receptor based affinity chromatography
EP3626254A1 (en) 2012-03-16 2020-03-25 University Health Network Soluble toso protein and its use in treating autoimmune disorders
CA2865082A1 (en) 2012-03-27 2013-10-03 Genentech, Inc. Diagnosis and treatments relating to her3 inhibitors
US9751942B2 (en) 2012-03-29 2017-09-05 Chugai Seiyaku Kabushiki Kaisha Anti-LAMP5 antibody and utilization thereof
CA2868965A1 (en) 2012-03-30 2013-10-03 Daiichi Sankyo Company, Limited Anti-siglec-15 antibody
AU2013241003A1 (en) 2012-03-30 2014-10-16 Daiichi Sankyo Company,Limited Cdr-modified anti-siglec-15 antibody
AR090549A1 (es) 2012-03-30 2014-11-19 Genentech Inc Anticuerpos anti-lgr5 e inmunoconjugados
AU2013247645B2 (en) 2012-04-09 2019-02-14 Daiichi Sankyo Company, Limited Anti-FGFR2 antibody
US10385395B2 (en) 2012-04-11 2019-08-20 The Regents Of The University Of California Diagnostic tools for response to 6-thiopurine therapy
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
JP5897205B2 (ja) 2012-04-27 2016-03-30 第一三共株式会社 抗ｒｏｂｏ４抗体
AR090903A1 (es) 2012-05-01 2014-12-17 Genentech Inc Anticuerpos e inmunoconjugados anti-pmel17
JP6351572B2 (ja) 2012-05-10 2018-07-04 ザイムワークス，インコーポレイテッド Ｆｃドメインに突然変異を有する免疫グロブリン重鎖のヘテロ多量体構築物
WO2013170191A1 (en) 2012-05-11 2013-11-14 Genentech, Inc. Methods of using antagonists of nad biosynthesis from nicotinamide
US9695454B2 (en) 2012-05-23 2017-07-04 Glykos Finland Oy Production of fucosylated glycoproteins
CN104335047B (zh) 2012-05-23 2017-08-15 弗·哈夫曼-拉罗切有限公司 治疗剂的选择方法
HK1203517A1 (en) 2012-05-24 2015-10-30 F. Hoffmann-La Roche Ag Multispecific antibodies
WO2013180200A1 (ja) 2012-05-30 2013-12-05 中外製薬株式会社 標的組織特異的抗原結合分子
JP6321633B2 (ja) 2012-06-04 2018-05-09 ノバルティス アーゲー 部位特異的標識法およびそれによって生成される分子
KR101566539B1 (ko) 2012-06-08 2015-11-05 국립암센터 신규한 Ｔｈ2 세포 전환용 에피토프 및 이의 용도
US9216219B2 (en) 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
KR20150023711A (ko) 2012-06-15 2015-03-05 제넨테크, 인크. 항-pcsk9 항체, 제제, 투여, 및 사용 방법
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
CA2877533C (en) 2012-06-22 2022-08-16 The Trustees Of Dartmouth College Novel vista-ig constructs and the use of vista-ig for treatment of autoimmune, allergic and inflammatory disorders
CN110256567B (zh) 2012-06-27 2023-04-25 弗·哈夫曼-拉罗切有限公司 用于选择并产生含有至少两种不同结合实体的定制靶向实体的方法及其用途
MX2014014804A (es) 2012-06-27 2015-02-12 Hoffmann La Roche Metodo para la elaboracion de conjugados de la region fc de anticuerpos que comprenden por lo menos una entidad de union que se une especificamente a un objetivo y usos del mismo.
US20140004121A1 (en) 2012-06-27 2014-01-02 Amgen Inc. Anti-mesothelin binding proteins
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
NZ701040A (en) 2012-07-04 2017-02-24 Hoffmann La Roche Covalently linked antigen-antibody conjugates
JP6247287B2 (ja) 2012-07-04 2017-12-13 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 抗ビオチン抗体および使用方法
CA2872184A1 (en) 2012-07-04 2014-01-09 F. Hoffmann-La Roche Ag Anti-theophylline antibodies and methods of use
JP6309518B2 (ja) 2012-07-05 2018-04-11 ジェネンテック， インコーポレイテッド 発現及び分泌システム
ES2927550T3 (es) 2012-07-06 2022-11-08 Univ School St Marianna Medicine Remedio para pacientes con mielopatía asociada a HTLV-1
MX2015000315A (es) 2012-07-09 2015-07-06 Genentech Inc Anticuerpos anti-cd22 e inmunoconjugados.
EP2869847B1 (en) 2012-07-09 2017-12-06 Genentech, Inc. Immunoconjugates comprising anti-cd79b antibodies
SG11201500093TA (en) 2012-07-09 2015-02-27 Genentech Inc Immunoconjugates comprising anti-cd79b antibodies
CA2873889A1 (en) 2012-07-09 2014-01-16 Genentech, Inc. Anti-cd22 antibodies and immunoconjugates
US9670276B2 (en) 2012-07-12 2017-06-06 Abbvie Inc. IL-1 binding proteins
LT3495387T (lt) 2012-07-13 2021-11-25 Roche Glycart Ag Bispecifiniai anti-vegf / anti-ang-2 antikūnai ir jų panaudojimas akių kraujagyslių ligoms gydyti
CA2875486A1 (en) 2012-07-18 2014-01-23 Glycotope Gmbh Novel therapeutic treatments with anti-her2 antibodies having a low fucosylation
ES2673847T3 (es) 2012-07-25 2018-06-26 Celldex Therapeutics, Inc. Anticuerpos anti KIT y usos de los mismos
GB201213652D0 (en) 2012-08-01 2012-09-12 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
EP2882777B1 (en) 2012-08-07 2018-10-10 Roche Glycart AG Composition comprising two antibodies engineered to have reduced and increased effector function
EP2888279A1 (en) 2012-08-22 2015-07-01 Glaxo Group Limited Anti lrp6 antibodies
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
CN105246507B (zh) 2012-09-07 2019-01-25 达特茅斯大学理事会 用于诊断和治疗癌症的vista调节剂
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
AU2013320972B2 (en) 2012-09-27 2018-08-30 Chugai Seiyaku Kabushiki Kaisha FGFR3 fusion gene and pharmaceutical drug targeting same
WO2014054804A1 (ja) 2012-10-05 2014-04-10 協和発酵キリン株式会社 ヘテロダイマータンパク質組成物
CA2885800C (en) 2012-10-11 2018-12-04 Daiichi Sankyo Company, Limited Antibody-drug conjugate
ES2782248T3 (es) 2012-10-19 2020-09-11 Daiichi Sankyo Co Ltd Conjugado de anticuerpo y fármaco producido por la unión a través de un enlazador que tiene estructura hidrófila
AU2013337775B2 (en) 2012-11-01 2017-03-30 Abbvie Inc. Anti-VEGF/DLL4 dual variable domain immunoglobulins and uses thereof
CA2890346A1 (en) 2012-11-05 2014-05-08 Foundation Medicine, Inc. Novel fusion molecules and uses thereof
CA2890575C (en) 2012-11-05 2021-11-09 Jumpei Enami Antibody and antibody composition production method
EP2914621B1 (en) 2012-11-05 2023-06-07 Foundation Medicine, Inc. Novel ntrk1 fusion molecules and uses thereof
MX2015005757A (es) 2012-11-08 2015-11-18 Hoffmann La Roche Proteinas ligantes de antigeno her3 de union a la horquilla beta de her3.
CA2890669A1 (en) 2012-11-13 2014-05-22 Genetech, Inc. Anti-hemagglutinin antibodies and methods of use
EP2733153A1 (en) 2012-11-15 2014-05-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the preparation of immunoconjugates and uses thereof
WO2014084859A1 (en) 2012-11-30 2014-06-05 Novartis Ag Molecules and methods for modulating tmem16a activities
HUE043903T2 (hu) 2012-12-03 2019-09-30 Bristol Myers Squibb Co Immunmodulációs FC fúziós proteinek rákellenes aktivitásának javítása
PT2928921T (pt) 2012-12-05 2021-04-06 Novartis Ag Composições e métodos para anticorpos que visam epo
KR20150090107A (ko) 2012-12-06 2015-08-05 도쿠리츠다이가쿠호징 가나자와다이가쿠 중피종의 치료 방법
AU2013355931B2 (en) 2012-12-07 2019-03-14 Kyowa Kirin Co., Ltd. Anti-FOLR1 antibody
JP6461808B2 (ja) 2012-12-17 2019-01-30 ラボラトワール フランセ ドゥ フラクションマン エ デ バイオテクノロジーズＬａｂｏｒａｔｏｉｒｅ Ｆｒａｎｃａｉｓ Ｄｕ Ｆｒａｃｔｉｏｎｎｅｍｅｎｔ Ｅｔ Ｄｅｓ Ｂｉｏｔｅｃｈｎｏｌｏｇｉｅｓ 炎症および細菌感染症処置におけるモノクローナル抗体の使用
WO2014100542A1 (en) 2012-12-21 2014-06-26 Abbvie, Inc. High-throughput antibody humanization
TWI693073B (zh) 2012-12-21 2020-05-11 日商中外製藥股份有限公司 對ｇｐｃ３標的治療劑療法為有效之患者投與的ｇｐｃ３標的治療劑
EP4119947A1 (en) 2012-12-21 2023-01-18 Chugai Seiyaku Kabushiki Kaisha Gpc3-targeting drug which is administered to patient responsive to gpc3-targeting drug therapy
PL2935328T3 (pl) 2012-12-21 2019-02-28 Hoffmann La Roche Połączone wiązaniem dwusiarczkowym wielowartościowe białka wielofunkcyjne zawierające MHC klasy I
AU2013370171B2 (en) 2012-12-28 2018-09-13 Precision Biologics, Inc. Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
EP2938636A2 (en) 2012-12-28 2015-11-04 AbbVie Inc. High-throughput system and method for identifying antibodies having specific antigen binding activities
US9458244B2 (en) 2012-12-28 2016-10-04 Abbvie Inc. Single chain multivalent binding protein compositions and methods
CN105229026B (zh) 2013-01-10 2021-07-30 根马布私人有限公司 人类IgG1 FC区变体及其用途
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
CA3211863A1 (en) 2013-01-14 2014-07-17 Xencor, Inc. Novel heterodimeric proteins
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
CA2897987A1 (en) 2013-01-15 2014-07-24 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
WO2014113729A2 (en) 2013-01-18 2014-07-24 Foundation Mecicine, Inc. Methods of treating cholangiocarcinoma
EP2948177A1 (en) 2013-01-22 2015-12-02 AbbVie Inc. Methods for optimizing domain stability of binding proteins
WO2014116749A1 (en) 2013-01-23 2014-07-31 Genentech, Inc. Anti-hcv antibodies and methods of using thereof
EP2953972B1 (en) 2013-02-05 2020-07-08 EngMab Sàrl Method for the selection of antibodies against bcma
EP2762496A1 (en) 2013-02-05 2014-08-06 EngMab AG Method for the selection of antibodies against BCMA
WO2014124258A2 (en) 2013-02-08 2014-08-14 Irm Llc Specific sites for modifying antibodies to make immunoconjugates
SG11201506025RA (en) 2013-02-08 2015-08-28 Irm Llc Specific sites for modifying antibodies to make immunoconjugates
MA38322B1 (fr) 2013-02-08 2018-09-28 Novartis Ag Anticorps anti-il-17a et leur utilisation dans le traitement de troubles auto-immuns et inflammatoires
GB201302447D0 (en) 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
US10344087B2 (en) 2013-02-14 2019-07-09 Innate Pharma Treatment of peripheral T cell lymphoma
WO2014128221A1 (en) 2013-02-20 2014-08-28 Innate Pharma A compound that specifically binds to kir3dl2 for use in the treatment of peripheral t cell lymphoma
WO2014130613A2 (en) 2013-02-22 2014-08-28 Amgen Inc. Carbohydrate phosphonate derivatives as modulators of glycosylation
EP2958592A1 (en) 2013-02-22 2015-12-30 F. Hoffmann-La Roche AG Methods of treating cancer and preventing drug resistance
HK1211301A1 (en) 2013-02-26 2016-05-20 罗切格利卡特公司 Anti-mcsp antibodies
JP2016510751A (ja) 2013-03-06 2016-04-11 ジェネンテック， インコーポレイテッド 抗がん剤耐性を治療及び予防する方法
CA2902505A1 (en) 2013-03-06 2014-09-12 Merrimack Pharmaceuticals, Inc. Anti-c-met tandem fc bispecific antibodies
AU2013381687A1 (en) 2013-03-12 2015-09-24 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
WO2014142117A1 (ja) 2013-03-12 2014-09-18 全薬工業株式会社 抗ブドウ球菌抗体、その製造方法並びにその使用
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
MX2015011606A (es) 2013-03-14 2016-05-17 Genentech Inc Metodo para tratar cancer y prevenir resistencia a farmacos contra cancer.
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
CA2902865A1 (en) 2013-03-14 2014-10-02 Genentech, Inc. Anti-b7-h4 antibodies and immunoconjugates
CN105246508A (zh) 2013-03-14 2016-01-13 基因泰克公司 Mek抑制剂化合物与her3/egfr抑制剂化合物的组合及使用方法
JP2016512241A (ja) 2013-03-14 2016-04-25 アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ 改良された抗体検出のためのｈｃｖｎｓ３組換え抗原およびこの突然変異体
EP3611189A1 (en) 2013-03-14 2020-02-19 Novartis AG Antibodies against notch 3
BR112015023239A8 (pt) 2013-03-14 2018-04-17 Abbott Lab ensaio de combinação de anticorpo-antígeno de hcv e métodos e composições para uso do mesmo
CN105378099B (zh) 2013-03-14 2021-05-11 雅培制药有限公司 Hcv核心脂质结合结构域单克隆抗体
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9260527B2 (en) 2013-03-15 2016-02-16 Sdix, Llc Anti-human CXCR4 antibodies and methods of making same
JP2016520528A (ja) 2013-03-15 2016-07-14 ジェネンテック， インコーポレイテッド 癌の治療及び抗癌剤耐性の防止方法
WO2014150937A1 (en) 2013-03-15 2014-09-25 Novartis Ag Antibody drug conjugates
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
UA118843C2 (uk) 2013-03-15 2019-03-25 Дженентек, Інк. ХИМЕРНИЙ БІЛОК IL-22 Fc ТА ЙОГО ЗАСТОСУВАННЯ
EP2968545B1 (en) 2013-03-15 2019-03-06 Memorial Sloan Kettering Cancer Center High affinity anti-gd2 antibodies
AR095432A1 (es) 2013-03-15 2015-10-14 Glaxosmithkline Ip Dev Ltd Proteínas de unión a antígeno
JP6594855B2 (ja) 2013-03-15 2019-10-23 ゼンコア インコーポレイテッド ヘテロ二量体タンパク質
CN118547067A (zh) 2013-03-15 2024-08-27 豪夫迈·罗氏有限公司 治疗pd-1和pd-l1相关疾患的生物标志物和方法
EP2970459A2 (en) 2013-03-15 2016-01-20 AbbVie Inc. Dual specific binding proteins directed against il-1beta and il-17
CN105142668B (zh) 2013-03-15 2018-04-27 达纳-法伯癌症研究院公司 治疗性肽
CA3093606A1 (en) 2013-03-15 2014-09-18 Xencor, Inc. Heterodimeric proteins for induction of t cells
TW201522374A (zh) 2013-03-15 2015-06-16 Genentech Inc 抗ｃｒｔｈ２抗體及使用方法
RU2661111C2 (ru) 2013-03-15 2018-07-11 Ац Иммуне С.А. Антитела к тау и способы применения
MX2015011444A (es) 2013-03-15 2015-12-16 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento del cancer hepatico.
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
MX2015014773A (es) 2013-04-22 2016-03-04 Glycotope Gmbh Tratamientos anti-cancer con anticuerpos anti-egfr que tienen una fucosilacion baja.
SG11201508910WA (en) 2013-04-29 2015-11-27 Hoffmann La Roche Fcrn-binding abolished anti-igf-1r antibodies and their use in the treatment of vascular eye diseases
MX2015015060A (es) 2013-04-29 2016-02-25 Hoffmann La Roche Anticuerpos asimetricos modificados que se unen al receptor fc y metodos de uso.
TWI747803B (zh) 2013-04-29 2021-12-01 瑞士商赫孚孟拉羅股份公司 人類結合ｆｃｒｎ之經修飾抗體及使用方法
JP6612214B2 (ja) 2013-05-20 2019-11-27 ジェネンテック， インコーポレイテッド 抗トランスフェリン受容体抗体及び使用方法
BR112015029838A2 (pt) 2013-05-31 2017-09-26 Genentech Inc anticorpos, composições, ácido nucleico isolado, vetor, célula hospedeira isolada, método de produção de anticorpos, composto, conjugado de anticorpo e antibiótico, processo de elaboração do composto, intermediário entre ligante e antibiótico, método de tratamento de infecções bacterianas e método de matar staphylococcus aureus
RU2687044C2 (ru) 2013-05-31 2019-05-06 Дженентек, Инк. Антитела против стеночной тейхоевой кислоты и их конъюгаты
US9562101B2 (en) 2013-06-21 2017-02-07 Novartis Ag Lectin-like oxidized LDL receptor 1 antibodies and methods of use
AR096601A1 (es) 2013-06-21 2016-01-20 Novartis Ag Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
HK1223567A1 (zh) 2013-06-24 2017-08-04 中外制药株式会社 含有人源化抗上皮调节蛋白抗体作爲有效成分的腺癌以外的非小细胞肺癌的治疗药
EP3022224A2 (en) 2013-07-18 2016-05-25 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
CN105814074B (zh) 2013-07-18 2020-04-21 图鲁斯生物科学有限责任公司 具有超长互补决定区的人源化抗体
NZ715201A (en) 2013-08-01 2021-12-24 Five Prime Therapeutics Inc Afucosylated anti-fgfr2iiib antibodies
US9862774B2 (en) * 2013-08-09 2018-01-09 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
BR112016002462A8 (pt) 2013-08-12 2018-06-12 Medimmune Llc Métodos para melhorar os sintomas da asma usando benralizumabe
HUE042607T2 (hu) 2013-08-12 2019-07-29 Astrazeneca Ab Eljárások asztma exacerbációs gyakoriságának csökkentésére benralizumab alkalmazásával
WO2015023596A1 (en) 2013-08-12 2015-02-19 Genentech, Inc. Compositions and method for treating complement-associated conditions
EP3520811B1 (en) 2013-08-12 2020-12-30 Astrazeneca AB Methods for increasing forced expiratory volume in asthmatics using benralizumab
JP2016528247A (ja) 2013-08-14 2016-09-15 ノバルティス アーゲー 孤発性封入体筋炎を治療する方法
WO2015033343A1 (en) 2013-09-03 2015-03-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Compositions and methods for expressing recombinant polypeptides
JP2016537399A (ja) 2013-09-17 2016-12-01 ジェネンテック， インコーポレイテッド 抗ｌｇｒ５抗体を使用する方法
BR112016006428A2 (pt) 2013-09-30 2017-09-26 Daiichi Sankyo Co Ltd anticorpo, fragmento de ligação a antígeno do anticorpo, composição farmacêutica, métodos para tratamento e/ou profilaxia de infecção por pseudomona e para produzir um anticorpo, agente de diagnóstico para infecção por pseudomona, kit de detecção para pseudomonas aeruginosa, polinucleotídeo, vetor, e, célula hospedeira transformada
WO2015050959A1 (en) 2013-10-01 2015-04-09 Yale University Anti-kit antibodies and methods of use thereof
SMT202000505T1 (it) 2013-10-02 2020-11-10 Medimmune Llc Anticorpi anti-influenza a neutralizzanti e relativi usi
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
JP6509735B2 (ja) 2013-10-08 2019-05-08 第一三共株式会社 抗ｆｇｆｒ２抗体と他剤の組合せ
WO2015052537A1 (en) 2013-10-11 2015-04-16 Oxford Biotherapeutics Ltd Conjugated antibodies against ly75 for the treatment of cancer
EP3055329B1 (en) 2013-10-11 2018-06-13 F. Hoffmann-La Roche AG Multispecific domain exchanged common variable light chain antibodies
AU2014331667B2 (en) 2013-10-11 2019-08-22 Biomed Valley Discoveries, Inc. TEM8 antibodies and their use
EP3055328A1 (en) 2013-10-11 2016-08-17 F. Hoffmann-La Roche AG Nsp4 inhibitors and methods of use
WO2015057668A1 (en) * 2013-10-15 2015-04-23 Medimmune, Llc Methods for treating chronic obstructive pulmonary disease using benralizumab
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
RU2016114074A (ru) 2013-10-18 2017-11-23 Дженентек, Инк. Анти-rspo антитела и способы применения
SG11201603127WA (en) 2013-10-23 2016-05-30 Genentech Inc Methods of diagnosing and treating eosinophilic disorders
CA2929386C (en) 2013-11-07 2023-01-03 Inserm (Institut National De La Sante Et De La Recherche Medicale) Neuregulin allosteric anti-her3 antibody
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
NZ717673A (en) 2013-11-21 2020-02-28 Hoffmann La Roche Anti-alpha-synuclein antibodies and methods of use
WO2015082446A1 (en) 2013-12-02 2015-06-11 F. Hoffmann-La Roche Ag Treatment of cancer using an anti-cdcp1 antibody and a taxane
KR102454360B1 (ko) 2013-12-04 2022-10-12 추가이 세이야쿠 가부시키가이샤 화합물의 농도에 따라 항원 결합능이 변화되는 항원 결합 분자 및 그의 라이브러리
EA201691078A1 (ru) 2013-12-06 2017-01-30 Дана-Фарбер Кэнсер Инститьют, Инк. Терапевтические пептиды
EP3079719B8 (en) 2013-12-09 2019-12-04 Allakos Inc. Anti-siglec-8 antibodies and methods of use thereof
EP3461845B1 (en) 2013-12-13 2020-09-16 Genentech, Inc. Anti-cd33 antibodies and immunoconjugates
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
EP3083690A1 (en) 2013-12-17 2016-10-26 F.Hoffmann-La Roche Ag Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
AU2014364606A1 (en) 2013-12-17 2016-07-07 Genentech, Inc. Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists
SG10202002334PA (en) 2013-12-17 2020-05-28 Genentech Inc Methods of treating cancers using pd-1 axis binding antagonists and taxanes
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
CA3055708C (en) 2013-12-17 2023-01-31 Xiaocheng Chen Anti-cd3 antibodies and methods of use
EP3083693B1 (en) 2013-12-20 2022-09-21 Intervet International B.V. Antagonistic anti-canine pd-1 antibodies
TWI670283B (zh) 2013-12-23 2019-09-01 美商建南德克公司 抗體及使用方法
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
NZ721866A (en) 2013-12-24 2017-10-27 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
CN105849126B (zh) 2013-12-25 2020-02-18 第一三共株式会社 抗trop2抗体－药物偶联物
TWI563003B (en) 2013-12-26 2016-12-21 Mitsubishi Tanabe Pharma Corp Human anti-il-33 neutralization monoclonal antibody
EP3087986B1 (en) 2013-12-27 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Fgfr gatekeeper mutant gene and drug targeting same
MX373097B (es) 2014-01-03 2020-04-27 Hoffmann La Roche Anticuerpos biespecíficos anti-hapteno/anti-receptor de barrera hematoencefálica, complejos de los mismos y su uso como transportadores a través de la barrera hematoencefálica.
CN105873616B (zh) 2014-01-03 2020-06-05 豪夫迈·罗氏有限公司 共价连接的多肽毒素-抗体缀合物
CA2930154A1 (en) 2014-01-03 2015-07-09 F. Hoffmann-La Roche Ag Covalently linked helicar-anti-helicar antibody conjugates and uses thereof
WO2015103549A1 (en) 2014-01-03 2015-07-09 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Neutralizing antibodies to hiv-1 env and their use
WO2015101588A1 (en) 2014-01-06 2015-07-09 F. Hoffmann-La Roche Ag Monovalent blood brain barrier shuttle modules
JP6786392B2 (ja) 2014-01-15 2020-11-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ＦｃＲｎ結合特性が改変され、プロテインＡ結合特性が保持されているＦｃ領域変異体
FR3016633B1 (fr) 2014-01-17 2018-04-13 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Immunoglobuline anti-toxine du charbon
WO2015110923A2 (en) 2014-01-21 2015-07-30 Acerta Pharma B.V. Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia usng a btk inhibitor
EP3096797A1 (en) 2014-01-24 2016-11-30 F. Hoffmann-La Roche AG Methods of using anti-steap1 antibodies and immunoconjugates
LT3466976T (lt) 2014-01-31 2021-11-10 Daiichi Sankyo Company, Limited Anti-her2 antikūno-vaisto konjugatas
WO2015120075A2 (en) 2014-02-04 2015-08-13 Genentech, Inc. Mutant smoothened and methods of using the same
KR20160111039A (ko) 2014-02-08 2016-09-23 제넨테크, 인크. 알츠하이머 질환을 치료하는 방법
EP3900738A1 (en) 2014-02-08 2021-10-27 F. Hoffmann-La Roche AG Methods of treating alzheimer's disease
PE20161335A1 (es) 2014-02-12 2016-12-07 Genentech Inc Anticuerpos anti-jagged1 y metodos de uso
CN106029693A (zh) 2014-02-21 2016-10-12 豪夫迈·罗氏有限公司 抗il-13/il-17双特异性抗体及其用途
TWI558399B (zh) 2014-02-26 2016-11-21 美國禮來大藥廠 癌症之組合療法
EP3110446B1 (en) 2014-02-28 2021-12-01 Allakos Inc. Methods and compositions for treating siglec-8 associated diseases
TW201622744A (zh) 2014-03-04 2016-07-01 美國禮來大藥廠 癌症之組合療法
AU2015225867B2 (en) 2014-03-07 2020-02-06 University Health Network Methods and compositions for modifying the immune response
WO2015138615A2 (en) 2014-03-12 2015-09-17 Irm Llc Specific sites for modifying antibodies to make immunoconjugates
CN106456728A (zh) 2014-03-14 2017-02-22 达纳－法伯癌症研究所公司 恢复对抗癌症的nkg2d通路功能的疫苗组合物和方法
EP3572431A1 (en) 2014-03-14 2019-11-27 Innate Pharma Humanized antibodies with stability
EP3116999B1 (en) 2014-03-14 2021-09-15 F. Hoffmann-La Roche AG Methods and compositions for secretion of heterologous polypeptides
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
WO2015140591A1 (en) 2014-03-21 2015-09-24 Nordlandssykehuset Hf Anti-cd14 antibodies and uses thereof
TW202515912A (zh) 2014-03-21 2025-04-16 美商艾伯維有限公司 抗-egfr抗體及抗體藥物結合物
MX2016012285A (es) 2014-03-24 2017-01-23 Genentech Inc Tratamiento de cáncer con antagonista de c-met y correlación de estos con la expresión de hgf.
EA201691925A1 (ru) 2014-03-28 2017-06-30 Ксенкор, Инк. Биспецифические антитела, которые связываются с cd38 и cd3
HUE046767T2 (hu) 2014-03-31 2020-03-30 Hoffmann La Roche Anti-OX40 antitestek és alkalmazási eljárások
MA39817A (fr) 2014-03-31 2017-02-08 Hoffmann La Roche Thérapie combinatoires comprenant des agents anti-angiogenèse et des agonistes se liant à ox40
UA117289C2 (uk) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
KR101660580B1 (ko) * 2014-04-02 2016-09-28 프레스티지 바이오파마 피티이. 엘티디. 항체의 당 함량 조절을 통한 항체의 제조 방법
TWI872824B (zh) 2014-04-10 2025-02-11 日商第一三共股份有限公司 抗ｈｅｒ３抗體-藥物結合物之製造方法
MX2016012830A (es) 2014-04-11 2017-01-05 Medimmune Llc Anticuerpos contra el receptor 2 del factor de crecimiento epidermico humano (her2) biespecificos.
TW201622746A (zh) 2014-04-24 2016-07-01 諾華公司 改善或加速髖部骨折術後身體復原之方法
WO2015164615A1 (en) 2014-04-24 2015-10-29 University Of Oslo Anti-gluten antibodies and uses thereof
EP3141603A4 (en) 2014-05-08 2017-12-27 Chugai Seiyaku Kabushiki Kaisha Gpc3-targeted therapeutic agent for administration to patients for whom gpc3-targeted therapeutic agent therapy is effective
JP2017522861A (ja) 2014-05-22 2017-08-17 ジェネンテック， インコーポレイテッド 抗ｇｐｃ３抗体及びイムノコンジュゲート
MX2016015163A (es) 2014-05-23 2017-03-03 Genentech Inc Biomarcadores mit y metodos para su uso.
WO2015184403A2 (en) 2014-05-30 2015-12-03 Henlius Biotech Co., Ltd. Anti-epidermal growth factor receptor (egfr) antibodies
EP3970747A3 (en) 2014-06-03 2022-10-05 XBiotech Inc. Compositions and methods for treating and preventing staphylococcus aureus infections
EP3151921B1 (en) 2014-06-06 2019-08-28 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
WO2015191881A2 (en) 2014-06-11 2015-12-17 Green Kathy A Use of vista agonists and antagonists to suppress or enhance humoral immunity
EP3155015A1 (en) 2014-06-11 2017-04-19 F. Hoffmann-La Roche AG Anti-lgr5 antibodies and uses thereof
CN107073121A (zh) 2014-06-13 2017-08-18 基因泰克公司 治疗及预防癌症药物抗性的方法
US20170291939A1 (en) 2014-06-25 2017-10-12 Novartis Ag Antibodies specific for il-17a fused to hyaluronan binding peptide tags
CN106687476B (zh) 2014-06-26 2020-11-13 豪夫迈·罗氏有限公司 抗brdu抗体及使用方法
AU2015279316B2 (en) 2014-06-27 2021-03-04 Innate Pharma Multispecific NKp46 binding proteins
EP3160994B1 (en) 2014-06-27 2025-02-19 Innate Pharma Multispecific antigen binding proteins
DK3309174T3 (da) 2014-07-11 2022-06-07 Ventana Med Syst Inc ANTI-PD-L1-antistoffer og diagnostiske anvendelser deraf
JP2017526641A (ja) 2014-07-11 2017-09-14 ジェネンテック， インコーポレイテッド Ｎｏｔｃｈ経路阻害
WO2016012468A1 (en) 2014-07-21 2016-01-28 Novartis Ag Production of glycoproteins with mammalian-like n-glycans in filamentous fungi
US20160060360A1 (en) 2014-07-24 2016-03-03 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
WO2016020791A1 (en) 2014-08-05 2016-02-11 Novartis Ag Ckit antibody drug conjugates
US9771417B2 (en) 2014-08-07 2017-09-26 Novartis Ag Angiopoietin-like 4 antibodies and methods of use
WO2016020882A2 (en) 2014-08-07 2016-02-11 Novartis Ag Angiopoetin-like 4 (angptl4) antibodies and methods of use
TW201609099A (zh) 2014-08-11 2016-03-16 艾森塔製藥公司 使用布魯頓（Ｂｒｕｔｏｎ）氏酪胺酸激酶（ＢＴＫ）抑制劑以治療慢性淋巴球性白血病和小淋巴球性白血病之方法
RS63364B1 (sr) 2014-08-11 2022-07-29 Acerta Pharma Bv Terapeutske kombinacije btk inhibitora, pd-1 inhibitora i/ili pd-l1 inhibitora
EP3180360A1 (en) 2014-08-12 2017-06-21 Novartis AG Anti-cdh6 antibody drug conjugates
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
AP2017009765A0 (en) 2014-08-19 2017-02-28 Merck Sharp & Dohme Anti-tigit antibodies
WO2016030488A1 (en) 2014-08-27 2016-03-03 Innate Pharma Treatment of celiac disease
TWI751102B (zh) 2014-08-28 2022-01-01 美商奇諾治療有限公司 對ｃｄ１９具專一性之抗體及嵌合抗原受體
MX2017002605A (es) 2014-08-28 2017-05-19 Bioatla Llc Receptores de antigeno quimerico condicionalmente activos para celulas t modificadas.
AR101848A1 (es) 2014-09-12 2017-01-18 Genentech Inc Anticuerpos de anti-b7-h4 e inmunoconjugados
CR20170131A (es) 2014-09-12 2017-07-19 Genentech Inc Anticuerpos anti-her2 e inmunoconjugados
WO2016040868A1 (en) 2014-09-12 2016-03-17 Genentech, Inc. Anti-cll-1 antibodies and immunoconjugates
JP6730261B2 (ja) 2014-09-17 2020-07-29 ジェネンテック， インコーポレイテッド 抗ｈｅｒ２抗体を含む免疫複合体
ES2796903T3 (es) 2014-09-23 2020-11-30 Hoffmann La Roche Procedimiento de uso de inmunoconjugados anti-CD79b
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
SG10201902924RA (en) 2014-10-03 2019-05-30 Massachusetts Inst Technology Antibodies that bind ebola glycoprotein and uses thereof
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
WO2016059602A2 (en) 2014-10-16 2016-04-21 Glaxo Group Limited Methods of treating cancer and related compositions
JP2017536102A (ja) 2014-10-16 2017-12-07 ジェネンテック， インコーポレイテッド 抗アルファ−シヌクレイン抗体及び使用方法
RU2721271C2 (ru) 2014-10-23 2020-05-18 Иннейт Фарма Лечение раковых заболеваний с применением анти-nkg2a средств
WO2016070001A1 (en) 2014-10-31 2016-05-06 Jounce Therapeutics, Inc. Methods of treating conditions with antibodies that bind b7-h4
BR112017009151A2 (pt) 2014-11-03 2018-03-06 Genentech, Inc. ensaios para detectar subgrupos imunológicos de célula t e métodos de uso dos mesmos
BR112017009159A2 (pt) 2014-11-03 2018-03-06 Genentech, Inc. métodos e biomarcadores para predizer a eficácia e avaliação de um tratamento com agonista de ox40
WO2016073789A2 (en) 2014-11-05 2016-05-12 Genentech, Inc. Anti-fgfr2/3 antibodies and methods using same
WO2016073282A1 (en) 2014-11-06 2016-05-12 Genentech, Inc. Combination therapy comprising ox40 binding agonists and tigit inhibitors
KR20170078677A (ko) 2014-11-06 2017-07-07 에프. 호프만-라 로슈 아게 Fcrn-결합이 개질된 fc-영역 변이체 및 이의 사용 방법
EP3842453A1 (en) 2014-11-06 2021-06-30 F. Hoffmann-La Roche AG Fc-region variants with modified fcrn- and protein a-binding properties
CN107105632A (zh) 2014-11-10 2017-08-29 豪夫迈·罗氏有限公司 肾病动物模型及其治疗剂
EP3218403B1 (en) 2014-11-10 2020-05-13 F.Hoffmann-La Roche Ag Anti-interleukin-33 antibodies and uses thereof
TN2017000173A1 (en) 2014-11-14 2018-10-19 Novartis Ag Antibody drug conjugates
EP3875481B1 (en) 2014-11-14 2025-01-22 The U.S.A. as represented by the Secretary, Department of Health and Human Services Neutralizing antibodies to ebola virus glycoprotein and their use
ES2809455T3 (es) 2014-11-17 2021-03-04 Regeneron Pharma Métodos para tratamiento tumoral usando anticuerpo biespecífico CD3xCD20
KR20170096112A (ko) 2014-11-17 2017-08-23 제넨테크, 인크. Ox40 결합 효능제 및 pd-1 축 결합 길항제를 포함하는 조합 요법
JP6779876B2 (ja) 2014-11-19 2020-11-04 ジェネンテック， インコーポレイテッド 抗トランスフェリン受容体抗体及びその使用方法
JP6993228B2 (ja) 2014-11-19 2022-03-03 ジェネンテック， インコーポレイテッド 抗トランスフェリン受容体／抗ｂａｃｅ１多重特異性抗体および使用方法
US10882920B2 (en) 2014-11-19 2021-01-05 Genentech, Inc. Antibodies against BACE1 and use thereof for neural disease immunotherapy
HRP20240959T1 (hr) 2014-11-20 2024-10-25 F. Hoffmann - La Roche Ag Kombinirana terapija bispecifičnom antigen vezujućom molekulom koja aktivira t stanice i antagonistom vezivanja osi pd-1
SMT202000413T1 (it) 2014-11-21 2020-09-10 Bristol Myers Squibb Co Anticorpi nei confronti di cd73 e loro usi
ES2826566T3 (es) 2014-11-21 2021-05-18 Bristol Myers Squibb Co Anticuerpos que comprenden regiones constantes pesadas modificadas
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
CN107406512A (zh) 2014-11-26 2017-11-28 Xencor公司 结合cd3和cd38的异二聚体抗体
RS62332B1 (sr) 2014-11-26 2021-10-29 Xencor Inc Heterodimerna antitela koja vezuju cd3 i cd20
ES2764111T3 (es) 2014-12-03 2020-06-02 Hoffmann La Roche Anticuerpos multiespecíficos
WO2016090040A1 (en) 2014-12-03 2016-06-09 Genentech, Inc. Anti-staphylococcus aureus antibody rifamycin conjugates and uses thereof
RU2731055C2 (ru) 2014-12-03 2020-08-28 Дженентек, Инк. Конъюгаты антитела к staphylococcus aureus с рифамицином и их применение
AU2015357463B2 (en) 2014-12-05 2021-10-07 Immunext, Inc. Identification of VSIG8 as the putative vista receptor and its use thereof to produce vista/VSIG8 modulators
US9975949B2 (en) 2014-12-05 2018-05-22 Genentech, Inc. Anti-CD79b antibodies and methods of use
US10398774B2 (en) 2014-12-09 2019-09-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Human monoclonal antibodies against AXL
EP3230317A2 (en) 2014-12-10 2017-10-18 F. Hoffmann-La Roche AG Blood brain barrier receptor antibodies and methods of use
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
EP3230438B1 (en) 2014-12-12 2024-12-04 University of Copenhagen N-glycosylation
CN107278206B (zh) 2014-12-19 2021-04-02 雷根尼桑斯公司 结合人c6的抗体及其用途
UY36449A (es) 2014-12-19 2016-07-29 Novartis Ag Composiciones y métodos para anticuerpos dirigidos a bmp6
AR103161A1 (es) 2014-12-19 2017-04-19 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina y regiones fc variantes así como métodos de uso
LT3233921T (lt) 2014-12-19 2021-12-10 Chugai Seiyaku Kabushiki Kaisha Anti-c5 antikūnai ir panaudojimo būdai
WO2016105450A2 (en) 2014-12-22 2016-06-30 Xencor, Inc. Trispecific antibodies
EA039219B1 (ru) 2014-12-23 2021-12-20 Бристол-Майерс Сквибб Компани Антитела к tigit
WO2016111947A2 (en) 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
AU2016206457B2 (en) 2015-01-16 2021-11-11 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for ROR1
US20180016327A1 (en) 2015-01-22 2018-01-18 Chugai Seiyaku Kabushiki Kaisha A Combination of Two or More Anti-C5 Antibodies and Methods of Use
MA41414A (fr) 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
AU2016215227A1 (en) 2015-02-04 2017-09-21 Assistance Publique-Hopitaux De Paris Mutant smoothened and methods of using the same
TWI844507B (zh) 2015-02-05 2024-06-11 日商中外製藥股份有限公司 包含離子濃度依賴之抗原結合域的抗體、Ｆｃ區變體與其用途
ES2789573T3 (es) 2015-02-09 2020-10-26 Memorial Sloan Kettering Cancer Center Anticuerpos multiespecíficos con afinidad por el antígeno A33 humano y el complejo metálico de DOTA
WO2016128912A1 (en) 2015-02-12 2016-08-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor, and/or a pd-l1 inhibitor
DK3259597T3 (da) 2015-02-19 2022-05-09 Compugen Ltd Pvrig-polypeptider og fremgangsmåder til behandling
JP7115856B2 (ja) 2015-02-19 2022-08-09 コンピュジェン リミテッド 抗ｐｖｒｉｇ抗体及び使用方法
KR20170140180A (ko) 2015-02-24 2017-12-20 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 중동 호흡기 증후군 코로나 바이러스 면역원, 항체 및 그 용도
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
US10227411B2 (en) 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
EP3271723A1 (en) 2015-03-16 2018-01-24 F. Hoffmann-La Roche AG Methods of detecting and quantifying il-13 and uses in diagnosing and treating th2-associated diseases
WO2016146833A1 (en) 2015-03-19 2016-09-22 F. Hoffmann-La Roche Ag Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
EP3683233A1 (en) 2015-03-20 2020-07-22 The U.S.A. as represented by the Secretary, Department of Health and Human Services Neutralizing antibodies to gp120 and their use
MX386500B (es) 2015-03-23 2025-03-19 Jounce Therapeutics Inc Anticuerpos contra icos
EP3072957B1 (en) 2015-03-23 2019-07-10 Lonza Ltd Methods for controlling protein glycosylation
US10472412B2 (en) 2015-03-25 2019-11-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bispecific multivalent fusion proteins
WO2016160976A2 (en) 2015-03-30 2016-10-06 Abbvie Inc. Monovalent tnf binding proteins
FR3034420A1 (fr) 2015-03-31 2016-10-07 Lab Francais Du Fractionnement Anticorps monoclonaux anti-cd303
DK3277722T3 (da) 2015-04-02 2021-10-11 Intervet Int Bv Antistoffer mod canin interleukin-4 receptor alpha
HK1249048A1 (zh) 2015-04-03 2018-10-26 Eureka Therapeutics, Inc. 靶向afp肽/mhc複合體的構建體及其用途
WO2016172551A2 (en) 2015-04-24 2016-10-27 Genentech, Inc. Methods of identifying bacteria comprising binding polypeptides
NZ775384A (en) 2015-04-28 2024-12-20 Mitsubishi Tanabe Pharma Corp Rgma binding protein and use thereof
EP3288981A1 (en) 2015-05-01 2018-03-07 Genentech, Inc. Masked anti-cd3 antibodies and methods of use
WO2016179194A1 (en) 2015-05-04 2016-11-10 Jounce Therapeutics, Inc. Lilra3 and method of using the same
EP3091033A1 (en) 2015-05-06 2016-11-09 Gamamabs Pharma Anti-human-her3 antibodies and uses thereof
CN115109158A (zh) 2015-05-07 2022-09-27 阿吉纳斯公司 抗ox40抗体及其使用方法
JP6963508B2 (ja) 2015-05-11 2021-11-10 ジェネンテック， インコーポレイテッド ループス腎炎を治療する組成物及び方法
EP3294770B2 (en) 2015-05-12 2024-03-20 F. Hoffmann-La Roche AG Therapeutic and diagnostic methods for cancer
WO2016181357A1 (en) * 2015-05-13 2016-11-17 Zumutor Biologics, Inc. Afucosylated protein, cell expressing said protein and associated methods
US10526415B2 (en) 2015-05-22 2020-01-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Human monoclonal antibodies fragments inhibiting both the Cath-D catalytic activity and its binding to the LRP1 receptor
PL3303619T3 (pl) 2015-05-29 2020-10-05 F. Hoffmann-La Roche Ag Metylacja promotora PD-L1 w chorobach nowotworowych
LT3303395T (lt) 2015-05-29 2020-02-25 Abbvie Inc. Anti-cd40 antikūnai ir jų panaudojimas
EP3302563A1 (en) 2015-05-29 2018-04-11 H. Hoffnabb-La Roche Ag Humanized anti-ebola virus glycoprotein antibodies and methods of use
CN107532217A (zh) 2015-05-29 2018-01-02 豪夫迈·罗氏有限公司 用于癌症的治疗和诊断方法
RS63897B1 (sr) 2015-05-29 2023-02-28 Bristol Myers Squibb Co Antitela protiv ox40 i njihova primena
HK1249016A1 (zh) 2015-06-02 2018-10-26 豪夫迈‧罗氏有限公司 使用抗il-34抗体治疗神经疾病的组合物和方法
WO2016196975A1 (en) 2015-06-03 2016-12-08 The United States Of America, As Represented By The Secretary Department Of Health & Human Services Neutralizing antibodies to hiv-1 env and their use
AU2016273028B2 (en) 2015-06-05 2019-02-14 Novartis Ag Antibodies targeting bone morphogenetic protein 9 (BMP9) and methods therefor
EP4465050A3 (en) 2015-06-05 2025-06-11 Genentech, Inc. Anti-tau antibodies and methods of use
MX2017014740A (es) 2015-06-08 2018-08-15 Genentech Inc Métodos de tratamiento del cáncer con anticuerpos anti-ox40.
MX2017015937A (es) 2015-06-08 2018-12-11 Genentech Inc Métodos de tratamiento del cáncer con anticuerpos anti-ox40 y antagonistas de unión al eje de pd-1.
CN108289950B (zh) 2015-06-09 2022-10-21 纪念斯隆凯特琳癌症中心 特异于人hla呈递的ebv潜伏膜蛋白2a肽的t细胞受体样抗体药剂
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
JP2018524295A (ja) 2015-06-15 2018-08-30 ジェネンテック， インコーポレイテッド 抗体及び免疫複合体
WO2016205200A1 (en) 2015-06-16 2016-12-22 Genentech, Inc. Anti-cll-1 antibodies and methods of use
EP3916018A1 (en) 2015-06-16 2021-12-01 Genentech, Inc. Anti-cd3 antibodies and methods of use
JP6871874B2 (ja) 2015-06-16 2021-05-19 ジェネンテック， インコーポレイテッド ＦｃＲＨ５に対するヒト化親和性成熟抗体及び使用方法
JP2018524312A (ja) 2015-06-17 2018-08-30 ジェネンテック， インコーポレイテッド 抗ｈｅｒ２抗体及び使用方法
EP3310813A1 (en) 2015-06-17 2018-04-25 Novartis AG Antibody drug conjugates
CA2987797A1 (en) 2015-06-17 2016-12-22 Christopher Robert Bebbington Methods and compositions for treating fibrotic diseases
IL256080B2 (en) 2015-06-17 2025-06-01 Genentech Inc Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
AU2016284871B2 (en) 2015-06-23 2022-09-29 Innate Pharma Multispecific NK engager proteins
EP3313890A1 (en) 2015-06-24 2018-05-02 H. Hoffnabb-La Roche Ag Trispecific antibodies specific for her2 and a blood brain barrier receptor and methods of use
EP3108897A1 (en) 2015-06-24 2016-12-28 F. Hoffmann-La Roche AG Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias
BR112017027870A2 (pt) 2015-06-24 2018-08-28 Janssen Pharmaceutica Nv anticorpos e fragmentos anti-vista
SI3313879T1 (sl) 2015-06-24 2022-04-29 F. Hoffmann-La Roche Ag Protitelesa z antitransferinskim receptorjem s prilagojeno afiniteto
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
CA2989936A1 (en) 2015-06-29 2017-01-05 Genentech, Inc. Type ii anti-cd20 antibody for use in organ transplantation
ES2878316T3 (es) 2015-06-29 2021-11-18 Ventana Med Syst Inc Materiales y procedimientos para realizar ensayos histoquímicos de pro-epirregulina y anfirregulina humanas
CN107922477B (zh) 2015-06-29 2022-11-01 第一三共株式会社 用于选择性制造抗体-药物缀合物的方法
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
WO2017009712A1 (en) 2015-07-13 2017-01-19 Compugen Ltd. Hide1 compositions and methods
US10709697B2 (en) 2015-07-16 2020-07-14 Emory University Bis-amines, compositions, and uses related to CXCR4 inhibition
CA3185706A1 (en) 2015-08-03 2017-02-09 Novartis Ag Methods of treating fgf21-associated disorders
HRP20200390T1 (hr) 2015-08-03 2020-06-12 Engmab Sàrl Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma)
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
WO2017033113A1 (en) 2015-08-21 2017-03-02 Acerta Pharma B.V. Therapeutic combinations of a mek inhibitor and a btk inhibitor
WO2017040342A1 (en) 2015-08-28 2017-03-09 Genentech, Inc. Anti-hypusine antibodies and uses thereof
MY205096A (en) 2015-09-02 2024-10-01 Immutep Sas Anti-lag-3 antibodies
EA038332B1 (ru) 2015-09-09 2021-08-10 Новартис Аг Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул
RU2731644C2 (ru) 2015-09-09 2020-09-07 Новартис Аг Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул
US20190022092A1 (en) 2015-09-15 2019-01-24 Acerta Pharma B.V. Therapeutic Combinations of a BTK Inhibitor and a GITR Binding Molecule, a 4-1BB Agonist, or an OX40 Agonist
MA44909A (fr) 2015-09-15 2018-07-25 Acerta Pharma Bv Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk
US9862760B2 (en) 2015-09-16 2018-01-09 Novartis Ag Polyomavirus neutralizing antibodies
MY203894A (en) 2015-09-18 2024-07-23 Chugai Pharmaceutical Co Ltd Il-8-binding antibodies and uses thereof
JP6904947B2 (ja) 2015-09-22 2021-07-21 スプリング バイオサイエンス コーポレーション 抗ｏｘ４０抗体及びその診断用途
PE20181363A1 (es) 2015-09-23 2018-08-27 Genentech Inc Variantes optimizadas de anticuerpos anti-vegf
US11046780B2 (en) 2015-09-24 2021-06-29 Daiichi Sankyo Company, Limited Anti-garp antibody
WO2017053906A1 (en) 2015-09-24 2017-03-30 Abvitro Llc Hiv antibody compositions and methods of use
EP3353210B8 (en) 2015-09-25 2024-12-18 F. Hoffmann-La Roche AG Anti-tigit antibodies and methods of use
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
EP3150636A1 (en) 2015-10-02 2017-04-05 F. Hoffmann-La Roche AG Tetravalent multispecific antibodies
CN108137697A (zh) 2015-10-02 2018-06-08 豪夫迈·罗氏有限公司 双特异性抗人cd20/人转铁蛋白受体抗体及使用方法
LT3359572T (lt) 2015-10-06 2025-02-10 F. Hoffmann-La Roche Ag Išsėtinės sklerozės gydymo būdas
CA2997809A1 (en) 2015-10-07 2017-04-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Il-7r-alpha specific antibodies for treating acute lymphoblastic leukemia
WO2017066714A1 (en) 2015-10-16 2017-04-20 Compugen Ltd. Anti-vsig1 antibodies and drug conjugates
US10604577B2 (en) 2015-10-22 2020-03-31 Allakos Inc. Methods and compositions for treating systemic mastocytosis
JP2018534927A (ja) 2015-10-22 2018-11-29 ジョンス セラピューティクス， インコーポレイテッド Ｉｃｏｓ発現を決定する遺伝子シグネチャー
JO3555B1 (ar) 2015-10-29 2020-07-05 Merck Sharp & Dohme جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
EP3184547A1 (en) 2015-10-29 2017-06-28 F. Hoffmann-La Roche AG Anti-tpbg antibodies and methods of use
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
IL295756A (en) 2015-10-29 2022-10-01 Hoffmann La Roche Anti-variant fc-region antibodies and methods of use
US10407510B2 (en) 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates
PH12022550450A1 (en) 2015-10-30 2023-05-03 Genentech Inc Anti-htra1 antibodies and methods of use thereof
EP4011911A1 (en) 2015-11-03 2022-06-15 The United States of America as represented by The Secretary Department of Health and Human Services Neutralizing antibodies to hiv-1 gp41 and their use
WO2017079768A1 (en) 2015-11-08 2017-05-11 Genentech, Inc. Methods of screening for multispecific antibodies
CN109071639B (zh) 2015-11-18 2022-07-08 默沙东公司 Pd1/ctla4结合剂
UA125337C2 (uk) 2015-11-18 2022-02-23 Мерк Шарп І Доум Корп. Ctla4-зв'язувальні речовини
SG11201804178YA (en) 2015-11-18 2018-06-28 Merck Sharp & Dohme Pd1 and/or lag3 binders
AU2016356780A1 (en) 2015-11-19 2018-06-28 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
BR112018010410A8 (pt) 2015-11-23 2019-02-26 Five Prime Therapeutics Inc método para tratar câncer em um sujeito, composição e métodos de aumento do número de células nk e de aumento do número de uma ou mais células positivas para pd-l1
JP6849694B2 (ja) 2015-11-30 2021-03-24 ブリストル−マイヤーズ スクウィブ カンパニー 抗ヒトｉｐ−１０抗体およびそれらの使用
AU2016362777B2 (en) 2015-12-04 2020-01-30 Novartis Ag Antibody cytokine engrafted compositions and methods of use for immunoregulation
AU2016365742A1 (en) 2015-12-07 2018-06-21 Xencor, Inc. Heterodimeric antibodies that bind CD3 and PSMA
IL257696B2 (en) 2015-12-09 2024-11-01 Hoffmann La Roche Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
EP3178848A1 (en) 2015-12-09 2017-06-14 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
CA3008244A1 (en) 2015-12-16 2017-06-22 Merck Sharp & Dohme Corp. Anti-lag3 antibodies and antigen-binding fragments
EA036756B1 (ru) 2015-12-18 2020-12-16 Чугаи Сейяку Кабусики Кайся Антитела к с5 и способы их применения
JP2019506844A (ja) 2015-12-18 2019-03-14 ノバルティス アーゲー ＣＤ３２ｂを標的とする抗体およびその使用方法
EA201891420A1 (ru) 2015-12-18 2019-02-28 Чугаи Сейяку Кабусики Кайся Антитела к миостатину, полипептиды, содержащие варианты fc-областей, и способы их применения
AR107303A1 (es) 2016-01-08 2018-04-18 Hoffmann La Roche Métodos de tratamiento de cánceres positivos para ace utilizando antagonistas de unión a eje pd-1 y anticuerpos biespecíficos anti-ace / anti-cd3, uso, composición, kit
PL3402503T3 (pl) 2016-01-13 2021-04-19 Acerta Pharma B.V. Kombinacje terapeutyczne antyfolianu oraz inhibitora btk
CN114019170A (zh) 2016-01-20 2022-02-08 基因泰克公司 用于阿尔茨海默氏病的高剂量治疗
WO2017136558A1 (en) 2016-02-04 2017-08-10 Curis, Inc. Mutant smoothened and methods of using the same
AU2017214692B2 (en) 2016-02-06 2021-11-04 Epimab Biotherapeutics, Inc. Fabs-in-tandem immunoglobulin and uses thereof
CN116920085A (zh) 2016-02-12 2023-10-24 詹森药业有限公司 抗-vista（b7h5）抗体
EP3416982A1 (en) 2016-02-17 2018-12-26 Novartis AG Tgfbeta 2 antibodies
CA3015528A1 (en) 2016-02-29 2017-09-08 Genentech, Inc. Therapeutic and diagnostic methods for cancer
EP3423490A1 (en) 2016-03-01 2019-01-09 H. Hoffnabb-La Roche Ag Obinutuzumab and rituximab variants having reduced adcp
JP2019514844A (ja) 2016-03-04 2019-06-06 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｃｄ７３抗体を用いた併用療法
SG11201806542PA (en) 2016-03-15 2018-08-30 Innate Pharma Anti-mica antibodies
EP3430054B1 (en) 2016-03-15 2021-12-29 Chugai Seiyaku Kabushiki Kaisha Methods of treating cancers using pd-1 axis binding antagonists and anti-gpc3 antibodies
KR102640157B1 (ko) 2016-03-22 2024-02-27 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 인간화 항-클라우딘-1 항체 및 이의 용도
CN108697799A (zh) 2016-03-22 2018-10-23 生态学有限公司 抗lgr5单克隆抗体的施用
CN108700598A (zh) 2016-03-25 2018-10-23 豪夫迈·罗氏有限公司 多路总抗体和抗体缀合的药物量化测定法
EP3865511A1 (en) 2016-04-14 2021-08-18 F. Hoffmann-La Roche AG Anti-rspo3 antibodies and methods of use
US11104739B2 (en) 2016-04-14 2021-08-31 Bristol-Myers Squibb Company Combination therapy using an anti-fucosyl-GM1 antibody and an anti-CD137 antibody
AU2017250296A1 (en) 2016-04-15 2018-11-01 Genentech, Inc. Methods for monitoring and treating cancer
MA44776A (fr) 2016-04-15 2019-03-06 Immunext Inc Anticorps anti-vista humain et leur utilisation
JP2019515670A (ja) 2016-04-15 2019-06-13 ジェネンテック， インコーポレイテッド がんをモニタリングし治療するための方法
WO2017180842A1 (en) 2016-04-15 2017-10-19 Bioatla, Llc Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereof
US11230591B2 (en) 2016-04-20 2022-01-25 Merck Sharp & Dohme Corp. CMV neutralizing antigen binding proteins
US11312766B2 (en) 2016-04-27 2022-04-26 Novartis Ag Antibodies against growth differentiation factor 15 and uses thereof
WO2017191101A1 (en) 2016-05-02 2017-11-09 F. Hoffmann-La Roche Ag The contorsbody - a single chain target binder
WO2017192589A1 (en) 2016-05-02 2017-11-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to influenza ha and their use and identification
IL321475A (en) 2016-05-06 2025-08-01 Medimmune Llc Bispecific binding proteins and their uses
CN109071640B (zh) 2016-05-11 2022-10-18 豪夫迈·罗氏有限公司 经修饰抗生腱蛋白抗体及使用方法
KR20240148936A (ko) 2016-05-13 2024-10-11 바이오아트라, 인코퍼레이티드 항 ror2 항체, 항체 단편 및 이의 면역접합체와 이것들의 용도
MA45031A (fr) 2016-05-18 2019-03-27 Genmab Bv Anticorps et leurs procédés d'utilisation dans le traitement de maladies infectieuses
JP2019522633A (ja) 2016-05-20 2019-08-15 ジェネンテック， インコーポレイテッド Ｐｒｏｔａｃ抗体コンジュゲート及び使用方法
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
WO2017205741A1 (en) 2016-05-27 2017-11-30 Genentech, Inc. Bioanalytical method for the characterization of site-specific antibody-drug conjugates
EP3252078A1 (en) 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
ES2861499T3 (es) 2016-06-08 2021-10-06 Abbvie Inc Anticuerpos anti-B7-H3 y conjugados anticuerpo-fármaco
WO2017214452A1 (en) 2016-06-08 2017-12-14 Xencor, Inc. Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b
CA3027047A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-cd98 antibodies and antibody drug conjugates
PE20190512A1 (es) 2016-06-08 2019-04-10 Abbvie Inc Conjugados de anticuerpo anti-egfr y farmaco
AU2017277422A1 (en) 2016-06-08 2019-01-03 Abbvie Inc. Anti-EGFR antibody drug conjugates
JP2019526529A (ja) 2016-06-08 2019-09-19 アッヴィ・インコーポレイテッド 抗ｂ７−ｈ３抗体及び抗体薬物コンジュゲート
US20200002432A1 (en) 2016-06-08 2020-01-02 Abbvie Inc. Anti-cd98 antibodies and antibody drug conjugates
US20200147235A1 (en) 2016-06-08 2020-05-14 Abbvie Inc. Anti-cd98 antibodies and antibody drug conjugates
JP2019521975A (ja) 2016-06-08 2019-08-08 アッヴィ・インコーポレイテッド 抗ｅｇｆｒ抗体薬物コンジュゲート
AU2017279554A1 (en) 2016-06-08 2019-01-03 Abbvie Inc. Anti-B7-H3 antibodies and antibody drug conjugates
JP7010854B2 (ja) 2016-06-14 2022-01-26 ゼンコア インコーポレイテッド 二重特異性チェックポイント阻害剤抗体
EP3471759A1 (en) 2016-06-15 2019-04-24 Novartis AG Methods for treating disease using inhibitors of bone morphogenetic protein 6 (bmp6)
CN109311969B (zh) 2016-06-17 2022-09-27 中外制药株式会社 抗-肌肉生长抑制因子抗体及使用方法
EP3257866A1 (en) 2016-06-17 2017-12-20 Academisch Medisch Centrum Modified anti-tnf antibody and use thereof in the treatment of ibd
JP7133477B2 (ja) 2016-06-24 2022-09-08 ジェネンテック， インコーポレイテッド 抗ポリユビキチン多重特異性抗体
MX2018016265A (es) 2016-06-28 2019-07-04 Xencor Inc Anticuerpos heterodimericos que se unen al receptor 2 de somatostatina.
CN117683135A (zh) 2016-07-14 2024-03-12 百时美施贵宝公司 针对tim3的抗体及其用途
EP3484923A1 (en) 2016-07-15 2019-05-22 Takeda Pharmaceutical Company Limited Methods and materials for assessing response to plasmablast- and plasma cell-depleting therapies
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
CA3031734A1 (en) 2016-07-29 2018-02-01 Juno Therapeutics, Inc. Anti-idiotypic antibodies against anti-cd19 antibodies
CN109661406A (zh) 2016-07-29 2019-04-19 国家医疗保健研究所 靶向肿瘤相关巨噬细胞的抗体及其用途
NL2017267B1 (en) 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
JP2019525934A (ja) 2016-07-29 2019-09-12 イーライ リリー アンド カンパニー 癌の治療に使用するためのメレスチニブおよび抗ｐｄ−ｌ１または抗ｐｄ−１阻害剤を用いた組み合わせ治療
EP3492496A4 (en) 2016-07-29 2020-07-29 Chugai Seiyaku Kabushiki Kaisha BISPECIFIC ANTIBODIES PRESENTING AN INCREASED ALTERNATIVE FUNCTIONAL ACTIVITY OF COFACTOR FVIII
NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
US11649285B2 (en) 2016-08-03 2023-05-16 Bio-Techne Corporation Identification of VSIG3/VISTA as a novel immune checkpoint and use thereof for immunotherapy
WO2018025982A1 (ja) 2016-08-05 2018-02-08 中外製薬株式会社 Ｉｌ－８関連疾患の治療用又は予防用組成物
WO2018027203A1 (en) 2016-08-05 2018-02-08 Allakos, Inc. Anti-siglec-7 antibodies for the treatment of cancer
JP7250674B2 (ja) 2016-08-08 2023-04-03 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト がんの治療及び診断方法
TWI672317B (zh) 2016-08-16 2019-09-21 英屬開曼群島商岸邁生物科技有限公司 單價不對稱串聯Fab雙特異性抗體
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
WO2018044970A1 (en) 2016-08-31 2018-03-08 University Of Rochester Human monoclonal antibodies to human endogenous retrovirus k envelope (herv-k) and uses thereof
EP3507305A1 (en) 2016-09-02 2019-07-10 Dana-Farber Cancer Institute, Inc. Composition and methods of treating b cell disorders
WO2018049083A1 (en) 2016-09-07 2018-03-15 The Regents Of The University Of California Antibodies to oxidation-specific epitopes
WO2018053032A1 (en) 2016-09-13 2018-03-22 Humanigen, Inc. Epha3 antibodies for the treatment of pulmonary fibrosis
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
EP3515932B1 (en) 2016-09-19 2023-11-22 F. Hoffmann-La Roche AG Complement factor based affinity chromatography
FI3528838T3 (fi) 2016-09-23 2023-10-02 Hoffmann La Roche IL-13-antagonistien käyttöjä atooppisen ihottuman hoitamiseksi
JOP20190055A1 (ar) 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
US11072660B2 (en) 2016-10-03 2021-07-27 Juno Therapeutics, Inc. HPV-specific binding molecules
CN110139674B (zh) 2016-10-05 2023-05-16 豪夫迈·罗氏有限公司 制备抗体药物缀合物的方法
KR102804118B1 (ko) 2016-10-06 2025-05-09 제넨테크, 인크. 암에 대한 치료 및 진단 방법
US20190330368A1 (en) 2016-10-07 2019-10-31 Daiichi Sankyo Company, Limited Therapy for drug-resistant cancer by administration of anti-her2 antibody/drug conjugate
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
CA3040189A1 (en) 2016-10-13 2018-04-19 Massachusetts Institute Of Technology Antibodies that bind zika virus envelope protein and uses thereof
CA3040504A1 (en) 2016-10-14 2018-04-19 Xencor, Inc. Il15/il15ra heterodimeric fc-fusion proteins
CA3037851A1 (en) 2016-10-21 2018-04-26 Innate Pharma Treatment with anti-kir3dl2 agents
BR112019008345A8 (pt) 2016-10-25 2023-03-07 Inst Nat Sante Rech Med Anticorpos monoclonais ligados à isoforma transmembrana cd160
EP3532101B1 (en) 2016-10-28 2021-12-08 Astute Medical, Inc. Use of antibodies to timp-2 for the improvement of renal function
EP3533466A4 (en) 2016-10-28 2020-06-10 Toray Industries, Inc. PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT AND / OR PREVENTION
US11555076B2 (en) 2016-10-29 2023-01-17 Genentech, Inc. Anti-MIC antibodies and methods of use
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
JP7277363B2 (ja) 2016-11-01 2023-05-18 ジェンマブ ビー．ブイ． ポリペプチド変異体およびその使用
EA201990787A1 (ru) 2016-11-02 2019-12-30 Энгмаб Сарл Биспецифичное антитело к всма и cd3 и иммунологическое лекарственное средство для комбинированного применения в лечении множественной миеломы
EP3988569A1 (en) 2016-11-02 2022-04-27 Jounce Therapeutics, Inc. Antibodies to pd-1 and uses thereof
BR112019008223A2 (pt) 2016-11-03 2019-07-16 Bristol-Myers Squibb Company anticorpos anti-ctla-4 ativáveis e usos dos mesmos
US11339209B2 (en) 2016-11-14 2022-05-24 Novartis Ag Compositions, methods, and therapeutic uses related to fusogenic protein minion
AU2017361081B2 (en) 2016-11-15 2024-12-19 Genentech, Inc. Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies
WO2018093669A1 (en) 2016-11-16 2018-05-24 Eli Lilly And Company Combination therapy for cancer with exon 14 skipping mutation(s) or exon 14 skipping phenotype
EP3468991A1 (en) 2016-11-21 2019-04-17 cureab GmbH Anti-gp73 antibodies and immunoconjugates
CR20190297A (es) 2016-11-23 2019-11-01 Bioverativ Therapeutics Inc Anticuerpos biespecíficos que se unen al factor de coagulación ix y al factor de coagulación x
CN108367075B (zh) 2016-11-23 2022-08-09 免疫方舟医药技术股份有限公司 4-1bb结合蛋白及其用途
WO2018101448A1 (en) 2016-11-30 2018-06-07 Kyowa Hakko Kirin Co., Ltd. Method of treating cancer using anti-ccr4 antibody and anti-pd-1 antibody
US10759855B2 (en) 2016-12-02 2020-09-01 Rigel Pharmaceuticals, Inc. Antigen binding molecules to TIGIT
MA50948A (fr) 2016-12-07 2020-10-14 Agenus Inc Anticorps et procédés d'utilisation de ceux-ci
WO2018106776A2 (en) 2016-12-07 2018-06-14 Genentech, Inc. Anti-tau antibodies and methods of use
SG10201911351SA (en) 2016-12-07 2020-02-27 Genentech Inc Anti-tau antibodies and methods of use
MX2019006331A (es) 2016-12-12 2019-07-12 Genentech Inc Métodos para tratar el cáncer usando anticuerpos anti-pd-l1 y antiandrógenos.
AU2017377233B2 (en) 2016-12-12 2024-12-19 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and immune checkpoint inhibitor
CN110234348B (zh) 2016-12-16 2024-06-25 蓝鳍生物医药公司 抗-含cub结构域蛋白1(cdcp1)抗体、抗体药物缀合物及其使用方法
BR112019012901A2 (pt) 2016-12-22 2020-01-07 Daiichi Sankyo Company, Limited Anticorpo ou fragmento de ligação a antígeno do anticorpo, polinucleotídeo, vetor, célula, métodos para produzir um anticorpo ou um fragmento de ligação a antígeno do anticorpo e uma molécula que se ligue ao cd3 humano e ao cd3 de macaco cinomolgo, composição farmacêutica, e, molécula
JOP20190134A1 (ar) 2016-12-23 2019-06-02 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
WO2018115262A1 (en) 2016-12-23 2018-06-28 Innate Pharma Heterodimeric antigen binding proteins
BR112019012667A2 (pt) 2016-12-23 2020-02-11 Novartis Ag Anticorpos do fator xi e métodos de uso
WO2018129029A1 (en) 2017-01-04 2018-07-12 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
WO2018129336A1 (en) 2017-01-06 2018-07-12 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
MA47236A (fr) 2017-01-06 2019-11-13 Iovance Biotherapeutics Inc Expansion de lymphocytes infiltrant les tumeurs (til) avec des agonistes de la superfamille des récepteurs du facteur de nécrose tumorale (tnfrsf) et des combinaisons thérapeutiques de til et d'agonistes de tnfrsf
CN112210010B (zh) 2017-01-06 2023-12-05 优特力克斯有限公司 抗-人4-1bb抗体及其应用
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
EP4046989A1 (en) 2017-01-09 2022-08-24 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
TW201831517A (zh) 2017-01-12 2018-09-01 美商優瑞科生物技術公司 靶向組織蛋白h3肽/mhc複合體之構築體及其用途
US11434289B2 (en) 2017-01-17 2022-09-06 Daiichi Sankyo Company, Limited Anti-GPR20 antibody and anti-GPR20 antibody-drug conjugate
EP3574918A4 (en) 2017-01-24 2021-03-03 Kyowa Kirin Co., Ltd. THERAPEUTIC OR PROPHYLACTIC AGENT, AND METHOD OF TREATMENT OR PREVENTION OF ACUTE IRRADIATION SYNDROME
CA3052938A1 (en) 2017-02-07 2018-08-16 Daiichi Sankyo Company, Limited Anti-gprc5d antibody and molecule comprising the antibody
ES3035810T3 (en) 2017-02-08 2025-09-09 Novartis Ag Fgf21 mimetic antibodies and uses thereof
MA47449A (fr) 2017-02-10 2019-12-18 Genmab Bv Variants polypeptidiques et ses utilisations
EP3580235B1 (en) 2017-02-10 2024-05-01 The United States of America, as represented by the Secretary, Department of Health and Human Services Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
US11471538B2 (en) 2017-02-10 2022-10-18 INSERM (Institut National de la Santéet de la Recherche Medicale) Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the MAPK pathway
AR110873A1 (es) 2017-02-10 2019-05-08 Genentech Inc Anticuerpos contra triptasa, composiciones de estos y usos de estos
WO2018146549A1 (en) 2017-02-10 2018-08-16 Eutilex Co., Ltd. IFN-γ-INDUCIBLE REGULATORY T CELL CONVERTIBLE ANTI-CANCER (IRTCA) ANTIBODY AND USES THEREOF
MX2019009117A (es) 2017-02-17 2019-09-13 Bristol Myers Squibb Co Anticuerpos anti alfa-sinucleina y usos de los mismos.
JP2020509037A (ja) 2017-02-28 2020-03-26 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ワクチンに対する免疫応答を増強するための、ａｄｃｃが増強された抗ｃｔｌａ−４抗体の使用
EP3590534A4 (en) 2017-02-28 2020-12-23 Kinki University METHOD OF TREATMENT OF EGFR-TKI-RESISTANT NON-SMALL-CELL LUNG CANCER BY ADMINISTRATION OF ANTI-HER3-DRUG ANTIBODY CONJUGATE
WO2018160841A1 (en) 2017-03-01 2018-09-07 Genentech, Inc. Diagnostic and therapeutic methods for cancer
EP3589654A1 (en) 2017-03-02 2020-01-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity to nectin-4 and uses thereof
JP6430082B1 (ja) 2017-03-02 2018-11-28 学校法人 聖マリアンナ医科大学 低用量抗ｃｃｒ４抗体を用いたｈｔｌｖ−１関連脊髄症の予防または治療剤
MA49279A (fr) 2017-03-22 2020-02-05 Hoffmann La Roche Compositions d'anticorps optimisées pour le traitement de troubles oculaires
US10982000B2 (en) 2017-03-24 2021-04-20 Novartis Ag Methods for treating and/or reducing the likelihood of heart failure by administering anti-activin receptor type II (anti-ActRII) antibody
SG10201911225WA (en) 2017-03-28 2020-01-30 Genentech Inc Methods of treating neurodegenerative diseases
JOP20190203A1 (ar) 2017-03-30 2019-09-03 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
WO2018185618A1 (en) 2017-04-03 2018-10-11 Novartis Ag Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
TWI796329B (zh) 2017-04-07 2023-03-21 美商默沙東有限責任公司 抗－ilt4抗體及抗原結合片段
US10851164B2 (en) 2017-04-13 2020-12-01 Aduro Biotech Holdings, Europe B.V. Anti-SIRPα antibodies
JP2020516253A (ja) 2017-04-14 2020-06-11 ジェネンテック， インコーポレイテッド がんのための診断及び治療方法
WO2018195302A1 (en) 2017-04-19 2018-10-25 Bluefin Biomedicine, Inc. Anti-vtcn1 antibodies and antibody drug conjugates
SG11201909048TA (en) 2017-04-21 2019-11-28 Genentech Inc Use of klk5 antagonists for treatment of a disease
AU2018258049B2 (en) 2017-04-26 2025-03-27 Eureka Therapeutics, Inc. Constructs specifically recognizing glypican 3 and uses thereof
EP3615572A1 (en) 2017-04-27 2020-03-04 Tesaro Inc. Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
JP2020518638A (ja) 2017-05-05 2020-06-25 アラコス インコーポレイテッド アレルギー性眼疾患を処置するための方法および組成物
MX2019013202A (es) 2017-05-10 2020-01-21 Iovance Biotherapeutics Inc Expansion de linfocitos de infiltracion de tumor a partir de tumores liquidos y usos terapeuticos de los mismos.
US11116835B2 (en) 2017-05-10 2021-09-14 Fred Hutchinson Cancer Research Center Epstein Barr virus antibodies, vaccines, and uses of the same
EP3625251A1 (en) 2017-05-15 2020-03-25 University Of Rochester Broadly neutralizing anti-influenza monoclonal antibody and uses thereof
TW202504644A (zh) 2017-05-15 2025-02-01 日商第一三共股份有限公司 抗體－藥物結合物之用途
EP3624837B1 (en) 2017-05-16 2025-07-30 Five Prime Therapeutics, Inc. Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment
JP2020520671A (ja) 2017-05-24 2020-07-16 ノバルティス アーゲー 抗体−サイトカイングラフト化タンパク質及び使用方法
JOP20190271A1 (ar) 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
BR112019024556A2 (pt) 2017-05-24 2020-06-23 Novartis Ag Proteínas enxertadas com citocina de anticorpo e métodos para uso no tratamento de câncer
WO2018215937A1 (en) 2017-05-24 2018-11-29 Novartis Ag Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
KR20240149979A (ko) 2017-05-25 2024-10-15 브리스톨-마이어스 스큅 컴퍼니 변형된 중쇄 불변 영역을 포함하는 항체
CA3064333A1 (en) 2017-05-29 2018-12-06 Gamamabs Pharma Cancer-associated immunosuppression inhibitor
US11225523B2 (en) 2017-06-01 2022-01-18 Compugen Ltd. Triple combination antibody therapies
UY37758A (es) 2017-06-12 2019-01-31 Novartis Ag Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
CA3066918A1 (en) 2017-06-12 2018-12-20 Bluefin Biomedicine, Inc. Anti-il1rap antibodies and antibody drug conjugates
WO2018229706A1 (en) 2017-06-16 2018-12-20 Novartis Ag Combination therapy for the treatment of cancer
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
CN111132733A (zh) 2017-06-30 2020-05-08 Xencor股份有限公司 含有IL-15/IL-15Rα和抗原结合结构域的靶向异源二聚体Fc融合蛋白
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
BR112020000719A2 (pt) 2017-07-11 2020-07-14 Compass Therapeutics Llc anticorpos agonistas que ligam o cd137 humano e seus usos
CA3070342A1 (en) 2017-07-18 2019-01-24 Kyowa Kirin Co., Ltd. Anti-human ccr1 monoclonal antibody
MX2020000604A (es) 2017-07-21 2020-09-10 Genentech Inc Métodos terapéuticos y de diagnóstico para el cáncer.
CA3071193A1 (en) 2017-07-26 2019-01-31 Forty Seven, Inc. Anti-sirp-alpha antibodies and related methods
BR112020001657A2 (pt) 2017-07-27 2020-07-21 Daiichi Sankyo Company, Limited Anticorpo contra cd147 humana, fragmento de ligação a antígeno do anticorpo, composição farmacêutica, uso do anticorpo ou do fragmento de ligação a antígeno,polinucleotídeo, vetor de expressão, célula hospedeira, método para produzir o anticorpo ou o fragmento de ligação a antígeno do mesmo, para prognosticar aresponsividade ao tratamento contra o câncer e para selecionar sujeitos para o tratamento contra o câncer, kit para determinar a responsividade ao tratamento contra o câncer, complexo de anticorpo-fármaco, e, anticorpo biespecífico
BR112020003474A2 (pt) 2017-08-23 2020-10-20 Daiichi Sankyo Company, Limited composição farmacêutica, e, método para produzir uma composição farmacêutica
CN119552248A (zh) 2017-08-25 2025-03-04 戊瑞治疗有限公司 B7-h4抗体及其使用方法
SG11202000997YA (en) 2017-08-31 2020-03-30 Daiichi Sankyo Co Ltd Improved method for producing antibody-drug conjugate
US11318212B2 (en) 2017-08-31 2022-05-03 Daiichi Sankyo Company, Limited Method for producing antibody-drug conjugate
US11780915B2 (en) 2017-09-11 2023-10-10 Monash University Binding proteins to the human thrombin receptor, PAR4
WO2019059411A1 (en) 2017-09-20 2019-03-28 Chugai Seiyaku Kabushiki Kaisha DOSAGE FOR POLYTHERAPY USING PD-1 AXIS BINDING ANTAGONISTS AND GPC3 TARGETING AGENT
AU2018342527B2 (en) 2017-09-29 2024-06-27 Daiichi Sankyo Company, Limited Antibody-pyrrolobenzodiazepine derivative conjugate
MA50613A (fr) 2017-10-03 2020-08-12 Editas Medicine Inc Molécules de liaison spécifique à l'hpv
RU2698048C2 (ru) 2017-10-03 2019-08-21 Закрытое Акционерное Общество "Биокад" МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
KR102818021B1 (ko) 2017-10-05 2025-06-10 다이이찌 산쿄 가부시키가이샤 세포 상해성 t 세포 고갈용 조성물
US11230601B2 (en) 2017-10-10 2022-01-25 Tilos Therapeutics, Inc. Methods of using anti-lap antibodies
AU2018347521A1 (en) 2017-10-12 2020-05-07 Immunowake Inc. VEGFR-antibody light chain fusion protein
WO2019081983A1 (en) 2017-10-25 2019-05-02 Novartis Ag CD32B TARGETING ANTIBODIES AND METHODS OF USE
WO2019089753A2 (en) 2017-10-31 2019-05-09 Compass Therapeutics Llc Cd137 antibodies and pd-1 antagonists and uses thereof
AU2018358067A1 (en) 2017-11-01 2020-05-07 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for B-cell maturation antigen
CA3077664A1 (en) 2017-11-06 2019-05-09 Genentech, Inc. Diagnostic and therapeutic methods for cancer
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
EP3708589A4 (en) 2017-11-08 2021-08-11 Kyowa Kirin Co., Ltd. BISPECIFIC ANTIBODIES THAT BIND TO CD40 AND EpCAM
AU2018366199A1 (en) 2017-11-08 2020-05-28 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences
US11851497B2 (en) 2017-11-20 2023-12-26 Compass Therapeutics Llc CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
EP3713959A1 (en) 2017-11-21 2020-09-30 Innate Pharma Multispecific antigen binding proteins
CA3083118A1 (en) 2017-11-22 2019-05-31 Iovance Biotherapeutics, Inc. Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
BR112020010016A2 (pt) 2017-11-22 2020-11-10 Novartis Ag agentes de ligação de reversão para anticorpos antifator xi/xia e usos dos mesmos
EP3717516A1 (en) 2017-12-01 2020-10-07 Pfizer Inc Anti-cxcr5 antibodies and compositions and uses thereof
JP7685835B2 (ja) 2017-12-01 2025-05-30 ノバルティス アーゲー ポリオーマウイルス中和抗体
US20210171598A1 (en) 2017-12-01 2021-06-10 University Of Copenhagen Peptide hormone with one or more o-glycans
EP3498293A1 (en) 2017-12-15 2019-06-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Treatment of monogenic diseases with an anti-cd45rc antibody
KR20200110745A (ko) 2017-12-15 2020-09-25 주노 쎄러퓨티크스 인코퍼레이티드 항 - ｃｃｔ5 결합 분자 및 이의 사용 방법
US20210369775A1 (en) 2017-12-15 2021-12-02 Iovance Biotherapeutics, Inc. Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof
AU2018390418B2 (en) 2017-12-19 2023-12-21 Xencor, Inc. Engineered IL-2 Fc fusion proteins
KR20200103706A (ko) 2017-12-22 2020-09-02 조운스 테라퓨틱스, 인크. Lilrb2에 대한 항체
WO2019126472A1 (en) 2017-12-22 2019-06-27 Genentech, Inc. Use of pilra binding agents for treatment of a disease
WO2019129136A1 (zh) 2017-12-27 2019-07-04 信达生物制药(苏州)有限公司 抗pd-l1抗体及其用途
CN115925943A (zh) 2017-12-27 2023-04-07 信达生物制药(苏州)有限公司 抗pd-l1抗体及其用途
WO2019129137A1 (zh) 2017-12-27 2019-07-04 信达生物制药(苏州)有限公司 抗lag-3抗体及其用途
CN111699198B (zh) 2017-12-28 2023-09-05 南京传奇生物科技有限公司 针对tigit的单域抗体和其变体
SG11202005273XA (en) 2017-12-28 2020-07-29 Nanjing Legend Biotech Co Ltd Antibodies and variants thereof against pd-l1
EP3732196A4 (en) 2017-12-28 2022-01-05 Astute Medical, Inc. ANTIBODIES AND ASSAYS FOR CCL14
WO2019136029A1 (en) 2018-01-02 2019-07-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to ebola virus glycoprotein and their use
CN111818943B (zh) 2018-01-04 2024-09-03 伊科尼克治疗公司 抗组织因子抗体、抗体-药物缀合物及相关方法
EA202091650A1 (ru) 2018-01-05 2020-12-02 Ас Иммьюн Са Неправильно свернутые tdp-43-связывающие молекулы
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
US11407723B2 (en) 2018-01-09 2022-08-09 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
WO2019140229A1 (en) 2018-01-12 2019-07-18 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
JP7366908B2 (ja) 2018-01-15 2023-10-23 ナンジン レジェンド バイオテック カンパニー，リミテッド Ｐｄ－１に対する単一ドメイン抗体及びその変異体
WO2019143636A1 (en) 2018-01-16 2019-07-25 Lakepharma, Inc. Bispecific antibody that binds cd3 and another target
WO2019148026A1 (en) 2018-01-26 2019-08-01 Genentech, Inc. Il-22 fc fusion proteins and methods of use
HRP20221448T1 (hr) 2018-01-26 2023-01-20 F. Hoffmann - La Roche Ag Il-22 fc pripravci i postupci njihove primjene
WO2019148412A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
TWI800854B (zh) 2018-02-01 2023-05-01 大陸商信達生物製藥（蘇州）有限公司 全人源的抗ｂ細胞成熟抗原（ｂｃｍａ）單鏈抗體及其應用
CN111868082A (zh) 2018-02-02 2020-10-30 博奥泰克尼公司 调节vista和vsig3的相互作用的化合物及其制备和使用方法
BR112020016169A2 (pt) 2018-02-08 2020-12-15 Genentech, Inc. Moléculas de ligação ao antígeno biespecíficas, ácido nucleico isolado, vetor, célula hospedeira, métodos para produzir a molécula de ligação, conjunto de ácidos nucleicos isolados, conjunto de vetores, conjunto de células hospedeiras, imunoconjugado, composição, uso da molécula de ligação, métodos para tratar ou retardar a progressão de um câncer, métodos para aperfeiçoar a função imune e kit
EP3749362A1 (en) 2018-02-09 2020-12-16 F. Hoffmann-La Roche AG Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases
MA51875A (fr) 2018-02-13 2020-12-23 Iovance Biotherapeutics Inc Expansion de lymphocytes infiltrant les tumeurs (til) avec des antagonistes du récepteur a2a de l'adénosine et combinaisons thérapeutiques de til et d'antagonistes du récepteur a2a de l'adénosine
CN111757894B (zh) 2018-02-14 2025-02-25 Abba疗法股份公司 抗人类pd-l2抗体
EP3755713A1 (en) 2018-02-21 2020-12-30 The United States of America, as represented by the Secretary, Department of Health and Human Services Neutralizing antibodies to hiv-1 env and their use
KR20200123118A (ko) 2018-02-21 2020-10-28 제넨테크, 인크. IL-22 Fc 융합 단백질로 치료를 위한 투약
MA51902A (fr) 2018-02-21 2021-05-26 Five Prime Therapeutics Inc Schémas posologiques d'anticorps b7-h4
JP2021514379A (ja) 2018-02-21 2021-06-10 ファイブ プライム セラピューティクス， インコーポレイテッド Ｂ７−ｈ４抗体製剤
US20200399376A1 (en) 2018-02-26 2020-12-24 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
NL2020520B1 (en) 2018-03-02 2019-09-12 Labo Bio Medical Invest B V Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders
MA52416A (fr) 2018-03-02 2021-04-21 Five Prime Therapeutics Inc Anticorps b7-h4 et leurs procédés d'utilisation
EP3763386A4 (en) 2018-03-05 2021-12-29 Saitama Medical University Pharmaceutical composition for treating or preventing heterotopic ossification
CN112166123B (zh) 2018-03-14 2022-09-30 北京轩义医药科技有限公司 抗紧密连接蛋白18.2抗体
EP3765517A1 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
US20200040103A1 (en) 2018-03-14 2020-02-06 Genentech, Inc. Anti-klk5 antibodies and methods of use
WO2019177543A1 (en) 2018-03-15 2019-09-19 Chugai Seiyaku Kabushiki Kaisha Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use
US12173069B2 (en) 2018-03-21 2024-12-24 Five Prime Therapeutics, Inc. Antibodies binding to vista at acidic pH
BR112020018539A2 (pt) 2018-03-23 2020-12-29 Bristol-Myers Squibb Company Anticorpos contra mica e/ou micb e usos dos mesmos
CN111886254B (zh) 2018-03-30 2023-12-08 南京传奇生物科技有限公司 针对lag-3的单结构域抗体及其用途
KR20200136935A (ko) 2018-03-30 2020-12-08 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
TW202011029A (zh) 2018-04-04 2020-03-16 美商建南德克公司 偵測及定量fgf21之方法
WO2019195623A2 (en) 2018-04-04 2019-10-10 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
RU2020135968A (ru) 2018-04-05 2022-05-06 Джуно Терапьютикс, Инк. T-клеточные рецепторы и модифицированные клетки, экспрессирующие
EP3552631A1 (en) 2018-04-10 2019-10-16 Inatherys Antibody-drug conjugates and their uses for the treatment of cancer
WO2019204665A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
CN112437777A (zh) 2018-04-18 2021-03-02 Xencor股份有限公司 包含IL-15/IL-15RA Fc融合蛋白和TIM-3抗原结合结构域的靶向TIM-3的异源二聚体融合蛋白
JP7402541B2 (ja) 2018-05-03 2023-12-21 ユニバーシティ オブ ロチェスター 抗インフルエンザノイラミニダーゼモノクローナル抗体およびその使用
AU2019264217A1 (en) 2018-05-03 2020-12-17 Genmab B.V. Antibody variant combinations and uses thereof
US12060425B2 (en) 2018-05-03 2024-08-13 Shanghai Epimab Biotherapeutics Co., Ltd. High affinity antibodies to PD-1 and LAG-3 and bispecific binding proteins made therefrom
CA3100007A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable interleukin-2 polypeptides and methods of use thereof
JP7497340B2 (ja) 2018-05-14 2024-06-10 ウェアウルフ セラピューティクス， インコーポレイテッド 活性化可能なインターロイキン１２ポリペプチド及びその使用方法
TWI825098B (zh) 2018-05-18 2023-12-11 德商葛萊高托普公司 抗ｍｕｃ１抗體
WO2019226617A1 (en) 2018-05-21 2019-11-28 Compass Therapeutics Llc Compositions and methods for enhancing the killing of target cells by nk cells
IL278988B2 (en) 2018-05-28 2024-10-01 Daiichi Sankyo Co Ltd Anti-her2 antibody-drug conjugates for use in the treatment of her-2 mutated cancer
AR126019A1 (es) 2018-05-30 2023-09-06 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
WO2019229699A1 (en) 2018-05-31 2019-12-05 Novartis Ag Hepatitis b antibodies
TWI875486B (zh) 2018-05-31 2025-03-01 日商第一三共股份有限公司 抗人類tlr7抗體、其用途及醫藥組成物
WO2019227490A1 (en) 2018-06-01 2019-12-05 Tayu Huaxia Biotech Medical Group Co., Ltd. Compositions and methods for imaging
MY199538A (en) 2018-06-01 2023-11-06 Novartis Ag Binding molecules against bcma and uses thereof
CA3102230A1 (en) 2018-06-01 2019-12-05 Tayu Huaxia Biotech Medical Group Co., Ltd. Compositions and uses thereof for treating disease or condition
EP3802599B1 (en) 2018-06-03 2023-12-20 LamKap Bio beta AG Bispecific antibodies against ceacam5 and cd47
JP7372237B2 (ja) 2018-06-04 2023-10-31 中外製薬株式会社 細胞質内での半減期が変化した抗原結合分子
TW202519270A (zh) 2018-06-07 2025-05-16 美商思進公司 喜樹鹼結合物
CA3103936A1 (en) 2018-06-18 2019-12-26 Eureka Therapeutics, Inc. Constructs targeting prostate-specific membrane antigen (psma) and uses thereof
EP3810653A1 (en) 2018-06-23 2021-04-28 F. Hoffmann-La Roche AG Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
EP3816291A4 (en) 2018-06-26 2022-03-16 Kyowa Kirin Co., Ltd. ANTIBODY BINDING TO CHONDROITIN SULFATE PROTEOGLYCAN-5
KR20210027295A (ko) 2018-06-26 2021-03-10 쿄와 기린 가부시키가이샤 세포 부착 분자3에 결합하는 항체
UY38289A (es) 2018-07-02 2020-01-31 Amgen Inc Proteína de unión al antígeno anti-steap1
JP7554742B2 (ja) 2018-07-03 2024-09-20 マレンゴ・セラピューティクス，インコーポレーテッド 抗ｔｃｒ抗体分子およびその使用
MY201995A (en) 2018-07-09 2024-03-28 Five Prime Therapeutics Inc Antibodies binding to ilt4
WO2020014306A1 (en) 2018-07-10 2020-01-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
EP3820902A2 (en) 2018-07-11 2021-05-19 Five Prime Therapeutics, Inc. Antibodies binding to vista at acidic ph
US20240254252A1 (en) 2018-07-13 2024-08-01 Genmab A/S Trogocytosis-mediated therapy using cd38 antibodies
CA3106146A1 (en) 2018-07-13 2020-01-16 Genmab A/S Variants of cd38 antibody and uses thereof
BR112021000673A2 (pt) 2018-07-18 2021-04-20 Genentech, Inc. métodos para tratar um indivíduo com câncer de pulmão, kits, anticorpo anti-pd-l1 e composições
MX2021000745A (es) 2018-07-20 2021-03-26 Surface Oncology Inc Composiciones anti-cd112r y metodos.
EP3828206A4 (en) 2018-07-25 2022-04-20 Daiichi Sankyo Company, Limited METHOD OF PREPARING AN ANTIBODY DRUG CONJUGATE
CA3108044A1 (en) 2018-07-31 2020-02-06 Daiichi Sankyo Company, Limited Treatment of metastatic brain tumor by administration of antibody-drug conjugate
SG11202101152QA (en) 2018-08-03 2021-03-30 Chugai Pharmaceutical Co Ltd Antigen-binding molecule containing two antigen-binding domains that are linked to each other
CA3108754A1 (en) 2018-08-06 2020-02-13 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and tubulin inhibitor
MA50586A (fr) 2018-08-09 2020-09-16 Regeneron Pharma Procédés d'évaluation de l'affinité de liaison d'une variante d'anticorps au récepteur fc néonatal
BR112021002037A2 (pt) 2018-08-10 2021-05-04 Chugai Seiyaku Kabushiki Kaisha molécula de ligação de antígeno anti-cd137 e uso da mesma
WO2020037258A1 (en) 2018-08-17 2020-02-20 Ab Studio Inc. Catabodies and methods of use thereof
TW202021618A (zh) 2018-08-17 2020-06-16 美商２３與我有限公司 抗ｉｌ１ｒａｐ抗體及其使用方法
US11401339B2 (en) 2018-08-23 2022-08-02 Seagen Inc. Anti-TIGIT antibodies
US12312641B2 (en) 2018-08-23 2025-05-27 Daiichi Sankyo Company, Limited Sensitivity marker for antibody-drug conjugate
TW202031273A (zh) 2018-08-31 2020-09-01 美商艾歐凡斯生物治療公司 抗ｐｄ－１抗體難治療性之非小細胞肺癌（ｎｓｃｌｃ）病患的治療
US11590223B2 (en) 2018-08-31 2023-02-28 Regeneron Pharmaceuticals, Inc. Dosing strategy that mitigates cytokine release syndrome for therapeutic antibodies
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
WO2020053742A2 (en) 2018-09-10 2020-03-19 Novartis Ag Anti-hla-hbv peptide antibodies
CA3110750A1 (en) 2018-09-10 2020-03-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies against cd33 and constructs thereof
WO2020056170A1 (en) 2018-09-12 2020-03-19 Fred Hutchinson Cancer Research Center Reducing cd33 expression to selectively protect therapeutic cells
CN112672760B (zh) 2018-09-13 2025-05-30 德克萨斯大学体系董事会 新颖lilrb4抗体和其用途
CA3111401A1 (en) 2018-09-19 2020-03-26 Genentech, Inc. Therapeutic and diagnostic methods for bladder cancer
JP7618950B2 (ja) 2018-09-19 2025-01-22 インサーム （インスティテュート ナショナル デ ラ サンテ エ デ ラ ルシェルシェ メディカル） 免疫チェックポイント治療に抵抗性のある癌の治療のための方法および医薬組成物
EP3854418A4 (en) 2018-09-20 2022-07-27 Daiichi Sankyo Company, Limited Treatment of her3 mutant cancer by administration of anti-her3 antibody-drug conjugate
US20220322655A1 (en) 2018-09-20 2022-10-13 Iovance Biotherapeutics, Inc. Expansion of TILs from Cryopreserved Tumor Samples
WO2020061349A1 (en) 2018-09-21 2020-03-26 Genentech, Inc. Diagnostic methods for triple-negative breast cancer
EP3626265A1 (en) 2018-09-21 2020-03-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-human cd45rc antibodies and uses thereof
AU2019347751B2 (en) 2018-09-27 2025-05-22 Xilio Development, Inc. Masked cytokine polypeptides
US20210380684A1 (en) 2018-09-28 2021-12-09 Kyowa Kirin Co., Ltd. Antibody composition
EP3861016A2 (en) 2018-10-03 2021-08-11 Xencor, Inc. Il-12 heterodimeric fc-fusion proteins
MY208925A (en) 2018-10-05 2025-06-11 Five Prime Therapeutics Inc Anti-fgfr2 antibody formulations
TW202035445A (zh) 2018-10-10 2020-10-01 美商帝洛斯療法股份有限公司 抗lap抗體變異體及其用途
MA53911A (fr) 2018-10-15 2022-01-19 Five Prime Therapeutics Inc Polythérapie contre le cancer
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
WO2020081493A1 (en) 2018-10-16 2020-04-23 Molecular Templates, Inc. Pd-l1 binding proteins
MX2021004348A (es) 2018-10-18 2021-05-28 Genentech Inc Procedimientos de diagnóstico y terapéuticos para el cáncer de riñón sarcomatoide.
EP3873532A1 (en) 2018-10-31 2021-09-08 Novartis AG Dc-sign antibody drug conjugates
WO2020089437A1 (en) 2018-10-31 2020-05-07 Engmab Sàrl Combination therapy
BR112021008549A2 (pt) 2018-11-05 2022-01-04 Iovance Biotherapeutics Inc Método de tratamento de carcinoma pulmonar de células não pequenas com uma população de linfócitos infiltrantes de tumor
MX2021004775A (es) 2018-11-05 2021-06-08 Iovance Biotherapeutics Inc Expansion de linfocitos infiltrantes de tumores (tils) usando inhibidores de la via de proteina cinasa b (akt).
US20220025058A1 (en) 2018-11-06 2022-01-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of acute myeloid leukemia by eradicating leukemic stem cells
CN119735694A (zh) 2018-11-13 2025-04-01 指南针制药有限责任公司 对抗检查点分子的多特异性结合构建体及其用途
BR112021009251A2 (pt) 2018-11-14 2021-08-10 Daiichi Sankyo Company, Limited conjugado anticorpo-fármaco, anticorpo ou um fragmento funcional do mesmo, polinucleotídeo, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos para produção de um anticorpo com glicano remodelado, de um conjugado anticorpo-fármaco, do anticorpo ou um fragmento funcional do mesmo e para tratamento de um tumor.
MX2021005751A (es) 2018-11-16 2021-10-01 Memorial Sloan Kettering Cancer Center Anticuerpos contra mucina 16 y métodos de uso de los mismos.
WO2020112781A1 (en) 2018-11-28 2020-06-04 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
MX2021006578A (es) 2018-12-05 2021-07-07 Genentech Inc Procedimientos de diagnostico y composiciones para la inmunoterapia contra el cancer.
MX2021006573A (es) 2018-12-06 2021-07-15 Genentech Inc Tratamiento conjunto de linfoma difuso de linfocitos b grandes que comprende un inmunoconjugado anti-cd79b, un agente alquilante y un anticuerpo anti-cd20.
CN113227119A (zh) 2018-12-10 2021-08-06 基因泰克公司 用于与含Fc的蛋白质进行位点特异性缀合的光交联肽
KR20210102341A (ko) 2018-12-11 2021-08-19 다이이찌 산쿄 가부시키가이샤 항체-약물 컨쥬게이트와 parp 저해제의 조합
WO2020120786A1 (en) 2018-12-14 2020-06-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Isolated mhc-derived human peptides and uses thereof for stimulating and activating the suppressive function of cd8+cd45rclow tregs
TW202039554A (zh) 2018-12-19 2020-11-01 瑞士商諾華公司 抗ＴＮＦ－α抗體
AR117327A1 (es) 2018-12-20 2021-07-28 23Andme Inc Anticuerpos anti-cd96 y métodos de uso de estos
JP2022514290A (ja) 2018-12-20 2022-02-10 ジェネンテック， インコーポレイテッド 改変抗体ｆｃおよび使用方法
US20220089694A1 (en) 2018-12-20 2022-03-24 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Ebola virus glycoprotein-specific monoclonal antibodies and uses thereof
BR112021011894A2 (pt) 2018-12-21 2021-09-08 Daiichi Sankyo Company, Limited Composição farmacêutica
KR20210107721A (ko) 2018-12-21 2021-09-01 23앤드미 인코포레이티드 항-il-36 항체 및 이의 사용 방법
AU2019416220A1 (en) 2018-12-26 2021-07-22 Xilio Development, Inc. anti-CTLA4 antibodies and methods of use thereof
CA3125316A1 (en) 2018-12-28 2020-07-02 Kyowa Kirin Co., Ltd. Bispecific antibody binding to tfr
JP7650802B2 (ja) 2018-12-30 2025-03-25 エフ． ホフマン－ラ ロシュ アーゲー 抗ウサギｃｄ１９抗体および使用方法
EP3908678A1 (en) 2019-01-10 2021-11-17 Iovance Biotherapeutics, Inc. System and methods for monitoring adoptive cell therapy clonality and persistence
WO2020148207A1 (en) 2019-01-14 2020-07-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Human monoclonal antibodies binding to hla-a2
CN115120716A (zh) 2019-01-14 2022-09-30 健泰科生物技术公司 用pd-1轴结合拮抗剂和rna疫苗治疗癌症的方法
CN109762067B (zh) 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 结合人Claudin 18.2的抗体及其用途
JP7285936B2 (ja) 2019-01-22 2023-06-02 ブリストル－マイヤーズ スクイブ カンパニー Ｉｌ－７ｒアルファサブユニットに対する抗体及びその使用
US12263234B2 (en) 2019-01-23 2025-04-01 Tayu Huaxia Biotech Medical Group Co., Ltd. Anti-PD-L1 diabodies and the use thereof
SG11202107941TA (en) 2019-01-23 2021-08-30 Encefa Cd31 competitors and uses thereof
WO2020153467A1 (ja) 2019-01-24 2020-07-30 中外製薬株式会社 新規がん抗原及びそれらの抗原に対する抗体
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
SG11202107976SA (en) 2019-01-29 2021-08-30 Juno Therapeutics Inc Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
AU2020226893B2 (en) 2019-02-21 2025-02-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
CN114127111B (zh) 2019-02-21 2024-09-10 马伦戈治疗公司 与nkp30结合的抗体分子及其用途
WO2020176748A1 (en) 2019-02-27 2020-09-03 Genentech, Inc. Dosing for treatment with anti-tigit and anti-cd20 or anti-cd38 antibodies
US11472890B2 (en) 2019-03-01 2022-10-18 Xencor, Inc. Heterodimeric antibodies that bind ENPP3 and CD3
EP3931310A1 (en) 2019-03-01 2022-01-05 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
MX2021010565A (es) 2019-03-08 2021-10-13 Genentech Inc Metodos para detectar y cuantificar proteinas asociadas a la membrana en vesiculas extracelulares.
WO2020185763A1 (en) 2019-03-11 2020-09-17 Memorial Sloan Kettering Cancer Center Cd22 antibodies and methods of using the same
MX2021010996A (es) 2019-03-14 2021-11-04 Genentech Inc Tratamiento de cancer con anticuerpos biespecificos contra her2xcd3 en combinacion con mab anti-her2.
WO2020189748A1 (ja) 2019-03-19 2020-09-24 中外製薬株式会社 Ｍｔａ依存的に抗原に対する結合活性が変化する抗原結合ドメインを含む抗原結合分子及び当該抗原結合ドメイン取得用ライブラリ
TW202102225A (zh) 2019-03-25 2021-01-16 日商第一三共股份有限公司 抗her2抗體-吡咯并苯二氮呯衍生物結合物
KR20210143237A (ko) 2019-03-25 2021-11-26 다이이찌 산쿄 가부시키가이샤 항체-피롤로벤조디아제핀 유도체 컨쥬게이트
WO2020196712A1 (ja) 2019-03-27 2020-10-01 第一三共株式会社 抗体－ピロロベンゾジアゼピン誘導体コンジュゲートとｐａｒｐ阻害剤の組み合わせ
CN113874392A (zh) 2019-03-28 2021-12-31 丹尼斯科美国公司 工程化抗体
ES3009719T3 (en) 2019-04-18 2025-03-31 Bristol Myers Squibb Co Ipilimumab variants with enhanced specificity for binding at low ph
BR112021020867A2 (pt) 2019-04-19 2022-01-04 Genentech Inc Anticorpos, ácido nucleico, vetor, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, usos do anticorpo, método de tratamento de um indivíduo com câncer e método para reduzir a depuração
AU2020257748A1 (en) 2019-04-19 2021-11-18 Chugai Seiyaku Kabushiki Kaisha Chimeric receptor recognizing modification site of antibody
KR20220004744A (ko) 2019-05-03 2022-01-11 제넨테크, 인크. 항-pd-l1 항체를 이용하여 암을 치료하는 방법
EP3962523A2 (en) 2019-05-03 2022-03-09 The United States of America, as represented by the Secretary, Department of Health and Human Services Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
BR112021022815A2 (pt) 2019-05-14 2021-12-28 Genentech Inc Métodos para tratar linfoma folicular, kits, imunoconjugados e polatuzumabe vedotina
KR20220023988A (ko) 2019-05-14 2022-03-03 웨어울프 세라퓨틱스, 인크. 분리 모이어티 및 이의 사용 방법
JPWO2020230899A1 (browse.php) 2019-05-15 2020-11-19
JP7502281B2 (ja) 2019-05-15 2024-06-18 協和キリン株式会社 Ｃｄ４０とｇｐｃ３に結合するバイスペシフィック抗体
EP3972650A2 (en) 2019-05-20 2022-03-30 Novartis AG Antibody drug conjugates having linkers comprising hydrophilic groups
WO2020234399A1 (en) 2019-05-20 2020-11-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Novel anti-cd25 antibodies
JP7664183B2 (ja) 2019-05-21 2025-04-17 ノバルティス アーゲー Ｂｃｍａに対する三重特異性結合分子及びその使用
AU2020279974C1 (en) 2019-05-21 2025-04-10 Novartis Ag CD19 binding molecules and uses thereof
US20230085439A1 (en) 2019-05-21 2023-03-16 University Of Georgia Research Foundation, Inc. Antibodies that bind human metapneumovirus fusion protein and their use
US12037378B2 (en) 2019-05-21 2024-07-16 Novartis Ag Variant CD58 domains and uses thereof
WO2020234473A1 (en) 2019-05-23 2020-11-26 Ac Immune Sa Anti-tdp-43 binding molecules and uses thereof
JP7705809B2 (ja) 2019-05-29 2025-07-10 第一三共株式会社 抗体薬物複合体の用量
JOP20210326A1 (ar) 2019-06-12 2023-01-30 Novartis Ag أجسام مضادة للمستقبل 1 لببتيد إدرار الصوديوم في البول وطرق استخدامها
BR112021025476A2 (pt) 2019-06-26 2022-10-11 Glaxosmithkline Ip Dev Ltd Proteínas de ligação à il1rap
EP3994173A1 (en) 2019-07-02 2022-05-11 The United States of America, as represented by the Secretary, Department of Health and Human Services Monoclonal antibodies that bind egfrviii and their use
EP3998083A4 (en) 2019-07-12 2023-08-23 Chugai Seiyaku Kabushiki Kaisha ANTI-MUTATION TYPE FGFR3 ANTIBODY AND USE THEREOF
EP3999539A1 (en) 2019-07-15 2022-05-25 Intervet International B.V. Caninized antibodies to human and canine ctla-4
WO2021009187A1 (en) 2019-07-15 2021-01-21 Intervet International B.V. Caninized antibodies against canine ctla-4
JP2022541200A (ja) 2019-07-16 2022-09-22 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） Ｃｄ３８に特異性を有する抗体及びその使用
JP2022542863A (ja) 2019-07-24 2022-10-07 ハー・ルンドベック・アクチエゼルスカベット 抗ｍＧｌｕＲ５抗体及びその使用
WO2021020282A1 (ja) 2019-07-26 2021-02-04 学校法人埼玉医科大学 Ａｌｋ２／ａｃｖｒ１の細胞外領域を認識する抗体
JP2022542505A (ja) 2019-07-29 2022-10-04 コンピュジェン リミテッド 抗ｐｖｒｉｇ抗体製剤およびそれらの使用
CN120204384A (zh) 2019-08-06 2025-06-27 葛兰素史密斯克莱知识产权发展有限公司 生物药物组合物和相关方法
AU2020325770B2 (en) 2019-08-06 2022-08-25 Aprinoia Therapeutics Limited Antibodies that bind to pathological tau species and uses thereof
EP4438056A3 (en) 2019-09-12 2025-01-01 F. Hoffmann-La Roche AG Compositions and methods of treating lupus nephritis
EP4031578A1 (en) 2019-09-18 2022-07-27 Novartis AG Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與ｅｎｔｐｄ２抗體之組合療法
BR112022004831A2 (pt) 2019-09-19 2022-06-07 Bristol Myers Squibb Co Anticorpos que se ligam a vista em ph ácido
CN114423454A (zh) 2019-09-20 2022-04-29 豪夫迈·罗氏有限公司 抗类胰蛋白酶抗体的给药
TW202126688A (zh) 2019-09-27 2021-07-16 瑞典商阿斯特捷利康公司 使用貝那利珠單抗治療遲發性氣喘之方法
PE20221110A1 (es) 2019-09-27 2022-07-11 Genentech Inc Administracion de dosis para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1
US20220363776A1 (en) 2019-10-04 2022-11-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer
WO2021074695A1 (en) 2019-10-16 2021-04-22 Avacta Life Sciences Limited PD-L1 INHIBITOR - TGFβ INHIBITOR BISPECIFIC DRUG MOIETIES.
CN118557751A (zh) 2019-10-18 2024-08-30 基因泰克公司 使用抗CD79b免疫缀合物治疗弥漫性大B细胞淋巴瘤的方法
EP4054632A1 (en) 2019-11-04 2022-09-14 Compugen Ltd. Combination therapy with anti-pvrig antibodies formulations and anti-pd-1 antibodies
US20220389103A1 (en) 2019-11-06 2022-12-08 Genentech, Inc. Diagnostic and therapeutic methods for treatment of hematologic cancers
JP2023503258A (ja) 2019-11-14 2023-01-27 ウェアウルフ セラピューティクス， インコーポレイテッド 活性化可能サイトカインポリペプチド及びその使用方法
IL293099B2 (en) 2019-11-20 2025-07-01 Chugai Pharmaceutical Co Ltd Antibody-containing preparation
EP3831849A1 (en) 2019-12-02 2021-06-09 LamKap Bio beta AG Bispecific antibodies against ceacam5 and cd47
BR112022010627A2 (pt) 2019-12-06 2022-08-16 Juno Therapeutics Inc Anticorpos anti-idiotípicos para domínios de ligação alvejados por bcma e composições e métodos relacionados
US20230192869A1 (en) 2019-12-06 2023-06-22 Juno Therapeutics, Inc. Anti-idiotypic antibodies to gprc5d-targeted binding domains and related compositions and methods
WO2021116119A1 (en) 2019-12-09 2021-06-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity to her4 and uses thereof
PE20221511A1 (es) 2019-12-13 2022-10-04 Genentech Inc Anticuerpos anti-ly6g6d y metodos de uso
BR112022012203A2 (pt) 2019-12-20 2022-09-13 Intervet Int Bv Anticorpos para receptor alfa da interleucina-4 canino
MX2022007636A (es) 2019-12-20 2022-07-19 Intervet Int Bv Anticuerpos biespecificos caninizados y pares de union biespecificos para el tratamiento contra dermatitis atopica.
WO2021127414A1 (en) 2019-12-20 2021-06-24 Bristol-Myers Squibb Company Use of fucosylation inhibitor for producing afucosylated antibody
CN110964090B (zh) * 2019-12-26 2021-02-19 江南大学 一种促进n-乙酰氨基葡萄糖生产的蛋白质起始因子if3突变体及其应用
AR120898A1 (es) 2019-12-26 2022-03-30 Univ Osaka Agente para tratar o prevenir neuromielitis óptica en fase aguda
CN113045655A (zh) 2019-12-27 2021-06-29 高诚生物医药(香港)有限公司 抗ox40抗体及其用途
MY202559A (en) 2019-12-27 2024-05-08 Chugai Pharmaceutical Co Ltd Anti-ctla-4 antibody and use thereof
TWI877278B (zh) 2019-12-30 2025-03-21 美商思進公司 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
CN110818795B (zh) 2020-01-10 2020-04-24 上海复宏汉霖生物技术股份有限公司 抗tigit抗体和使用方法
CN119656311A (zh) 2020-01-15 2025-03-21 国立大学法人大阪大学 痴呆症的预防或治疗剂
PE20230113A1 (es) 2020-01-16 2023-01-27 Genmab As Formulaciones de anticuerpos anti-cd38 y usos de las mismas
WO2021194481A1 (en) 2020-03-24 2021-09-30 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
WO2022050954A1 (en) 2020-09-04 2022-03-10 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
CN115768800A (zh) 2020-01-31 2023-03-07 克利夫兰诊所基金会 抗苗勒管激素受体2抗体和使用方法
EP4096708A1 (en) 2020-01-31 2022-12-07 Genentech, Inc. Methods of inducing neoepitope-specific t cells with a pd-1 axis binding antagonist and an rna vaccine
CN115397848A (zh) 2020-02-05 2022-11-25 拉利玛生物医药公司 Tat肽结合蛋白及其用途
PE20230168A1 (es) 2020-02-12 2023-02-01 Chugai Pharmaceutical Co Ltd Moleculas de union a antigeno anti-cd137 para su administracion en el tratamiento contra el cancer
MX2022009947A (es) 2020-02-14 2022-11-07 Jounce Therapeutics Inc Anticuerpos y proteinas de fusion que se unen a ccr8 y usos de estos.
EP4105330A4 (en) 2020-02-14 2024-03-13 Kyowa Kirin Co., Ltd. BISPECIFIC ANTIBODY BINDING TO CD3
WO2021168292A1 (en) 2020-02-20 2021-08-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Epstein-barr virus monoclonal antibodies and uses thereof
MX2022010665A (es) 2020-02-27 2022-09-23 Chia Tai Tianqing Pharmaceutical Group Co Ltd Anticuerpos que se unen al receptor de interleucina 4 (il4r) y usos de los mismos.
EP4112642A4 (en) 2020-02-28 2024-06-26 Shanghai Henlius Biotech, Inc. ANTI-CD137 CONSTRUCTION AND ITS USE
CA3169910A1 (en) 2020-02-28 2021-09-02 Shanghai Henlius Biotech, Inc. Anti-cd137 constructs, multispecific antibody and uses thereof
JPWO2021182572A1 (browse.php) 2020-03-12 2021-09-16
BR112022018157A2 (pt) 2020-03-12 2022-10-25 Toray Industries Medicamento para o tratamento e/ou prevenção do câncer, agentes que aumentam a eficácia de um fármaco e método para o tratamento e/ou prevenção do câncer
US20230340114A1 (en) 2020-03-12 2023-10-26 Immune-Onc Therapeutics, Inc. Novel anti-lilrb4 antibodies and derivative products
BR112022018161A2 (pt) 2020-03-12 2022-10-25 Toray Industries Medicamento para o tratamento e/ou prevenção do câncer, agentes que aumentam a eficácia de um fármaco e método para o tratamento e/ou prevenção do câncer
WO2021182570A1 (ja) 2020-03-12 2021-09-16 東レ株式会社 癌の治療及び／又は予防のための医薬品
BR112022018166A2 (pt) 2020-03-12 2022-10-25 Toray Industries Medicamento para tratamento e/ou prevenção de câncer, agentes que aumentam a eficácia de droga de uma composição farmacêutica e método para tratar e/ou prevenir câncer
CN115605507A (zh) 2020-03-13 2023-01-13 基因泰克公司（Us） 抗白介素-33抗体及其用途
MX2022011455A (es) 2020-03-19 2022-10-03 Genentech Inc Anticuerpos anti-tgf-beta con selectividad de isoforma y metodos de uso.
JP2023519254A (ja) 2020-03-23 2023-05-10 ブリストル－マイヤーズ スクイブ カンパニー がんを処置するための抗ｃｃｒ８抗体
MX2022011752A (es) 2020-03-24 2022-10-18 Genentech Inc Agentes de fijacion a tie2 y metodos de uso.
FI4045533T3 (fi) 2020-03-26 2024-02-02 Univ Vanderbilt Ihmisen monoklonaalisia vasta-aineita vakavalle akuutille koronavirus 2 -hengityselinoireyhtymälle (sars-cov-2)
EP4126241A1 (en) 2020-03-27 2023-02-08 Novartis AG Bispecific combination therapy for treating proliferative diseases and autoimmune disorders
PH12022500012A1 (en) 2020-03-30 2023-04-03 Daiichi Sankyo Co Ltd Bispecific antibody
KR20220161337A (ko) 2020-04-01 2022-12-06 쿄와 기린 가부시키가이샤 항체 조성물
WO2021202235A1 (en) 2020-04-01 2021-10-07 University Of Rochester Monoclonal antibodies against the hemagglutinin (ha) and neuraminidase (na) of influenza h3n2 viruses
JP2023520515A (ja) 2020-04-03 2023-05-17 ジェネンテック， インコーポレイテッド がんに対する治療方法及び診断方法
US20230272056A1 (en) 2020-04-09 2023-08-31 Merck Sharp & Dohme Llc Affinity matured anti-lap antibodies and uses thereof
WO2021207662A1 (en) 2020-04-10 2021-10-14 Genentech, Inc. Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
CA3175530A1 (en) 2020-04-24 2021-10-28 Genentech, Inc. Methods of using anti-cd79b immunoconjugates
AU2021262744A1 (en) 2020-04-27 2022-10-06 The Regents Of The University Of California Isoform-independent antibodies to lipoprotein(a)
EP4143345A1 (en) 2020-04-28 2023-03-08 Genentech, Inc. Methods and compositions for non-small cell lung cancer immunotherapy
EP3921034A2 (en) 2020-04-28 2021-12-15 The Rockefeller University Neutralizing anti-sars-cov-2 antibodies and methods of use thereof
WO2021219871A2 (en) 2020-04-30 2021-11-04 Aduro Biotech Holdings, Europe B.V. Anti-cd103 antibodies
AU2021267995A1 (en) 2020-05-03 2022-12-08 Levena (Suzhou) Biopharma Co., Ltd. Antibody-drug conjugates (ADCs) comprising an anti-Trop-2 antibody, compositions comprising such ADCs, as well as methods of making and using the same
CA3178564A1 (en) 2020-05-12 2021-11-18 Zhengping Zhang St2 antigen binding protein
KR20230008751A (ko) 2020-05-12 2023-01-16 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 피부 t-세포 림프종 및 tfh 유래된 림프종을 치료하는 신규한 방법
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
WO2021231732A1 (en) 2020-05-15 2021-11-18 Bristol-Myers Squibb Company Antibodies to garp
WO2021233834A1 (en) 2020-05-17 2021-11-25 Astrazeneca Uk Limited Sars-cov-2 antibodies and methods of selecting and using the same
WO2021242815A1 (en) 2020-05-26 2021-12-02 Regeneron Pharmaceuticals, Inc. Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
CN113993900B (zh) 2020-05-27 2023-08-04 舒泰神（北京）生物制药股份有限公司 特异性识别神经生长因子的抗体及其用途
AU2021281417A1 (en) 2020-05-29 2022-12-08 23Andme, Inc. Anti-CD200R1 antibodies and methods of use thereof
CN116529260A (zh) 2020-06-02 2023-08-01 当康生物技术有限责任公司 抗cd93构建体及其用途
JP2023529842A (ja) 2020-06-02 2023-07-12 ダイナミキュア バイオテクノロジー エルエルシー 抗ｃｄ９３構築物およびその使用
BR112022024662A2 (pt) 2020-06-03 2023-04-04 Regeneron Pharma Métodos para tratamento ou prevenção de infecções por sars-cov-2 e covid-19 com anticorpos de glicoproteína spike anti-sars-cov-2
GB202101299D0 (en) 2020-06-09 2021-03-17 Avacta Life Sciences Ltd Diagnostic polypetides and methods
WO2021252977A1 (en) 2020-06-12 2021-12-16 Genentech, Inc. Methods and compositions for cancer immunotherapy
JP2023531406A (ja) 2020-06-16 2023-07-24 ジェネンテック， インコーポレイテッド トリプルネガティブ乳がんを処置するための方法および組成物
KR20230024368A (ko) 2020-06-18 2023-02-20 제넨테크, 인크. 항-tigit 항체 및 pd-1 축 결합 길항제를 사용한 치료
WO2021259880A1 (en) 2020-06-22 2021-12-30 Almirall, S.A. Anti-il-36 antibodies and methods of use thereof
KR20230027270A (ko) 2020-06-23 2023-02-27 지앙수 카니온 파마수티컬 씨오., 엘티디. 항-cd38 항체 및 그의 용도
AU2021297873A1 (en) 2020-06-25 2023-02-09 Merck Sharp & Dohme Llc High affinity antibodies targeting tau phosphorylated at serine 413
EP4173638A1 (en) 2020-06-30 2023-05-03 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-cd70 antibody and application thereof
TW202216212A (zh) 2020-07-17 2022-05-01 日商第一三共股份有限公司 抗體-藥物結合物之製造方法
CN115884794A (zh) 2020-07-20 2023-03-31 第一三共株式会社 抗her2抗体药物缀合物与her二聚化抑制剂的组合
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
TW202221029A (zh) 2020-07-29 2022-06-01 美商當康生物科技有限公司 抗cd93之構築體及其用途
WO2022029080A1 (en) 2020-08-03 2022-02-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Population of treg cells functionally committed to exert a regulatory activity and their use for adoptive therapy
EP4189121A1 (en) 2020-08-03 2023-06-07 Genentech, Inc. Diagnostic and therapeutic methods for lymphoma
JP2023536326A (ja) 2020-08-05 2023-08-24 ジュノー セラピューティクス インコーポレイテッド Ｒｏｒ１標的結合ドメインに対する抗イディオタイプ抗体ならびに関連する組成物および方法
IL300260A (en) 2020-08-07 2023-03-01 Genentech Inc FLT3 ligand fusion proteins and methods of use
BR112023002234A2 (pt) 2020-08-10 2023-03-07 Astrazeneca Uk Ltd Anticorpos sars-cov-2 para tratamento e prevenção de covid-19
WO2022036079A1 (en) 2020-08-13 2022-02-17 Bristol-Myers Squibb Company Methods of redirecting of il-2 to target cells of interest
JP2023537761A (ja) 2020-08-14 2023-09-05 エイシー イミューン ソシエテ アノニム ヒト化抗ｔｄｐ－４３結合分子およびその使用
WO2022040482A1 (en) 2020-08-19 2022-02-24 Xencor, Inc. Anti-cd28 and/or anti-b7h3 compositions
WO2022043517A2 (en) 2020-08-27 2022-03-03 Cureab Gmbh Anti-golph2 antibodies for macrophage and dendritic cell differentiation
US20230391878A1 (en) 2020-09-01 2023-12-07 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for prevention and/or treatment of dialysis pruritus containing il-31 antagonist as active ingredient
JP2023541627A (ja) 2020-09-14 2023-10-03 イシュノス サイエンシズ ソシエテ アノニム Ｉｌ１ｒａｐに結合する抗体及びその使用
WO2022069940A1 (en) 2020-09-30 2022-04-07 Compugen Ltd. Combination therapy with anti-pvrig antibodies formulations, anti-tigit antibodies, and anti-pd-1 antibodies
JP2023543835A (ja) 2020-09-30 2023-10-18 ドレン バイオ， インコーポレイテッド 抗ｃｄ９４抗体及びその使用方法
KR20230082632A (ko) 2020-10-05 2023-06-08 제넨테크, 인크. 항-fcrh5/항-cd3 이중특이성 항체를 사용한 치료를 위한 투약
WO2022076606A1 (en) 2020-10-06 2022-04-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
EP4225330A1 (en) 2020-10-06 2023-08-16 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
CA3198102A1 (en) 2020-10-07 2022-04-14 Dren Bio, Inc. Anti-dectin-1 antibodies and methods of use thereof
WO2022081516A1 (en) 2020-10-13 2022-04-21 Janssen Biotech, Inc. Bioengineered t cell mediated immunity, materials and other methods for modulating cluster of differentiation iv &/or viii
US20230416382A1 (en) 2020-10-14 2023-12-28 Five Prime Therapeutics, Inc. Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
KR20230091871A (ko) 2020-10-20 2023-06-23 에프. 호프만-라 로슈 아게 Pd-1 축 결합 길항제 및 lrrk2 억제제의 병용 요법
CA3192306A1 (en) 2020-10-20 2022-04-28 Burkhard Ludewig Antibodies or antigen-binding fragments specifically binding to gremlin-1 and uses thereof
US20230400467A1 (en) 2020-10-26 2023-12-14 Compugen Ltd. Pvrl2 and/or pvrig as biomarkers for treatment
WO2022093981A1 (en) 2020-10-28 2022-05-05 Genentech, Inc. Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
EP4240492A2 (en) 2020-11-04 2023-09-13 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
WO2022098648A2 (en) 2020-11-04 2022-05-12 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates
EP4240766A2 (en) 2020-11-04 2023-09-13 Genentech, Inc. Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies
TW202227481A (zh) 2020-11-04 2022-07-16 美國洛克菲勒大學 中和抗sars-cov-2抗體
AU2021374083A1 (en) 2020-11-06 2023-06-01 Novartis Ag Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
KR20230097156A (ko) 2020-11-06 2023-06-30 브리스톨-마이어스 스큅 컴퍼니 단독요법으로서 비-푸코실화 항-ctla-4 항체의 투약 및 투여
AU2021373366A1 (en) 2020-11-06 2023-06-01 Novartis Ag Cd19 binding molecules and uses thereof
JPWO2022102634A1 (browse.php) 2020-11-11 2022-05-19
CA3198382A1 (en) 2020-11-12 2022-05-19 Michiko Yamato Treatment of mesothelioma by administration of anti-b7-h3 antibody-drug conjugate
KR20230118108A (ko) 2020-11-20 2023-08-10 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 항-cd25 항체
EP4247496A1 (en) 2020-11-20 2023-09-27 Institut National de la Santé et de la Recherche Médicale (INSERM) Anti-cd25 antibodies
EP4251187A4 (en) 2020-11-25 2025-09-10 Xilio Dev Inc TUMOR-SPECIFIC CLASSIBLE LINKERS
TW202237638A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 烏苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
TW202237639A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 鳥苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
WO2022125941A1 (en) 2020-12-11 2022-06-16 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors
WO2022130182A1 (en) 2020-12-14 2022-06-23 Novartis Ag Reversal binding agents for anti-natriuretic peptide receptor 1 (npr1) antibodies and uses thereof
AU2021401302A1 (en) 2020-12-17 2023-07-06 Iovance Biotherapeutics, Inc. Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
WO2022132904A1 (en) 2020-12-17 2022-06-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies targeting sars-cov-2
JP2024500403A (ja) 2020-12-17 2024-01-09 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球によるがんの治療
JP2024500920A (ja) 2020-12-23 2024-01-10 カンタージア アクチエボラーグ 抗ｉｌ１ｒａｐ抗体
WO2022140797A1 (en) 2020-12-23 2022-06-30 Immunowake Inc. Immunocytokines and uses thereof
CN114685669A (zh) 2020-12-30 2022-07-01 和铂医药(苏州)有限公司 结合trop2的抗体及其用途
TW202242085A (zh) 2020-12-31 2022-11-01 美商艾歐凡斯生物治療公司 供自動生產腫瘤浸潤淋巴球的裝置和方法
CN116710482A (zh) 2021-01-08 2023-09-05 北京韩美药品有限公司 特异性结合4-1bb的抗体及其抗原结合片段
KR20230129481A (ko) 2021-01-08 2023-09-08 베이징 한미 파마슈티컬 컴퍼니 리미티드 Cd47과 특이적으로 결합하는 항체 및 그 항원 결합단편
WO2022153194A1 (en) 2021-01-13 2022-07-21 Memorial Sloan Kettering Cancer Center Antibody-pyrrolobenzodiazepine derivative conjugate
US20240115721A1 (en) 2021-01-13 2024-04-11 Memorial Sloan Kettering Cancer Center Anti-dll3 antibody-drug conjugate
EP4277926A1 (en) 2021-01-15 2023-11-22 The Rockefeller University Neutralizing anti-sars-cov-2 antibodies
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
JP2024504493A (ja) 2021-01-28 2024-01-31 ヴァクスィーンヴェント ゲーエムベーハー Ｂ細胞媒介性免疫応答を調節するための方法及び手段
US20240076373A1 (en) 2021-01-28 2024-03-07 Compugen Ltd. Combination therapy with anti-pvrig antibodies formulations and anti-pd-1 antibodies
WO2022162203A1 (en) 2021-01-28 2022-08-04 Vaccinvent Gmbh Method and means for modulating b-cell mediated immune responses
CN117120084A (zh) 2021-01-28 2023-11-24 维肯芬特有限责任公司 用于调节b细胞介导的免疫应答的方法和手段
WO2022165266A1 (en) 2021-01-28 2022-08-04 Compugen Ltd. Anti-pvrig antibodies formulations and uses thereof
TW202241508A (zh) 2021-01-29 2022-11-01 美商艾歐凡斯生物治療公司 細胞介素相關之腫瘤浸潤性淋巴球組合物及方法
JP2024506315A (ja) 2021-02-09 2024-02-13 ザ ユナイテッド ステイツ オブ アメリカ アズ リプリゼンテッド バイ ザ セクレタリー、デパートメント オブ ヘルス アンド ヒューマン サービシーズ コロナウイルスのスパイクタンパク質を標的とする抗体
US20240117019A1 (en) 2021-02-09 2024-04-11 University Of Georgia Research Foundation, Inc. Human monoclonal antibodies against pneumococcal antigens
JP2024506200A (ja) 2021-02-15 2024-02-09 武田薬品工業株式会社 細胞治療用組成物及びｔｇｆ－ｂシグナル伝達を調節する方法
AR124914A1 (es) 2021-02-18 2023-05-17 Mitsubishi Tanabe Pharma Corp Nuevo anticuerpo anti-pad4
US20220378929A1 (en) 2021-02-25 2022-12-01 MediBoston Limted Anti-her2 antibody-drug conjugates and uses thereof
US20220306743A1 (en) 2021-03-01 2022-09-29 Xilio Development, Inc. Combination of ctla4 and pd1/pdl1 antibodies for treating cancer
CA3209364A1 (en) 2021-03-01 2022-09-09 Jennifer O'neil Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer
CN117440832A (zh) 2021-03-03 2024-01-23 索伦托药业有限公司 包括抗bcma抗体的抗体-药物缀合物
JP2024509191A (ja) 2021-03-05 2024-02-29 ダイナミキュア バイオテクノロジー エルエルシー 抗ｖｉｓｔａ構築物およびその使用
CA3210755A1 (en) 2021-03-05 2022-09-09 Kenneth ONIMUS Tumor storage and cell culture compositions
CN117157319A (zh) 2021-03-09 2023-12-01 Xencor股份有限公司 结合cd3和cldn6的异二聚抗体
EP4294927A2 (en) 2021-03-10 2023-12-27 Immunowake Inc. Immunomodulatory molecules and uses thereof
US11859012B2 (en) 2021-03-10 2024-01-02 Xencor, Inc. Heterodimeric antibodies that bind CD3 and GPC3
MX2023010812A (es) 2021-03-15 2023-09-27 Genentech Inc Composiciones y metodos para tratar la nefritis lupica.
KR102805310B1 (ko) 2021-03-18 2025-05-13 메디뮨 리미티드 Ccr9에 결합하는 치료용 결합 분자
WO2022197877A1 (en) 2021-03-19 2022-09-22 Genentech, Inc. Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
TW202304480A (zh) 2021-03-19 2023-02-01 美商艾歐凡斯生物治療公司 腫瘤浸潤淋巴球（ｔｉｌ）中之與ｃｄ３９／ｃｄ６９選擇及基因剔除相關之ｔｉｌ擴增之方法
JP2024511414A (ja) 2021-03-23 2024-03-13 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球のｃｉｓｈ遺伝子編集及び免疫療法におけるその使用
WO2022200303A1 (en) 2021-03-23 2022-09-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of t cell-lymphomas
WO2022204724A1 (en) 2021-03-25 2022-09-29 Dynamicure Biotechnology Llc Anti-igfbp7 constructs and uses thereof
WO2022204564A2 (en) 2021-03-25 2022-09-29 Iovance Biotherapeutics, Inc. Methods and compositions for t-cell coculture potency assays and use with cell therapy products
MX2023011310A (es) 2021-03-26 2023-10-05 Innate Pharma Anclajes de citocina para proteinas de celulas nk de union a nkp46.
US20240182569A1 (en) 2021-03-29 2024-06-06 Daiichi Sankyo Company, Limited Stable multispecific molecule and use thereof
US20240382592A1 (en) 2021-04-09 2024-11-21 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of anaplastic large cell lymphoma
AR125344A1 (es) 2021-04-15 2023-07-05 Chugai Pharmaceutical Co Ltd Anticuerpo anti-c1s
KR20240037185A (ko) 2021-04-19 2024-03-21 이오반스 바이오테라퓨틱스, 인크. 키메라 공동자극 수용체, 케모카인 수용체, 및 세포 면역치료에서의 이의 용도
CN117222412A (zh) 2021-04-23 2023-12-12 豪夫迈·罗氏有限公司 Nk细胞接合剂相关的不良反应的预防或减轻
CA3213632A1 (en) 2021-04-30 2022-11-03 F. Hoffmann-La Roche Ag Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
EP4334343A2 (en) 2021-05-06 2024-03-13 The Rockefeller University Neutralizing anti-sars- cov-2 antibodies and methods of use thereof
WO2022234003A1 (en) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Cd33 binding polypeptides with stefin a protein
EP4337266A1 (en) 2021-05-12 2024-03-20 Genentech, Inc. Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
BR112023023777A2 (pt) 2021-05-14 2024-01-30 Genentech Inc Anticorpos isolados, composição farmacêutica, ácido nucleico isolado, vetor isolado, célula hospedeira isolada, método para produzir um anticorpo, método para tratar uma condição associada à perda de função de trem2, método para reduzir os níveis de strem2 e uso de um anticorpo
JP2023546368A (ja) 2021-05-14 2023-11-02 ジェネンテック， インコーポレイテッド モスネツズマブおよびポラツズマブベドチンを用いたｃｄ２０陽性増殖性障害の処置のための方法
US20230115257A1 (en) 2021-05-17 2023-04-13 Curia Ip Holdings, Llc Sars-cov-2 spike protein antibodies
WO2022245754A1 (en) 2021-05-17 2022-11-24 Iovance Biotherapeutics, Inc. Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy
US20240239875A1 (en) 2021-05-17 2024-07-18 Curia Ip Holdings, Llc Sars-cov-2 spike protein antibodies
CN117396513A (zh) 2021-05-28 2024-01-12 葛兰素史密斯克莱知识产权发展有限公司 治疗癌症的联合疗法
CN117480184A (zh) 2021-06-04 2024-01-30 中外制药株式会社 抗ddr2抗体及其用途
AR126089A1 (es) 2021-06-07 2023-09-13 Amgen Inc Uso de fucosidasa para controlar el nivel de afucosilación de proteínas glucosiladas
JP2024521579A (ja) 2021-06-09 2024-06-03 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト がんの治療における使用のための特定のｂｒａｆ阻害剤（パラドックスブレーカー）とｐｄ－１軸結合アンタゴニストとの組み合わせ
US20240392008A1 (en) 2021-06-09 2024-11-28 Innate Pharma Multispecific proteins binding to nkp46, a cytokine receptor, a tumour antigen and cd16a
WO2022258678A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
WO2022258691A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
IL308531A (en) 2021-06-09 2024-01-01 Innate Pharma Multispecific antibodies binding to cd20, nkp46, cd16 and conjugated to il-2
US12227574B2 (en) 2021-06-17 2025-02-18 Amberstone Biosciences, Inc. Anti-CD3 constructs and uses thereof
WO2022266540A2 (en) 2021-06-18 2022-12-22 Therini Bio, Inc. ANTIBODIES WHICH BIND HUMAN FIBRIN OR FIBRINOGEN γC DOMAIN AND METHODS OF USE
CA3219360A1 (en) 2021-06-22 2022-12-29 Novartis Ag Bispecific antibodies for use in treatment of hidradenitis suppurativa
EP4360648A1 (en) 2021-06-23 2024-05-01 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
JPWO2022270524A1 (browse.php) 2021-06-23 2022-12-29
BR112023022992A2 (pt) 2021-06-25 2024-01-23 Chugai Pharmaceutical Co Ltd Anticorpo anti-ctla-4
KR102690145B1 (ko) 2021-06-25 2024-07-30 추가이 세이야쿠 가부시키가이샤 항ctla-4 항체의 사용
US20240165229A1 (en) 2021-06-29 2024-05-23 Seagen Inc. Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist
WO2023275621A1 (en) 2021-07-01 2023-01-05 Compugen Ltd. Anti-tigit and anti-pvrig in monotherapy and combination treatments
WO2023283611A1 (en) 2021-07-08 2023-01-12 Staidson Biopharma Inc. Antibodies specifically recognizing tnfr2 and uses thereof
CA3225575A1 (en) 2021-07-14 2023-01-19 Regeneron Pharmaceuticals, Inc. Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
JP2024525769A (ja) 2021-07-14 2024-07-12 舒泰神（北京）生物製薬股フン有限公司 Ｃｄ４０を特異的に認識する抗体およびその使用
MX2024000501A (es) 2021-07-14 2024-01-31 Jiangsu Hengrui Pharmaceuticals Co Ltd Molecula de union a antigeno que se une especificamente a hgfr y egfr, y su uso farmaceutico.
JP2024526898A (ja) 2021-07-22 2024-07-19 アイオバンス バイオセラピューティクス，インコーポレイテッド 固形腫瘍断片の凍結保存のための方法
EP4373576A1 (en) 2021-07-22 2024-05-29 Genentech, Inc. Brain targeting compositions and methods of use thereof
JPWO2023008461A1 (browse.php) 2021-07-27 2023-02-02
JPWO2023008462A1 (browse.php) 2021-07-27 2023-02-02
CA3227698A1 (en) 2021-07-27 2023-02-02 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
TW202327631A (zh) 2021-07-28 2023-07-16 美商艾歐凡斯生物治療公司 利用腫瘤浸潤性淋巴球療法與ｋｒａｓ抑制劑組合治療癌症患者
JP2024530643A (ja) 2021-08-03 2024-08-23 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド バイオ医薬組成物および安定同位体標識ペプチドマッピング法
US20240336697A1 (en) 2021-08-07 2024-10-10 Genentech, Inc. Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
CN117897409A (zh) 2021-08-13 2024-04-16 基因泰克公司 抗类胰蛋白酶抗体的给药
EP4384223A1 (en) 2021-08-13 2024-06-19 GlaxoSmithKline Intellectual Property Development Limited Cytotoxicity targeting chimeras for ccr2-expressing cells
WO2023017484A1 (en) 2021-08-13 2023-02-16 Glaxosmithkline Intellectual Property Development Limited Cytotoxicity targeting chimeras
WO2023021055A1 (en) 2021-08-19 2023-02-23 F. Hoffmann-La Roche Ag Multivalent anti-variant fc-region antibodies and methods of use
CN117836326A (zh) 2021-08-26 2024-04-05 协和麒麟株式会社 与cd116和cd131结合的双特异性抗体
EP4392067A1 (en) 2021-08-27 2024-07-03 Genentech, Inc. Methods of treating tau pathologies
JP2024534853A (ja) 2021-08-30 2024-09-26 ジェネンテック， インコーポレイテッド 抗ポリビキチン多重特異性抗体
JPWO2023033129A1 (browse.php) 2021-09-03 2023-03-09
JP2024533234A (ja) 2021-09-06 2024-09-12 ジェンマブ エー／エス Ｃｄ２７に結合する能力を有する抗体、そのバリアントおよびその使用
IL311333A (en) 2021-09-09 2024-05-01 Iovance Biotherapeutics Inc Processes for generating til products using pd-1 talen knockdown
TW202508643A (zh) 2021-09-15 2025-03-01 日商第一三共股份有限公司 抗體-藥物結合物之用途
CN118369344A (zh) 2021-09-16 2024-07-19 阿博莱斯制药公司 抗人cd45rc结合结构域及其用途
KR20240058167A (ko) 2021-09-17 2024-05-03 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 Sars-cov-2 중화 항체 동정을 위한 합성 인간화 라마 나노바디 라이브러리 및 이의 용도
CA3232700A1 (en) 2021-09-24 2023-03-30 Rafael CUBAS Expansion processes and agents for tumor infiltrating lymphocytes
US20240400690A1 (en) 2021-09-30 2024-12-05 Bio-Thera Solutions, Ltd. Anti-b7-h3 antibody and application thereof
WO2023056403A1 (en) 2021-09-30 2023-04-06 Genentech, Inc. Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
CA3233953A1 (en) 2021-10-05 2023-04-13 Matthew Bruce Combination therapies for treating cancer
US20240409638A1 (en) 2021-10-07 2024-12-12 Avacta Life Sciences Limited Serum half-life extended pd-l1 binding polypeptides
EP4413038A1 (en) 2021-10-07 2024-08-14 Avacta Life Sciences Limited Pd-l1 binding affimers
EP4413998A1 (en) 2021-10-08 2024-08-14 Chugai Seiyaku Kabushiki Kaisha Method for preparing prefilled syringe formulation
WO2023064958A1 (en) 2021-10-15 2023-04-20 Compugen Ltd. Combination therapy with anti-pvrig antibodies formulations, anti-tigit antibodies, and anti-pd-1 antibodies
AU2022368385A1 (en) 2021-10-18 2024-04-11 Daiichi Sankyo Company, Limited Anti-cd37 antibody-drug conjugate
AR127482A1 (es) 2021-10-27 2024-01-31 Iovance Biotherapeutics Inc Sistemas y métodos para coordinar la fabricación de células para inmunoterapia específica de paciente
US20250251400A1 (en) 2021-11-05 2025-08-07 American Diagnostics & Therapy, Llc (Adxrx) Monoclonal Antibodies Against Carcinoembryonic Antigens, and Their Uses
TW202342095A (zh) 2021-11-05 2023-11-01 英商阿斯特捷利康英國股份有限公司 用於治療和預防ｃｏｖｉｄ—１９之組成物
WO2023081434A2 (en) 2021-11-07 2023-05-11 Regeneron Pharmaceuticals, Inc. Methods for treating or preventing sars-cov-2 infections and covid-19 with anti-sars-cov-2 spike glycoprotein antibodies
JP2024544885A (ja) 2021-11-10 2024-12-05 ジェネンテック， インコーポレイテッド 抗インターロイキン－３３抗体及びその使用
US20250032618A1 (en) 2021-11-10 2025-01-30 Iovance Biotherapeutics, Inc. Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
MX2024005680A (es) 2021-11-16 2024-05-30 Genentech Inc Metodos y composiciones para tratar lupus eritematoso sistemico (sle) con mosunetuzumab.
KR20240100369A (ko) 2021-11-16 2024-07-01 에이씨 이뮨 에스에이 치료 및 진단을 위한 신규한 분자
KR20240125925A (ko) 2021-11-18 2024-08-20 아스트라제네카 유케이 리미티드 항체-약물 콘쥬게이트와 parp1 선택적 억제제의 조합
EP4437005A1 (en) 2021-11-25 2024-10-02 Veraxa Biotech GmbH Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
EP4186529B1 (en) 2021-11-25 2025-07-09 Veraxa Biotech GmbH Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
WO2023093816A1 (zh) 2021-11-25 2023-06-01 诺纳生物（苏州）有限公司 抗Siglec-15抗体及其应用
CA3241006A1 (en) 2021-11-30 2023-06-08 Daiichi Sankyo Company Limited Protease-cleavable masked antibodies
WO2023103788A1 (zh) 2021-12-06 2023-06-15 北京三诺佳邑生物技术有限责任公司 特异性结合肺炎克雷伯菌o2抗原和o1抗原的双特异性抗体以及组合物
US20250051440A1 (en) 2021-12-14 2025-02-13 Institut National de la Santé et de la Recherche Médicale Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling
WO2023109900A1 (en) 2021-12-17 2023-06-22 Shanghai Henlius Biotech, Inc. Anti-ox40 antibodies, multispecific antibodies and methods of use
KR20240122784A (ko) 2021-12-17 2024-08-13 상하이 헨리우스 바이오테크, 인크. 항-ox40 항체 및 사용 방법
EP4456922A1 (en) 2021-12-28 2024-11-06 AstraZeneca UK Limited Combination of antibody-drug conjugate and atr inhibitor
WO2023126822A1 (en) 2021-12-28 2023-07-06 Astrazeneca Uk Limited Combination of antibody-drug conjugate and rasg12c inhibitor
PE20242347A1 (es) 2022-01-07 2024-12-16 Johnson And Johnson Entpr Innovation Inc Materiales y metodos de proteinas de union a il-1 beta
WO2023139292A1 (en) 2022-01-24 2023-07-27 Cambridge Enterprise Limited Tau therapy
WO2023147399A1 (en) 2022-01-27 2023-08-03 The Rockefeller University Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof
WO2023147486A1 (en) 2022-01-28 2023-08-03 Iovance Biotherapeutics, Inc. Tumor infiltrating lymphocytes engineered to express payloads
WO2023147488A1 (en) 2022-01-28 2023-08-03 Iovance Biotherapeutics, Inc. Cytokine associated tumor infiltrating lymphocytes compositions and methods
US20250067745A1 (en) 2022-01-31 2025-02-27 Institut National de la Santé et de la Recherche Médicale Cd38 as a biomarker and biotarget in t-cell lymphomas
WO2023153442A1 (ja) 2022-02-09 2023-08-17 第一三共株式会社 環境応答性マスク抗体及びその利用
CN118679260A (zh) 2022-02-09 2024-09-20 国立研究开发法人医药基盘·健康·营养研究所 与fcrl1结合的抗体或该抗体片段
EP4477665A4 (en) 2022-02-10 2025-08-20 Affyxell Therapeutics Co Ltd STEFIN A PROTEIN VARIANTS THAT SPECIFICALLY BIND TO CD40L AND THEIR USES
JP2025506172A (ja) 2022-02-10 2025-03-07 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ コロナウイルスを広く標的とするヒトモノクローナル抗体
JP2025507569A (ja) 2022-02-16 2025-03-21 エイシー イミューン ソシエテ アノニム ヒト化抗ｔｄｐ－４３結合分子およびその使用
TW202342510A (zh) 2022-02-18 2023-11-01 英商Ｒｑ生物科技有限公司 抗體
AU2023221861A1 (en) 2022-02-18 2024-09-05 Rakuten Medical, Inc. Anti-programmed death-ligand 1 (pd-l1) antibody molecules, encoding polynucleotides, and methods of use
WO2023161877A1 (en) 2022-02-25 2023-08-31 Glaxosmithkline Intellectual Property Development Limited Cytotoxicity targeting chimeras for integrin avb6-expressing cells
WO2023161876A1 (en) 2022-02-25 2023-08-31 Glaxosmithkline Intellectual Property Development Limited Cytotoxicity targeting chimeras for cxcr3-expressing cells
WO2023161879A1 (en) 2022-02-25 2023-08-31 Glaxosmithkline Intellectual Property Development Limited Cytotoxicity targeting chimeras for fibroblast activation protein-expressing cells
WO2023161881A1 (en) 2022-02-25 2023-08-31 Glaxosmithkline Intellectual Property Development Limited Cytotoxicity targeting chimeras for ccr2-expressing cells
WO2023161878A1 (en) 2022-02-25 2023-08-31 Glaxosmithkline Intellectual Property Development Limited Cytotoxicity targeting chimeras for folate receptor-expressing cells
EP4482527A1 (en) 2022-02-25 2025-01-01 GlaxoSmithKline Intellectual Property Development Limited Cytotoxicity targeting chimeras for c-c chemokine receptor 2-expressing cells
WO2023161875A1 (en) 2022-02-25 2023-08-31 Glaxosmithkline Intellectual Property Development Limited Cytotoxicity targeting chimeras for prostate specific membrane antigen-expressing cells
JP2025509286A (ja) 2022-03-10 2025-04-11 ビバソル， インコーポレイテッド 抗体－薬物コンジュゲートおよびその使用
WO2023178192A1 (en) 2022-03-15 2023-09-21 Compugen Ltd. Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
TW202400232A (zh) 2022-03-16 2024-01-01 日商第一三共股份有限公司 多特異性分子與免疫檢查點抑制劑之組合
CN118891525A (zh) 2022-03-16 2024-11-01 阿斯利康(英国)有限公司 用于抗trop2抗体-药物缀合物疗法的评分方法
EP4245374A3 (en) 2022-03-18 2024-07-10 Compugen Ltd. Pvrl2 and/or pvrig as biomarkers for treatment
JP2025512785A (ja) 2022-03-23 2025-04-22 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｃｄ２０／抗ｃｄ３二重特異性抗体及び化学療法の併用処置
WO2023179740A1 (en) 2022-03-25 2023-09-28 Shanghai Henlius Biotech , Inc. Anti-msln antibodies and methods of use
WO2023192827A1 (en) 2022-03-26 2023-10-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bispecific antibodies to hiv-1 env and their use
WO2023192881A1 (en) 2022-03-28 2023-10-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to hiv-1 env and their use
IL315552A (en) 2022-03-30 2024-11-01 Novartis Ag Methods for treating disorders using anti-natriuretic peptide 1 (NPR1) antibodies
WO2023191816A1 (en) 2022-04-01 2023-10-05 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
JP2025512313A (ja) 2022-04-06 2025-04-17 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球療法によるｎｓｃｌｃ患者の治療
WO2023194565A1 (en) 2022-04-08 2023-10-12 Ac Immune Sa Anti-tdp-43 binding molecules
WO2023198648A1 (en) 2022-04-11 2023-10-19 Institut National de la Santé et de la Recherche Médicale Methods for the diagnosis and treatment of t-cell malignancies
KR20250004776A (ko) 2022-04-13 2025-01-08 에프. 호프만-라 로슈 아게 항-cd20/항-cd3 이중특이성 항체의 약학 조성물 및 사용 방법
JP2025512342A (ja) 2022-04-13 2025-04-17 ジェネンテック， インコーポレイテッド 治療用タンパク質の医薬組成物および使用方法
EP4507704A1 (en) 2022-04-15 2025-02-19 Iovance Biotherapeutics, Inc. Til expansion processes using specific cytokine combinations and/or akti treatment
WO2023198874A1 (en) 2022-04-15 2023-10-19 Institut National de la Santé et de la Recherche Médicale Methods for the diagnosis and treatment of t cell-lymphomas
WO2023203177A1 (en) 2022-04-20 2023-10-26 Kantonsspital St. Gallen Antibodies or antigen-binding fragments pan-specifically binding to gremlin-1 and gremlin-2 and uses thereof
IL316421A (en) 2022-04-27 2024-12-01 Daiichi Sankyo Co Ltd Combination of an antibody-drug conjugate with an EZH1 and/or EZH2 inhibitor
JP2025514374A (ja) 2022-04-29 2025-05-02 ２３アンドミー・インコーポレイテッド 抗原結合タンパク質
JP2025514858A (ja) 2022-04-29 2025-05-09 アストラゼネカ・ユーケイ・リミテッド ＳＡＲＳ－ＣｏＶ－２抗体、及びその使用方法
EP4519322A1 (en) 2022-05-03 2025-03-12 Genentech, Inc. Anti-ly6e antibodies, immunoconjugates, and uses thereof
WO2023217068A1 (zh) 2022-05-09 2023-11-16 舒泰神（北京）生物制药股份有限公司 特异性识别gdf15的抗体及其应用
JP2025516551A (ja) 2022-05-10 2025-05-30 アイオバンス バイオセラピューティクス，インコーポレイテッド Ｉｌ－１５ｒアゴニストと併用した腫瘍浸潤リンパ球療法によるがん患者の治療
EP4522658A1 (en) 2022-05-11 2025-03-19 Daiichi Sankyo Company, Limited Combination of an antibody specific for a tumor antigen and a cd47 inhibitor
CN119317641A (zh) 2022-05-11 2025-01-14 基因泰克公司 针对用抗fcrh5/抗cd3双特异性抗体进行治疗的给药
WO2023218243A1 (en) 2022-05-12 2023-11-16 Avacta Life Sciences Limited Lag-3/pd-l1 binding fusion proteins
WO2023222886A1 (en) 2022-05-20 2023-11-23 Depth Charge Ltd Antibody-cytokine fusion proteins
KR20250012631A (ko) 2022-05-24 2025-01-24 다이이찌 산쿄 가부시키가이샤 항-cdh6 항체-약물 접합체의 투약
WO2023235699A1 (en) 2022-05-31 2023-12-07 Jounce Therapeutics, Inc. Antibodies to lilrb4 and uses thereof
EP4541377A1 (en) 2022-06-03 2025-04-23 UBE Corporation Antibody-multidrug conjugate
JPWO2023234427A1 (browse.php) 2022-06-03 2023-12-07
AU2023284422A1 (en) 2022-06-07 2024-12-19 Genentech, Inc. Method for determining the efficacy of a lung cancer treatment comprising an anti-pd-l1 antagonist and an anti-tigit antagonist antibody
WO2023237706A2 (en) 2022-06-08 2023-12-14 Institute For Research In Biomedicine (Irb) Cross-specific antibodies, uses and methods for discovery thereof
WO2023246891A1 (zh) 2022-06-23 2023-12-28 信达生物制药（新加坡）有限公司 结合egfr和b7-h3的双特异性抗体
KR20250031149A (ko) 2022-06-30 2025-03-06 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
WO2024003310A1 (en) 2022-06-30 2024-01-04 Institut National de la Santé et de la Recherche Médicale Methods for the diagnosis and treatment of acute lymphoblastic leukemia
EP4551681A1 (en) 2022-07-06 2025-05-14 Iovance Biotherapeutics, Inc. Devices and processes for automated production of tumor infiltrating lymphocytes
AU2023305619A1 (en) 2022-07-13 2025-01-23 F. Hoffmann-La Roche Ag Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
EP4558226A1 (en) 2022-07-19 2025-05-28 Staidson Biopharma Inc. Antibodies specifically recognizing b- and t-lymphocyte attenuator (btla) and uses thereof
WO2024020432A1 (en) 2022-07-19 2024-01-25 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2024018046A1 (en) 2022-07-22 2024-01-25 Institut National de la Santé et de la Recherche Médicale Garp as a biomarker and biotarget in t-cell malignancies
AU2023312051A1 (en) 2022-07-22 2025-01-09 Genentech, Inc. Anti-steap1 antigen-binding molecules and uses thereof
US20240228664A9 (en) 2022-07-22 2024-07-11 Bristol-Myers Squibb Company Antibodies Binding to Human PAD4 and Uses Thereof
EP4561635A1 (en) 2022-07-28 2025-06-04 AstraZeneca UK Limited Combination of antibody-drug conjugate and bispecific checkpoint inhibitor
WO2024026496A1 (en) 2022-07-28 2024-02-01 Compugen Ltd. Combination therapy with anti-pvrig antibodies formulations and anti-pd-1 antibodies
WO2024023283A1 (en) 2022-07-29 2024-02-01 Institut National de la Santé et de la Recherche Médicale Lrrc33 as a biomarker and biotarget in cutaneous t-cell lymphomas
EP4565329A1 (en) 2022-08-01 2025-06-11 The United States of America, as represented by the Secretary, Department of Health and Human Services Monoclonal antibodies that bind to the underside of influenza viral neuraminidase
WO2024030758A1 (en) 2022-08-01 2024-02-08 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
MA71684A (fr) 2022-08-05 2025-05-30 Janssen Biotech, Inc. Protéines de liaison de récepteur de transferrine pour traitement de tumeurs cérébrales
WO2024028732A1 (en) 2022-08-05 2024-02-08 Janssen Biotech, Inc. Cd98 binding constructs for treating brain tumors
WO2024031032A1 (en) 2022-08-05 2024-02-08 Bristol-Myers Squibb Company Anti-ctla-4 antibodies for treatment of kras mutant cancers
KR20250049554A (ko) 2022-08-19 2025-04-11 이바이브 바이오테크놀로지 (상하이) 엘티디 G-csf를 포함하는 제형 및 이의 용도
JP2025529896A (ja) 2022-08-22 2025-09-09 アブデラ セラピューティクス インク． Ｄｌｌ３結合分子およびその使用
EP4578459A1 (en) 2022-08-24 2025-07-02 Toray Industries, Inc. Pharmaceutical product for treatment and/or prevention of cancer
WO2024043252A1 (ja) 2022-08-24 2024-02-29 東レ株式会社 癌の治療及び／又は予防のための医薬品
WO2024043257A1 (ja) 2022-08-24 2024-02-29 東レ株式会社 癌の治療及び／又は予防のための医薬品
WO2024044675A1 (en) 2022-08-25 2024-02-29 Beigene, Ltd. Methods of cancer treatment using anti-pd1 antibodies in combination with anti-tim3 antibodies
KR20250053904A (ko) 2022-08-25 2025-04-22 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 항원 결합 단백질 및 그의 용도
EP4577235A2 (en) 2022-08-26 2025-07-02 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for delta-like ligand 3 (dll3)
CN119768184A (zh) 2022-08-30 2025-04-04 东丽株式会社 用于癌的治疗和/或预防的药品
JPWO2024048541A1 (browse.php) 2022-08-30 2024-03-07
WO2024049949A1 (en) 2022-09-01 2024-03-07 Genentech, Inc. Therapeutic and diagnostic methods for bladder cancer
EP4584296A1 (en) 2022-09-07 2025-07-16 Dynamicure Biotechnology LLC Anti-vista constructs and uses thereof
WO2024054822A1 (en) 2022-09-07 2024-03-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Engineered sars-cov-2 antibodies with increased neutralization breadth
WO2024052503A1 (en) 2022-09-08 2024-03-14 Institut National de la Santé et de la Recherche Médicale Antibodies having specificity to ltbp2 and uses thereof
WO2024056861A1 (en) 2022-09-15 2024-03-21 Avidicure Ip B.V. Multispecific antigen binding proteins for stimulating nk cells and use thereof
WO2024064826A1 (en) 2022-09-22 2024-03-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
CN119998321A (zh) 2022-09-27 2025-05-13 舒泰神（北京）生物制药股份有限公司 特异性识别light的抗体及其应用
EP4602372A1 (en) 2022-10-12 2025-08-20 Institut National de la Santé et de la Recherche Médicale Cd81 as a biomarker and biotarget in t-cell malignancies
WO2024083021A1 (zh) 2022-10-20 2024-04-25 北京三诺佳邑生物技术有限责任公司 特异性结合TRAIL或FasL的抗体组合以及双特异性抗体
EP4609201A1 (en) 2022-10-25 2025-09-03 Genentech, Inc. Therapeutic and diagnostic methods for multiple myeloma
WO2024098024A1 (en) 2022-11-04 2024-05-10 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
WO2024098027A1 (en) 2022-11-04 2024-05-10 Iovance Biotherapeutics, Inc. Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd103 selection
AU2023373363A1 (en) 2022-11-04 2025-05-08 Gilead Sciences, Inc. Anticancer therapies using anti-ccr8 antibody, chemo and immunotherapy combinations
IL320654A (en) 2022-11-07 2025-07-01 The Univ Of Osaka Agent for preventing or treating disease associated with accumulation of abnormal protein aggregates
KR20250099701A (ko) 2022-11-08 2025-07-02 제넨테크, 인크. 소아기 발병 특발성 신증후군의 치료 조성물 및 치료 방법
WO2024100200A1 (en) 2022-11-09 2024-05-16 Cis Pharma Ag Anti-l1-cam antibodies and their uses for diagnostic and therapeutic applications
US20240190978A1 (en) 2022-11-15 2024-06-13 CSBioAsset LLC Compositions and methods for immunomodulatory bifunctional fusion molecules
WO2024108053A1 (en) 2022-11-17 2024-05-23 Sanofi Ceacam5 antibody-drug conjugates and methods of use thereof
CN120584182A (zh) 2022-11-21 2025-09-02 艾欧凡斯生物治疗公司 肿瘤浸润淋巴细胞扩增的二维过程及其疗法
CN120225666A (zh) 2022-11-21 2025-06-27 艾欧凡斯生物治疗公司 用于评估基因编辑的t细胞的增殖效力的方法
AR131143A1 (es) 2022-11-24 2025-02-19 Beigene Switzerland Gmbh Conjugados anticuerpo-fármaco anti-cea y métodos de uso
WO2024111657A1 (ja) 2022-11-25 2024-05-30 中外製薬株式会社 タンパク質の製造方法
TW202440169A (zh) 2022-11-30 2024-10-16 日商第一三共股份有限公司 抗體-藥物結合物與dnmt抑制劑之組合
WO2024127366A1 (en) 2022-12-16 2024-06-20 Pheon Therapeutics Ltd Antibodies to cub domain-containing protein 1 (cdcp1) and uses thereof
WO2024137381A1 (en) 2022-12-19 2024-06-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies for treating sars-cov-2 infection
WO2024135809A1 (ja) 2022-12-23 2024-06-27 東レ株式会社 癌の治療及び／又は予防のための医薬品
WO2024151885A1 (en) 2023-01-13 2024-07-18 Iovance Biotherapeutics, Inc. Use of til as maintenance therapy for nsclc patients who achieved pr/cr after prior therapy
AR131637A1 (es) 2023-01-19 2025-04-16 Beigene Ltd ANTICUERPOS ANTI-cMET Y MÉTODOS DE USO
WO2024158047A1 (ja) 2023-01-27 2024-08-02 第一三共株式会社 抗ｌｒｒｃ１５抗体
WO2024170543A1 (en) 2023-02-14 2024-08-22 Institut National de la Santé et de la Recherche Médicale Anti-cd44 antibodies and uses thereof
WO2024182443A2 (en) 2023-02-27 2024-09-06 Compugen Ltd. Triple combination therapy with anti-pvrig antibodies, anti-tigit antibodies, and pembrolizumab
WO2024186635A2 (en) 2023-03-03 2024-09-12 Celldex Therapeutics, Inc. Anti-stem cell factor (scf) and anti-thymic stromal lymphopoietin (tslp) antibodies and bispecific constructs
AR132043A1 (es) 2023-03-03 2025-05-21 Beigene Switzerland Gmbh Anticuerpos muc1 y métodos de uso
TW202436344A (zh) 2023-03-03 2024-09-16 瑞士商百濟神州瑞士有限責任公司 Ｃｄ１６ａ抗體及使用方法
TW202436343A (zh) 2023-03-03 2024-09-16 瑞士商百濟神州瑞士有限責任公司 Muc1與cd16a抗體以及其使用方法
AR132064A1 (es) 2023-03-06 2025-05-21 Beigene Switzerland Gmbh Anticuerpos anti-cldn6 y métodos de uso
TW202436345A (zh) 2023-03-06 2024-09-16 瑞士商百濟神州瑞士有限責任公司 抗ｃｄ３多特異性抗體及使用方法
TW202436353A (zh) 2023-03-06 2024-09-16 瑞士商百濟神州瑞士有限責任公司 抗ｃｌｄｎ６與抗ｃｄ３多重特異性抗體以及使用方法
WO2024184494A1 (en) 2023-03-08 2024-09-12 Ac Immune Sa Anti-tdp-43 binding molecules and uses thereof
WO2024200987A1 (en) 2023-03-31 2024-10-03 Avacta Life Sciences Limited Tnfr2 binding polypeptides and methods of use
WO2024206738A1 (en) 2023-03-31 2024-10-03 Immunai Inc. Humanized anti-trem2 antibodies
FR3147278A1 (fr) 2023-03-31 2024-10-04 Avacta Life Sciences Limited Polypeptides de liaison au tnfr2 et procedes d'utilisation
WO2024211236A2 (en) 2023-04-05 2024-10-10 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
WO2024211234A1 (en) 2023-04-05 2024-10-10 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
WO2024211235A1 (en) 2023-04-05 2024-10-10 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
WO2024212827A1 (en) 2023-04-12 2024-10-17 Shanghai Kangabio Co., Limited Multifunctional molecules comprising masked interleukin 12 and methods of use
WO2024220546A2 (en) 2023-04-17 2024-10-24 Peak Bio, Inc. Antibodies and antibody-drug conjugates and methods of use and synthetic processes and intermediates
WO2024218345A1 (en) 2023-04-21 2024-10-24 Glaxosmithkline Intellectual Property Development Limited Cytotoxicity targeting chimeras for antibody-drug conjugates and bispecific antibodies
WO2024218361A1 (en) 2023-04-21 2024-10-24 Glaxosmithkline Intellectual Property Development Limited Bispecific cytotoxicity targeting chimeras
AR132494A1 (es) 2023-04-24 2025-07-02 Merck Sharp & Dohme Llc Aglutinantes de trop2 y conjugados de estos
WO2024231251A1 (en) 2023-05-05 2024-11-14 Cantargia Ab Anti-il1rap antibodies
TW202448949A (zh) 2023-05-05 2024-12-16 美商建南德克公司 用抗ｆｃｒｈ５／抗ｃｄ３雙特異性抗體進行治療之給藥
WO2024233646A1 (en) 2023-05-10 2024-11-14 Genentech, Inc. Methods and compositions for treating cancer
US12410258B2 (en) 2023-05-12 2025-09-09 Ganmab A/S Antibodies capable of binding to OX40, variants thereof and uses thereof
WO2024243355A1 (en) 2023-05-24 2024-11-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that target the rh5 complex of blood-stage plasmodium falciparum
TW202504641A (zh) 2023-06-08 2025-02-01 美商建南德克公司 用於淋巴瘤之診斷及治療方法的巨噬細胞特徵
WO2024251884A1 (en) 2023-06-09 2024-12-12 Innate Pharma Nk cell engager proteins comprising anti-cd20 and ant-nkp46 antibody, linked to il-2 in treatment of r/r b-nhl
EP4477236A1 (en) 2023-06-14 2024-12-18 Inatherys Combination therapy for treating a tumor using adc comprising anti-cd71 antibodies and bh3 mimetics
TW202504929A (zh) 2023-06-22 2025-02-01 美商建南德克公司 用於癌症治療之方法及組成物
TW202515608A (zh) 2023-06-26 2025-04-16 以色列商坎布根有限公司 Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途
WO2025002410A1 (en) 2023-06-30 2025-01-02 Evive Biotechnology (Shanghai) Ltd G-csf dimer for use in the treatment or prevention of chemotherapy or radiotherapy induced neutropenia
WO2025014896A1 (en) 2023-07-07 2025-01-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Humanized 40h3 antibody
WO2025012417A1 (en) 2023-07-13 2025-01-16 Institut National de la Santé et de la Recherche Médicale Anti-neurotensin long fragment and anti-neuromedin n long fragment antibodies and uses thereof
TW202509219A (zh) 2023-07-13 2025-03-01 美商艾歐凡斯生物治療公司 編碼細胞介素之慢病毒載體及其用於製備腫瘤浸潤性淋巴球之用途
WO2025019790A1 (en) 2023-07-19 2025-01-23 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with trop-2 targeting adc
WO2025024265A1 (en) 2023-07-21 2025-01-30 Bristol-Myers Squibb Company Methods of assessing citrullination and activity of pad4 modulators
WO2025024233A1 (en) 2023-07-21 2025-01-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bispecific antibodies that broadly target coronaviruses
WO2025027529A1 (en) 2023-07-31 2025-02-06 Advesya Anti-il-1rap antibody drug conjugates and methods of use thereof
WO2025034806A1 (en) 2023-08-08 2025-02-13 Wisconsin Alumni Research Foundation Single-domain antibodies and variants thereof against fibroblast activation protein
WO2025032069A1 (en) 2023-08-09 2025-02-13 F. Hoffmann-La Roche Ag Mono and multispecific anti-trem2 antibodies, methods and uses thereof
WO2025032071A1 (en) 2023-08-09 2025-02-13 F. Hoffmann-La Roche Ag Mono and multispecific anti-trem2 antibodies, methods and uses thereof
WO2025032070A1 (en) 2023-08-09 2025-02-13 F. Hoffmann-La Roche Ag Anti-a-beta protein antibodies, methods and uses thereof
WO2025038362A1 (en) 2023-08-11 2025-02-20 Merck Sharp & Dohme Llc Monovalent interleukin 12 (il-12) heterodimeric fc proteins
WO2025038492A1 (en) 2023-08-11 2025-02-20 Abalytics Oncology, Inc. Anti-ctla-4 antibodies and related binding molecules and methods and uses thereof
WO2025045250A1 (en) 2023-09-03 2025-03-06 Kira Pharmaceuticals (Us) Llc Anti-human factor d antibody constructs and uses thereof
WO2025064539A1 (en) 2023-09-19 2025-03-27 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Herv-e antibodies and methods of their use
WO2025072888A2 (en) 2023-09-28 2025-04-03 Novavax, Inc. Anti-sars-cov-2 spike (s) antibodies and their use in treating covid-19
WO2025068957A1 (en) 2023-09-29 2025-04-03 Novartis Ag Bispecific antibodies for use in lowering the risk of cardiovascular disease events in subjects known to be a carrier of clonal expansion of hematopoietic cell lines with somatic mutations
WO2025085489A1 (en) 2023-10-17 2025-04-24 Bristol-Myers Squibb Company Gspt1-degrading compounds, anti-cd33 antibodies and antibody-drug conjugates and uses thereof
WO2025088496A1 (en) 2023-10-24 2025-05-01 Astrazeneca Uk Limited Combination of antibody-drug conjugate and anti-pd-1/tim-3 bispecific binding protein
WO2025101484A1 (en) 2023-11-06 2025-05-15 Iovance Biotherapeutics, Inc. Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies
WO2025099280A1 (en) 2023-11-08 2025-05-15 Oxion Biologics Ab Improved anti-ox40l antibodies
WO2025106427A1 (en) 2023-11-14 2025-05-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing and protective monoclonal antibodies against respiratory syncytial virus (rsv)
WO2025106474A1 (en) 2023-11-14 2025-05-22 Genentech, Inc. Therapeutic and diagnostic methods for treating cancer with anti-fcrh5/anti-cd3 bispecific antibodies
WO2025111402A1 (en) 2023-11-21 2025-05-30 Board Of Regents Of The University Of Nebraska Anti-amyloid beta antibodies and related compositions and methods thereof
WO2025117384A1 (en) 2023-12-01 2025-06-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Broadly neutralizing influenza hemagglutinin stem-directed antibodies
WO2025120513A1 (en) 2023-12-05 2025-06-12 Astrazeneca Uk Limited Combination of antibody-drug conjugate and blood brain barrier-penetrant parp1 selective inhibitor
WO2025120015A1 (en) 2023-12-06 2025-06-12 Institut National de la Santé et de la Recherche Médicale Cd5 targeting antibodies with depleting and t or b-cell activation effects
WO2025126157A1 (en) 2023-12-15 2025-06-19 Advesya Anti-il-1rap binding domains and antibody-drug conjugates thereof
WO2025137523A2 (en) 2023-12-20 2025-06-26 Apogee Therapeutics, Inc. Pharmaceutical formulations of antibodies that bind interleukin 13
US20250230251A1 (en) 2023-12-20 2025-07-17 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rb) and related methods
WO2025137410A1 (en) 2023-12-20 2025-06-26 Apogee Therapeutics, Inc. Pharmaceutical compositions of anti-il-13 antibodies with and without c-terminal lysine
WO2025137284A2 (en) 2023-12-21 2025-06-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Broadly neutralizing antibodies against sars-cov-2 and sars-cov variants
US20250215087A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg depleting agent
US20250222125A1 (en) 2024-01-05 2025-07-10 Beigene, Ltd. Anti-FGFR2b Antibodies, Conjugates and Methods of Use
WO2025155877A2 (en) 2024-01-18 2025-07-24 The Regents Of The University Of California Antibodies binding to pad4 and uses thereof
WO2025171182A1 (en) 2024-02-08 2025-08-14 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with cancer vaccine
WO2025174974A1 (en) 2024-02-14 2025-08-21 Bristol-Myers Squibb Company Anti-cd33 antibodies and uses thereof
WO2025179281A1 (en) 2024-02-23 2025-08-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Treatment of cardiovascular disease with antxr1 antibodies
WO2025184208A1 (en) 2024-02-27 2025-09-04 Bristol-Myers Squibb Company Anti-ceacam5 antibodies and uses thereof
WO2025184416A1 (en) 2024-02-27 2025-09-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Single-domain antibodies and bispecific antibodies against hiv-1 and their use
WO2025184211A1 (en) 2024-02-27 2025-09-04 Bristol-Myers Squibb Company Anti-ceacam5 antibody drug conjugates
WO2025184421A1 (en) 2024-02-28 2025-09-04 Juno Therapeutics, Inc. Chimeric antigen receptors and antibodies specific for delta-like ligand 3 (dll3) and related methods

Family Cites Families (158)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
CA1142466A (en) 1979-01-09 1983-03-08 Cesar Milstein Cell lines
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPH0669961B2 (ja) 1984-09-25 1994-09-07 株式会社ミドリ十字 免疫グロブリンの加熱処理方法
US4757018A (en) 1985-02-11 1988-07-12 Hazleton Biotechnologies, Inc. Myeloma cell lines and uses thereof
EP0216846B2 (en) 1985-04-01 1995-04-26 Celltech Limited Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US4865968A (en) 1985-04-01 1989-09-12 The Salk Institute For Biological Studies DNA sequencing
US5672502A (en) 1985-06-28 1997-09-30 Celltech Therapeutics Limited Animal cell culture
US5453363A (en) * 1985-10-23 1995-09-26 Boehringer Mannheim Gmbh Process for the activation of t-PA or Ing after genetic expression in prokaryotes
JPS62194459A (ja) 1986-02-21 1987-08-26 Sankyo Co Ltd 固相化試薬の安定化剤
US4925796A (en) * 1986-03-07 1990-05-15 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
JPS62244441A (ja) 1986-04-16 1987-10-24 Green Cross Corp:The 抗体固定化担体
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0832981A1 (en) 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
US4849509A (en) 1987-02-20 1989-07-18 The Wistar Institute Monoclonal antibodies against melanoma-associated antigens and hybrid cell lines producing these antibodies
US5001065A (en) 1987-05-27 1991-03-19 Cetus Corporation Human cell line and triomas, antibodies, and transformants derived therefrom
JPH02257891A (ja) 1989-03-31 1990-10-18 Kyowa Hakko Kogyo Co Ltd 組換え動物細胞による蛋白質の製造
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5324663A (en) 1990-02-14 1994-06-28 The Regents Of The University Of Michigan Methods and products for the synthesis of oligosaccharide structures on glycoproteins, glycolipids, or as free molecules, and for the isolation of cloned genetic sequences that determine these structures
US5072502A (en) 1990-04-27 1991-12-17 Yoshida Kogyo K. K. Method and apparatus for applying slide fastener end stop
WO1991019501A1 (en) * 1990-06-15 1991-12-26 Cytel Corporation Intercellular adhesion mediators
US5453491A (en) 1990-09-11 1995-09-26 Kiyoshi Takatsu Murine interleukin-5 receptor
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
CZ96893A3 (en) * 1990-11-23 1993-12-15 Gen Hospital Corp Inhibition of adhesive protein cells and their carbohydrates interaction
US5272070A (en) 1991-03-08 1993-12-21 Board Of Regents, The University Of Texas System Method for the preparation of cell lines producing Man3 GlcNac 2 asparagine-linked gylcans and cell lines produced thereby
DE4110405A1 (de) 1991-03-28 1992-10-01 Birchmeier Walter Prof Dr Verfahren zum nachweis der differenzierung und der invasivitaet von karzinomzellen
CS103091A3 (en) 1991-04-12 1992-10-14 Ustav Organicke Chemie A Bioch Protected substituted benzhydrylamines as shoulders for the synthesis ofpeptides on solid phase, process of their preparation and use
WO1994004574A1 (en) * 1991-08-22 1994-03-03 Nissin Shokuhin Kabushiki Kaisha Hiv immunotherapeutics
AU669124B2 (en) 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
FR2682283B1 (fr) 1991-10-10 1994-01-28 Gerard Scortecci Implant dentaire a penetration verticale, concu pour s'adapter aux differents degres de durete de l'os.
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
US5869262A (en) 1992-01-27 1999-02-09 Icos Corporation Method for monitoring an inflammatory disease state by detecting circulating ICAM-R
CA2133205C (en) 1992-04-30 2007-04-17 Robert L. Swift Stable polypeptide composition
CA2120745A1 (en) 1992-06-30 1994-01-06 Philip G. Kasprzyk A combination of anti-erbb-2 monoclonal antibodies and method of using
AU669379B2 (en) * 1992-09-07 1996-06-06 Kyowa Hakko Kirin Co., Ltd. Humanized antibodies
JP3154564B2 (ja) 1992-09-07 2001-04-09 科学技術振興事業団 モノクローナル抗体の改変方法
WO1994011401A1 (en) 1992-11-17 1994-05-26 Yale University Human homolog of the e-cadherin gene and methods based thereon
JPH06189781A (ja) 1992-12-25 1994-07-12 Mitsui Toatsu Chem Inc 培養液中の生理活性タンパク質の安定化方法
NZ261259A (en) 1993-01-12 1996-12-20 Biogen Inc Humanised recombinant anti-vla4 antibody and diagnostic compositions and medicaments
JP3756946B2 (ja) 1993-03-29 2006-03-22 協和醗酵工業株式会社 α１，３−フコシルトランスフェラーゼ
WO1994022478A1 (en) 1993-03-30 1994-10-13 The Trustees Of The University Of Pennsylvania PREVENTION OF TUMORS WITH MONOCLONAL ANTIBODIES AGAINST $i(NEU)
US5422264A (en) 1993-11-12 1995-06-06 Desmos, Inc. Soluble factor stimulation of attachment and hemidesmosome assembly in epithelial cells
DE4314556A1 (de) * 1993-05-04 1994-11-10 Behringwerke Ag Modifizierte Antikörperenzymkonjugate und Fusionsproteine sowie ihre Anwendung zur tumorselektiven Therapie
JPH0819397A (ja) 1993-05-19 1996-01-23 Takeda Chem Ind Ltd 生理活性ペプチド製造方法およびその産生細胞
EP0625574A1 (en) 1993-05-19 1994-11-23 Takeda Chemical Industries, Ltd. Production for biologically active polypeptide
FR2708467B1 (fr) 1993-07-30 1995-10-20 Pasteur Merieux Serums Vacc Préparations d'immunoglobulines stabilisées et procédé pour leur préparation.
US5585237A (en) 1993-10-25 1996-12-17 Creative Biomolecules, Inc. Methods and compositions for high protein production from recombinant DNA
US5558789A (en) 1994-03-02 1996-09-24 University Of Florida Method of applying a laser beam creating micro-scale surface structures prior to deposition of film for increased adhesion
CA2184687A1 (en) 1994-03-09 1995-09-14 Pedro Antonio Prieto Humanized milk
GB9418092D0 (en) 1994-09-08 1994-10-26 Red Cross Found Cent Lab Blood Organic compounds
US6129913A (en) 1994-12-23 2000-10-10 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US5783184A (en) 1994-12-23 1998-07-21 Smithkline Beecham Corporation Method for treatment and diagnosis of IL-5 mediated disorders
US5977316A (en) * 1995-01-17 1999-11-02 The Board Of Trustees Of The University Of Kentucky Monoclonal antibody 1A7 and related polypeptides
US5935821A (en) 1995-01-17 1999-08-10 Board Of Trustees Of The University Of Kentucky Polynucleotides related to monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
GB9501683D0 (en) 1995-01-27 1995-03-15 Glaxo Group Ltd Substances and their uses
US5843705A (en) 1995-02-21 1998-12-01 Genzyme Transgenic Corporation Transgenically produced antithrombin III
ES2225874T3 (es) 1995-03-10 2005-03-16 Genentech, Inc. Activacion de receptor mediante gas.
EP0778892A1 (en) 1995-06-07 1997-06-18 Icos Corporation Macrophage derived chemokine and chemokine analogs
US6498015B1 (en) 1995-06-07 2002-12-24 Icos Corporation Methods of identifying agents that modulate the binding between MDC and an MDC receptor
US6057115A (en) 1995-06-16 2000-05-02 Ludwig Institute For Cancer Research Process for producing GM2 specific antibodies
JPH0949836A (ja) 1995-08-08 1997-02-18 Hitachi Ltd 抗体による蛋白質構造の評価方法
EP0811691B1 (en) * 1995-09-11 2004-12-01 Kyowa Hakko Kogyo Co., Ltd. Antibody againts alpha-chain of human interleukin 5 receptor
ATE449849T1 (de) 1996-01-08 2009-12-15 Genentech Inc Ob rezeptor-variante und liganden
EP0816503B1 (en) 1996-01-24 2006-07-05 Toyo Boseki Kabushiki Kaisha Alpha-1-6 fucosyltransferases
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
WO1997033978A1 (en) 1996-03-12 1997-09-18 Life Technologies, Inc. Hematopoietic cell culture nutrient supplement
CA2251465A1 (en) 1996-04-10 1997-10-16 Cytel Corporation Nucleic acids encoding gdp-fucose pyrophosphorylase
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
US6986890B1 (en) 1996-11-21 2006-01-17 Kyowa Hakko Kogyo Co., Ltd. Anti-human VEGF receptor Flt-1 monoclonal antibody
US5728568A (en) 1996-11-22 1998-03-17 Genetics Institute, Inc. Human GDP-mannose 4,6 dehydratase
US7033589B1 (en) 1997-02-20 2006-04-25 Biogen Idec Ma Inc. γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
JP4550947B2 (ja) 1997-03-19 2010-09-22 協和発酵キリン株式会社 ガングリオシドｇｍ２に対するヒト型相補性決定領域（ｃｄｒ）移植抗体
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
JP2002503233A (ja) 1997-06-06 2002-01-29 ビーエーエスエフ アクチェンゲゼルシャフト 殺菌剤混合物
US6762172B1 (en) 1997-07-17 2004-07-13 Nova Biogenetics, Inc. Water-stabilized organosilane compounds and methods for using the same
JPH11127890A (ja) 1997-10-31 1999-05-18 Kazuo Shimada 糖蛋白質の生産方法
US6355244B1 (en) 1997-11-17 2002-03-12 University Of Kentucky Research Foundation Methods and compositions for the treatment of psoriasis
AU2444899A (en) 1998-01-22 1999-08-09 Astrazeneca Ab Pharmaceutical formulation comprising an antibody and a citrate buffer
CA2319160A1 (en) 1998-01-23 1999-07-29 Merck Patent Gesellschaft Mit Beschraenkter Haftung Monoclonal antibody anti .alpha.v-integrin and its use to inhibit .alpha.v.beta.6-integrin attachment to fibronectin
US6762174B1 (en) 1998-02-24 2004-07-13 Dovetail Technologies, Inc. Low molecular weight compounds administered together with anti-cancer agents to prevent or treat cancer and pharmaceutical compositions thereof
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
AU3657899A (en) * 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
EP1092037B1 (en) 1998-05-29 2005-12-28 Genentech, Inc. Cell culture process for producing glycoproteins
US20020012979A1 (en) 1998-06-08 2002-01-31 Alan Berry Vitamin c production in microorganisms and plants
WO2000000219A1 (fr) 1998-06-26 2000-01-06 Chugai Seiyaku Kabushiki Kaisha Remedes contre des crises d'hypercalcemie
WO2000009160A1 (en) 1998-08-11 2000-02-24 Idec Pharmaceuticals Corporation Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody
DE69927831T2 (de) 1998-08-31 2006-07-20 Biogen, Inc., Cambridge Modulierung von gedächtnis-effector- zellen unter verwendung eines cd2-bindungsagens
AU773028B2 (en) 1998-11-03 2004-05-13 Adherex Technologies Inc. Compounds and methods for modulating claudin-mediated functions
US6238894B1 (en) 1998-11-04 2001-05-29 Diane Taylor α1,2 fucosyltransferase
WO2000034490A1 (en) 1998-12-09 2000-06-15 Tatsuji Seki A method for manufacturing glycoproteins having human-type glycosylation
US7109003B2 (en) * 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US6245332B1 (en) 1999-01-15 2001-06-12 The Board Of Trustees Of The Leland Stanford Junior University Modulation of systemic memory T cell trafficking
US6488930B1 (en) 1999-01-15 2002-12-03 Millennium Pharmaceuticals, Inc. Anti-CCR4 antibodies and methods of use therefor
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
AT408446B (de) 1999-02-18 2001-11-26 Altmann Friedrich Dr Fucosyltransferase-gen
CA2366774A1 (en) 1999-04-02 2000-10-12 Center For Molecular Medicine And Immunology Method of detecting endometriosis
EP2270148A3 (en) 1999-04-09 2011-06-08 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
WO2000062790A2 (en) 1999-04-19 2000-10-26 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US6350868B1 (en) 1999-04-26 2002-02-26 University Of North Carolina At Chapel Hill Antisense human fucosyltransferase sequences and methods of use thereof
EP1174148A4 (en) 1999-04-28 2005-05-04 Yamanouchi Pharma Co Ltd PARENTAL MEDICAL COMPOSITIONS CONTAINING FRAGMENTS OF HUMANIZED MONOCLONAL ANTIBODIES AND METHOD FOR STABILIZING THE SAME
JP2000308526A (ja) 1999-04-28 2000-11-07 Yoshihiro Inomura 鐙型ブラシ
US6939545B2 (en) 1999-04-28 2005-09-06 Genetics Institute, Llc Composition and method for treating inflammatory disorders
EP1050307A1 (en) 1999-05-06 2000-11-08 Applied Research Systems ARS Holding N.V. CCR4 antagonists in sepsis
ES2312344T3 (es) 1999-05-28 2009-03-01 Targeted Genetics Corporation Metodos y composiciones para disminuir el nivel de factor de necrosis tumoral (tnf) en trastornos asociados con tnf.
US7504256B1 (en) 1999-10-19 2009-03-17 Kyowa Hakko Kogyo Co., Ltd. Process for producing polypeptide
EP1254666A4 (en) 1999-12-28 2004-12-22 Chugai Pharmaceutical Co Ltd STABLE ANTIBODY COMPOSITIONS AND INJECTION FORMULATIONS
US7404953B2 (en) 2000-02-15 2008-07-29 Kyowa Hakko Kogyo Co., Ltd. Methods using eosinophil-specific apoptosis inducer
DK1270595T3 (da) 2000-03-03 2008-11-10 Kyowa Hakko Kogyo Kk Anti-CCR4-antistof og dets fragment
JP5623683B2 (ja) 2000-03-22 2014-11-12 フィトン ホールディングス，リミティド ライアビリティ カンパニー 動物型糖鎖付加機能をもつ植物細胞
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
WO2002002793A1 (fr) 2000-07-05 2002-01-10 Japan As Represented By Secretary Of Osaka University Processus de production de glycoproteine
CZ2003311A3 (cs) 2000-08-02 2004-04-14 Ortho-Mcneil Pharmaceutical, Inc. Protivirová a protinádorová terapie za použití erythropoetinu
ATE444309T1 (de) 2000-08-08 2009-10-15 Immunomedics Inc Immuntherapie für kronische myelozytische leukämie mit nacktem anti-nca-90 antikörper
US8632778B2 (en) 2000-08-11 2014-01-21 Chugai Seiyaku Kabushiki Kaisha Stabilized anti-interleukin-6 antibody-containing preparations
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
PL218428B1 (pl) 2000-10-06 2014-12-31 Kyowa Hakko Kogyo Kk Komórka, sposoby wytwarzania przeciwciał, leki zawierające przeciwciała, komórka CHO i przeciwciało klasy IgG
DK2813582T3 (en) 2000-12-01 2017-07-31 Max-Planck-Gesellschaft Zur Förderung Der Wss E V Small RNA molecules that mediate RNA interference
AU2002221080A1 (en) 2000-12-08 2002-06-18 Masami Kusaka Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparingthe same and use thereof
JP2004525620A (ja) 2001-01-17 2004-08-26 トルビオン・ファーマシューティカルズ・インコーポレイテッド 結合ドメイン−免疫グロブリン融合タンパク質
DK1449850T3 (da) 2001-08-31 2011-02-14 Kyowa Hakko Kirin Co Ltd Humane CDR-graftede antistoffer eller antistoffragmenter deraf
ES2326964T3 (es) 2001-10-25 2009-10-22 Genentech, Inc. Composiciones de glicoproteina.
AU2002365925A1 (en) 2001-11-02 2003-09-02 Centocor Rsv proteins, antibodies, compositions, methods and uses
EP1462525B1 (en) 2001-11-28 2010-10-06 Toudai Tlo, Ltd. siRNA EXPRESSION SYSTEM AND PROCESS FOR PRODUCING FUNCTIONAL GENE KNOCKDOWN CELL OR THE LIKE USING THE SAME
AU2002343792A1 (en) 2001-11-28 2003-06-10 Center For Advanced Science And Technology Incubation, Ltd. siRNA EXPRESSION SYSTEM AND PROCESS FOR PRODUCING FUNCTIONAL GENE-KNOCKDOWN CELLS AND THE LIKE USING THE SAME
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
WO2003069307A2 (en) 2002-02-14 2003-08-21 The Johns Hopkins University School Of Medicine Claudins, markers for diagnosis, prognosis and therapy of breast, bone, brain cancer
CN1326879C (zh) 2002-03-29 2007-07-18 先灵公司 人源抗白细胞介素5单克隆抗体及其制备方法和包含这些抗体的组合物
AU2003236018A1 (en) 2002-04-09 2003-10-20 Kyowa Hakko Kirin Co., Ltd. METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa
CA2481920A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Antibody composition-containing medicament
AU2003236020B2 (en) 2002-04-09 2009-03-19 Kyowa Hakko Kirin Co., Ltd. Cell with depression or deletion of the activity of protein participating in GDP-fucose transport
WO2003085118A1 (fr) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Procede de production de composition anticorps
CA2481657A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cells of which genome is modified
EP2284266B1 (en) 2002-11-14 2013-11-06 Thermo Fisher Scientific Biosciences Inc. siRNA targeting tp53
US20050160485A1 (en) 2003-03-18 2005-07-21 Kyowa Hakko Kogyo Co., Ltd. Mouse in which genome is modified
JP2006525351A (ja) 2003-04-30 2006-11-09 ナステック・ファーマシューティカル・カンパニー・インコーポレーテッド ガンを診断および治療するための方法
JP2005058111A (ja) 2003-08-14 2005-03-10 Univ Osaka 糖鎖修飾制御方法
US20050287138A1 (en) * 2003-10-08 2005-12-29 Kyowa Hakko Kogyo Co., Ltd. CCR4-specific antibody composition
US20050226867A1 (en) * 2003-10-08 2005-10-13 Kyowa Hakko Kogyo Co., Ltd. IL-5R-specific antibody composition
US7691810B2 (en) 2003-10-09 2010-04-06 Kyowa Hakko Kirin Co., Ltd Method of producing recombinant antithrombin III composition
CA2542125A1 (en) 2003-10-09 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Process for producing antibody composition by using rna inhibiting the function of .alpha.1,6-fucosyltransferase
JPWO2005035741A1 (ja) 2003-10-09 2006-12-21 協和醗酵工業株式会社 ゲノムが改変された細胞
BRPI0506771A (pt) 2004-01-12 2007-05-22 Applied Molecular Evolution anticorpo, e, composição farmacêutica
JP2005224240A (ja) * 2004-01-13 2005-08-25 Kyowa Hakko Kogyo Co Ltd ノックアウト非ヒト動物から樹立された不死化細胞株
US20050208519A1 (en) 2004-03-12 2005-09-22 Genenews Inc. Biomarkers for diagnosing schizophrenia and bipolar disorder
CN1842509A (zh) 2004-06-09 2006-10-04 出光兴产株式会社 蒽衍生物以及使用该衍生物的有机电致发光器件
US8435530B2 (en) 2004-06-11 2013-05-07 Sbi Biotech Co., Ltd. Methods for suppressing activity of activated interferon-producing cells
US20060262593A1 (en) * 2004-07-27 2006-11-23 Stephane Aouba Magnetic memory composition and method of manufacture
WO2006020114A2 (en) 2004-08-04 2006-02-23 Applied Molecular Evolution, Inc. Variant fc regions
US20060223147A1 (en) 2004-08-05 2006-10-05 Kyowa Hakko Kogyo Co., Ltd., Process for producing glycoprotein composition
WO2006044335A2 (en) 2004-10-14 2006-04-27 The Board Of Trustees Of The University Of Arkansas Therapy with clostridium perfringens enterotoxin to treat ovarian and uterine cancer
US7150443B2 (en) * 2005-01-18 2006-12-19 Mills Douglas W Control valve for nitrous oxide injection system
AU2006230413B8 (en) 2005-03-31 2011-01-20 Xencor, Inc Fc variants with optimized properties
MX2007013924A (es) 2005-05-09 2008-01-28 Glycart Biotechnology Ag Moleculas que unen antigeno que tienen regiones fc modificadas y union alterada a receptores fc.
US7923538B2 (en) 2005-07-22 2011-04-12 Kyowa Hakko Kirin Co., Ltd Recombinant antibody composition
MX2008003054A (es) 2005-08-31 2008-03-25 Centocor Inc Lineas de celulas hospederas para la produccion de la region constante de anticuerpos, con fusion efectora mejorada.
CA2672581A1 (en) 2006-12-14 2008-06-19 Forerunner Pharma Research Co., Ltd. Anti-claudin 3 monoclonal antibody and treatment and diagnosis of cancer using the same
JP6189781B2 (ja) 2014-04-01 2017-08-30 東京エレクトロン株式会社 熱処理装置、熱処理方法、プログラム、コンピュータ記憶媒体及び基板処理システム

Also Published As

Publication number Publication date
US10233247B2 (en) 2019-03-19
CA2369292A1 (en) 2000-10-19
ES2569919T3 (es) 2016-05-13
US7682610B2 (en) 2010-03-23
US7687061B2 (en) 2010-03-30
EP2275541B1 (en) 2016-03-23
FR18C1021I2 (fr) 2020-09-04
NL300939I2 (nl) 2021-03-18
EP2278003A2 (en) 2011-01-26
PT1914244E (pt) 2013-07-26
EP2264166A2 (en) 2010-12-22
US20080177043A1 (en) 2008-07-24
WO2000061739A1 (en) 2000-10-19
EP2270150B1 (en) 2016-04-06
DK2270149T3 (en) 2016-05-09
US20140234300A1 (en) 2014-08-21
CY2018015I2 (el) 2018-09-05
DK1176195T3 (da) 2013-06-24
EP2278003A3 (en) 2011-06-08
EP1176195A4 (en) 2005-03-02
EP2270147A2 (en) 2011-01-05
US7708992B2 (en) 2010-05-04
JP2009171976A (ja) 2009-08-06
ES2574826T5 (es) 2020-03-30
ES2572623T5 (es) 2021-06-08
EP2278003B1 (en) 2016-03-23
DK2275540T3 (en) 2016-05-09
ES2571230T3 (es) 2016-05-24
DK2278003T3 (en) 2016-05-17
EP2264166B1 (en) 2016-03-23
CA2704600A1 (en) 2000-10-19
EP1176195A1 (en) 2002-01-30
DK2270147T4 (da) 2020-08-31
US20100196371A1 (en) 2010-08-05
US7763246B2 (en) 2010-07-27
ES2572623T3 (es) 2016-06-01
US20070207151A1 (en) 2007-09-06
ES2574826T3 (es) 2016-06-22
EP2278003B2 (en) 2020-08-05
DK2270150T4 (da) 2019-08-26
JP4850922B2 (ja) 2012-01-11
CY2018015I1 (el) 2018-09-05
EP2264166A3 (en) 2011-06-08
EP1914244B1 (en) 2013-05-29
ES2568898T3 (es) 2016-05-05
CA2704600C (en) 2016-10-25
EP2270147A3 (en) 2011-06-08
AU3672800A (en) 2000-11-14
DK2275541T3 (en) 2016-05-09
US7655228B2 (en) 2010-02-02
EP2270150B2 (en) 2019-08-07
EP1914244A2 (en) 2008-04-23
EP2275540A2 (en) 2011-01-19
EP1176195B1 (en) 2013-05-22
FR18C1021I1 (fr) 2018-07-13
EP2270149B1 (en) 2016-03-23
US20050272916A1 (en) 2005-12-08
EP2275540B1 (en) 2016-03-23
US20070166303A1 (en) 2007-07-19
US7718175B2 (en) 2010-05-18
ES2601882T3 (es) 2017-02-16
US7651688B2 (en) 2010-01-26
DK2270150T3 (en) 2016-06-20
EP2270148A2 (en) 2011-01-05
CY1117551T1 (el) 2017-04-26
CA2369292C (en) 2010-09-21
EP2270149A3 (en) 2011-06-08
US20070166300A1 (en) 2007-07-19
US7682611B2 (en) 2010-03-23
US7214775B2 (en) 2007-05-08
US7708997B2 (en) 2010-05-04
DK1914244T3 (da) 2013-07-22
EP2270147B1 (en) 2016-08-31
US20060024800A1 (en) 2006-02-02
ES2420835T3 (es) 2013-08-27
US8679491B2 (en) 2014-03-25
EP2275540A3 (en) 2011-06-08
US20070166305A1 (en) 2007-07-19
US20070166302A1 (en) 2007-07-19
ES2601882T5 (es) 2021-06-07
JP4368530B2 (ja) 2009-11-18
US20200017593A1 (en) 2020-01-16
US20070166301A1 (en) 2007-07-19
EP2270150A3 (en) 2011-06-08
CY1114164T1 (el) 2016-08-31
EP2270147B2 (en) 2020-07-22
EP3031917A1 (en) 2016-06-15
ES2418360T3 (es) 2013-08-13
ES2568899T3 (es) 2016-05-05
DK2278003T4 (da) 2020-08-31
EP2270148A3 (en) 2011-06-08
US20070166304A1 (en) 2007-07-19
EP2270149A2 (en) 2011-01-05
JP2009275049A (ja) 2009-11-26
CY1114197T1 (el) 2016-08-31
EP2275541A2 (en) 2011-01-19
PT1176195E (pt) 2013-07-18
US20050276805A1 (en) 2005-12-15
US20170240647A1 (en) 2017-08-24
EP2270150A2 (en) 2011-01-05
LUC00074I2 (en) 2018-07-30
EP1914244A3 (en) 2008-06-18
DK2270147T3 (en) 2016-11-21
JP4886010B2 (ja) 2012-02-29
EP2275541A3 (en) 2011-06-08

Similar Documents

Publication Publication Date Title
BE2018C020I2 (browse.php)
BE2016C007I2 (browse.php)
BE2015C057I2 (browse.php)
BE2015C018I2 (browse.php)
BE2014C017I2 (browse.php)
BE2013C051I2 (browse.php)
BE2013C020I2 (browse.php)
BE2013C015I2 (browse.php)
BE2013C001I2 (browse.php)
BE2012C036I2 (browse.php)
BE2011C004I2 (browse.php)
BE2008C046I2 (browse.php)
BE1025464I2 (browse.php)
BE2010C011I2 (browse.php)
BRPI0017527B8 (browse.php)
BE2008C047I2 (browse.php)
BRPI0001672A2 (browse.php)
BRPI0001542A2 (browse.php)
BRPI0012675B8 (browse.php)
BRPI0017522A2 (browse.php)
BRMU7902607U2 (browse.php)
BRPI9917761A2 (browse.php)
BRPI0303609A (browse.php)
IN188359B (browse.php)
CN3097509S (browse.php)